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SUMMARY 
 
Cyclic dipeptides have been widely used as pharmaceutical agents due to their 
favourable properties and the fact that they are more stable and membrane 
permeable than their linear analogues. These characteristics make cyclic dipeptides 
attractive to protein-based drug developers (Martins & Carvalho, 2007).  
 
In this research study, the method of Milne et al. (1992) was used to synthesize the 
protected linear dipeptide esters. This was followed by boiling the unprotected, linear 
dipeptide esters under reflux in an oil bath (Sec-butanol: toluene (4:1)). This method 
gave good yields and pure cyclic dipeptides. Scanning electron microscopy, thermal 
analysis, X-ray powder diffraction and differential scanning calorimetry were used for 
evaluation of the physiochemical properties of the cyclic dipeptides. High-
performance liquid chromatography and thin layer chromatography were used to 
determine the purity of the cyclic dipeptides. The structures of the cyclic dipeptides 
were elucidated using infrared spectroscopy, mass spectrometry, nuclear magnetic 
resonance spectroscopy and molecular modeling and computational chemistry. 
 
The aim of the study was to determine the possible therapeutic activity of cyclo(D-
Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) with regard to antimicrobial, anticancer, 
antidiabetes and haematological effects. Both cyclic dipeptides showed a significant 
growth inhibition of Gram-positive, Gram-negative and fungal microorganisms in the 
antimicrobial study. Anticancer studies showed that both cyclic dipeptides caused 
growth inhibition of the MCF-7, HT-29 and HeLa cancer cell lines. Both cyclic 
dipeptides showed no antidiabetic activity. Haematological studies revealed that both 
cyclic dipeptides caused a significant effect on the clotting time and platelet 
aggregation. They caused an increase in clotting time and also inhibited platelet 
aggregation.  
 
Key words: cyclic dipeptides, cyclo(D-Phe-4I-Pro), cyclo(L-Phe-4I-Pro), antimicrobial, 
anticancer, antidiabetic, haematological effects. 
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CHAPTER 1 
 
1.1. Background of the study 
 
Cyclic dipeptides and their derivatives continue to hold the attention of synthetic 
chemists and biologists alike. Apart from the occurrence of a variety of naturally 
occurring bioactive metabolites, cyclic dipeptides are often more stable in vivo than 
their linear counterparts and therefore often represent promising drug candidates. 
Another feature that contributes to the appeal of cyclic dipeptides is their reduced 
conformational mobility which allows them to be used in the study and mimicry of 
protein folding and to present diverse functionality in a defined and predictable 
manner. Given the continuing and growing interest in cyclic dipeptides and their 
chemistry, a review of the area seems timely (Lambert et al., 2001). 
 
Cyclic dipeptides are important natural products. They have been widely used as 
pharmaceutical agents due to their favourable properties and the fact that they are 
more stable and membrane permeable than their linear analogues. These 
characteristics make cyclic dipeptides attractive to protein-based drug developers 
(Martins & Carvalho, 2007) 
 
No extensive studies have been undertaken to determine the biological activities 
(anticancer, antidiabetic, antimicrobial and haematological effects) of cyclo(D-Phe-4I-
Pro) and cyclo(L-Phe-4I-Pro), therefore this study will aim to investigate the 
prospective therapeutic and medicinal properties of cyclo(D-Phe-4I-Pro) and cyclo(L-
Phe-4I-Pro) as these compounds have several advantages over ordinary peptides 
i.e., higher binding affinities and a greater degree of specificity in peptide-receptor 
interactions which may result after cyclization of the peptides. Therefore the 
investigation of halogenated cyclic dipeptides is necessary. 
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1.2. Aims 
 
The primary aims of this research are to: (1) synthesize the two halogenated 
diketopiperazines, (2) perform structural elucidation and (3) determine the biological 
activity through quantitative and qualitative methods. 
 
1.3. Objectives 
 
The following objectives were set to fulfill the aims: 
 The synthesis of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro), 
 To evaluate the physical properties of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-
4I-Pro),  
 The structural elucidation of the synthesized cyclo(D-Phe-4I-Pro) and cyclo(L-
Phe-4I-Pro), 
 To investigate the biological activity of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-
4I-Pro) as anticancer, antidiabetic and antimicrobial agents, 
 To determine the haematological effects of cyclo(D-Phe-4I-Pro) and cyclo(L-
Phe-4I-Pro). 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1. Background  
 
Cyclic dipeptides have found tremendous attention in diverse aspects of science 
ranging from rational drug design to nanomaterials.  These diverse applications are 
due to their distinctive properties, such as ease of synthesis and characterization, 
introduction of chemical diversity by simple amino acid substitution, and modulation 
of 3D structure by chemical modification. The application of peptides as drugs has 
become a priority especially because of their key role in many signal transduction 
pathways, which makes them an attractive avenue to target diseases (Marx, 2005; 
Teixido & Giralt, 2008).  
 
DKPs exhibit biological properties in tissue and body fluids. Some derivatives of 
DKPs show antiviral activities (gliotoxin, sporidesmins), potential as antibiotics 
(bicyclomycin), while others are phototoxic (cyclo(Pro-Tyr)) (Martins & Carvalho, 
2007). 
 
Most cyclic dipeptides to date appear to be derived from fermentation and food 
processing. Despite the high activity and receptor selectivity of naturally occurring 
bioactive peptides (or active protein fragments), they have distinct disadvantages for 
practical application in medicine, such as short half-life in vivo and lack of oral 
availability. Another major problem in developing peptidic drugs is their enzymatic 
degradation in vivo, which eventually results in the lowering of the pharmacokinetic 
profile (half-life, bioavailability, etc.). The initial step in drug research of peptides is 
usually simplification (e.g., reduction in size), followed by peptidomimetic approaches 
to ensure metabolic stability, with the final goal of an orally available, highly active, 
and selective drug. It is therefore necessary to investigate the development of 
peptides with improved properties and little undesirable effects (Chatterjee et al., 
2008). 
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Cyclic dipeptides, also known as diketopiperazines are the smallest cyclic dipeptides 
known, commonly biosynthesized from amino acids by different organisms, including 
mammals, and are mainly considered to be secondary functional metabolites or side 
products of terminal peptide cleavage. Cyclic dipeptides are extensively obtained by 
extraction from natural sources, but may be easily synthesized (Delaforge et al., 
2001).  Cyclic dipeptides are heterocyclic compounds comprising of two amino acids 
residues linked to the central DKP ring structure. The R1 and R2 amino acid chain 
groups can be substituted with any of the 20 L-α amino acids and can result in a 
potential structure with a degree of biological activity. 
 
NH
NH
O
O
R
1
R
2
 
Figure 2.1: General structure of 2,5-diketopiperazines, where R
1
 and R
2
 represent the 
substituting amino acid residues. 
 
 
2.2. Amino acids 
 
Amino acids are the bifunctional products and the building blocks of proteins. The -
amino acid consists of an amino group, a carboxyl group, R-group, and a hydrogen 
atom bonded to the -carbon. 
 
The R-group represents a side chain specific for each amino acid. Twenty different 
kinds of side chains which may vary in size, shape, chemical reactivity and hydrogen 
bonding capacity are attached to the amino acid. Amino acids exist in either the L- or 
D-stereoisomer but most amino acids found in nature are of the L-type and are 
isolated from proteins that contain only L-amino acids. L- and D- refer to the absolute 
configuration of optically active compounds (Nelson & Cox, 2005). 
 
With the exception of glycine, all the amino acids have four different groups attached 
to the -carbon, and the two stereoisomers are mirror images that cannot be 
superimposed. Eukaryotic proteins are always composed of L-amino acids although 
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D-amino acids are found in certain peptide antibiotics and some peptides of bacterial 
cell walls (Nelson & Cox, 2005). 
 
2.2.1. Classification of amino acids 
 
Amino acids are classified into five main classes based on the properties of their R-
groups (polarity and charge): (1) non polar (hydrophobic), (2) aliphatic, (3) aromatic, 
(4) polar (hydrophilic) and (5) uncharged, positively charged (basic), negatively 
charged (acidic) (Nelson & Cox, 2005). 
 
They are also divided into seven groups based on the properties of their side chains: 
(1) aliphatic side chains, (2) hydroxyl aliphatic side chains, (3) aromatic side chains, 
(4) basic side chains, (5) acidic side chains, (6) amide side chains and (7) sulfur side 
chains. In biochemical terms they can be divided into either glycogenic and 
ketogenic amino acids depending on the metabolism of the carbon chains (Stryer, 
1988).  
 
Amino acids can also be classified as essential or non-essential and conditionally 
essential. Food and tissue proteins contain twenty amino acids of nutritional 
importance. Nine of these amino acids (histamine, isoleucine, leucine, lysine, 
methionine, phenylalanine, threonine, tryptophan and valine) cannot be synthesized 
by the body and they are therefore essential or indispensable nutrients that must be 
obtained from the diet. The other eleven amino acids (alanine, arginine, aspartic 
acid, asparagine, cysteine, glutamic acid, glutamine, glycine, proline, serine and 
tyrosine) are also ordinarily obtained from the diet, but the body can synthesize 
them. They are therefore nutritionally dispensable or non-essential nutrients. They 
are, nevertheless, equally as important as the indispensable amino acids for the 
nutrition of cells and for normal cell and organ function (Harper & Yoshimura, 1993). 
For the conditionally essential amino acids, there is either an increased demand of 
certain amino acids as seen in specific diseases or decreased endogenous 
synthesis. Therefore the supplementation of these amino acids has a positive effect 
on clinical outcomes under specific conditions (Meier, 2005). 
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Table 2.1 illustrates the nutritional classification of amino acids (essential and non-
essential). 
 
Table 2.1: Nutritional classification of amino acids 
Indispensable 
 (Essential) 
Dispensable  
(Non-essential) 
Histidine (His) Alanine (Ala) 
Isoleucine (Ile)  Arginine (Arg) 
Leucine (Leu) Aspartic acid (Asp) 
Lysine (Lys) Asparagine (Asn) 
Methionine (Met) Cysteine (Cys) 
Phenylalanine (Phe) Glutamic acid (Glu) 
Threonine (Thr) Glutamine (Gln) 
Tryptophan (Trp) Glycine (Gly) 
Valine (Val) Proline (Pro) 
 Serine (Ser) 
 Tyrosine (Tyr) 
(Meier, 2005). 
 
2.3. Cyclic dipeptides 
 
Cyclic dipeptides are heterocyclic compounds comprising of two amino acid residues 
linked to a central diketopiperazine (DKP) ring structure. Cyclic dipeptides are 
divided into two broad classes. They are called homodetic if the linkage that 
contributes to the formation of the DKP ring is a peptide bond and they are called 
heterodetic if the cyclization includes other bonds such as disulphide, ester (lactone), 
ether or thioether bonds. Several chemical strategies, including head-to-tail 
cyclization reactions utilising solid- or solution-phase synthetic methods, have been 
developed to convert linear peptides to cyclic structures (Adessi & Soto, 2002). 
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2.3.1. The physicochemical properties of cyclic dipeptides 
 
2.3.1.1. Solubility of cyclic dipeptides 
 
DKPs do not exist as zwitterions and are neutral. DKPs share the capability of 
establishing hydrogen bonds with solvents through the two cis-amide groups in the 
DPK ring. In contrast, they may give rise to hydrophobic interaction; the extent of 
which is determined by the R1 and R2 substituents. The solubility of the non-ionic 
DKPs is still less than those with short alkyl groups (Crescenzi et al., 1973). 
 
2.3.1.2. Stability of cyclic dipeptides 
 
The application of cyclic dipeptides as drugs originates from their key role in many 
signal transduction pathways (from the initial phase of binding to the receptors on the 
cell to triggering pharmacological response), which makes them an attractive avenue 
to target diseases. Despite the high activity and receptor selectivity of naturally 
occurring bioactive peptides (or active protein fragments), they have distinct 
disadvantages for practical application in medicine, such as short half-life in vivo and 
lack of oral availability. Another major problem in developing cyclic dipeptides drugs 
is their enzymatic degradation in vivo, which eventually results in the lowering of the 
pharmacokinetic profile (half-life, bioavailability, etc.) (Chatterjee, 2008). 
 
2.3.1.3. Isomerization factor of cyclic dipeptides 
 
DKPs exist as cis-fused and trans-fused DKPs, and the cis-fused DKPs appear to be 
more stable than the trans-fused DKPs. This is due to the fact that the cis-fused 
DKPs are originally synthesized from two L-α-amino acids. Biological activities of 
different isomers also differ in a number of ways: all isomers may be as active as the 
next one without exhibiting any stereochemistry of interation. The isomers may differ 
in biological activities: one isomer may not show any biological activity while the 
other isomer may show unique biological activities (Chatterjee, 2008; Triggle, 1997). 
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Substitution of the L-α-amino acid with the D-amino acid configuration always 
increases the resistance of the DPK to enzymatic cleavage of peptides bonds 
(Chatterjee, 2008). 
2.3.2. Absorption and transportation of cyclic dipeptides 
 
Once ingested, peptides must be transported to the systemic circulation without 
being metabolized in order to exert their pharmacological effects, but the overall 
absorption of peptides is poor due to metabolic degradation by peptidases. 
 
Peptides and other peptidomimetics are transported across the cell membrane by 
the peptide transporters (PET1 and PET2). Both transporters function electronically 
as they are driven electrochemically through a gradient of protons across the 
intestinal or renal brush border membrane in the lumen-to-cytoplasm direction 
(Nussberger & Hediger, 1995). 
 
Mizuma et al. (2003) also observed the uptake of DKPs through the PET1 peptide 
transporters. They noted that the cellular uptake of the DKPs was pH dependent, 
and that it was inhibited by the addition of PET1 substrates, which indicates PET1-
mediated transport of the DPKs. 
 
2.3.3. Biological activities of cyclic dipeptides 
 
An increasing number of multi-drug resistance diseases have become a serious 
problem for pharmaceutical manufacturers and this has led to intensive research 
efforts to develop new and more effective drugs. Antimicrobial peptides have already 
played a crucial role in pharmaceutical research as biomedically useful agents or as 
lead compounds for drug development (Shai, 2002).  
 
The modes of action by which antimicrobial peptides denature bacteria vary and 
include the following: (1) the disrupting of membranes, (2) interference with 
metabolism and (3) targeting cytoplasmic components (see Figure 2.2). The initial 
contact between the peptide and the target organism would be electrostatic, as most 
bacterial surfaces are anionic. Their amino acid composition, amphipathicity, cationic 
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charge and size allow them to attach to and enter into membrane bilayers to form 
pores, or allow them to penetrate and bind to intracellular molecules. Intracellular 
binding results in (1) inhibition of cell wall synthesis, (2) alteration of the cytoplasmic 
membrane, (3) activation of autolysin, (4) inhibition of DNA, RNA, protein synthesis 
and (5) inhibition of certain enzymes. However, in many cases, the exact mechanism 
of action is not known. In contrast to many conventional antibiotics these peptides 
appear to be bacteriocidal instead of bacteriostic. In general the antimicrobial activity 
of these peptides is determined by measuring the minimal inhibitory concentration 
(MIC), which is the lowest concentration of drug that inhibits bacterial growth 
(Brogden, 2005; Martins & Carvalho, 2007). 
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Figure 2.2: Mode of action of antimicrobials (Brogden, 2005) 
 
It was shown that the DKPs exhibit or cause the following activities: (see Table 2.2). 
 
Table 2.2: Biological activity of some cyclic dipeptides 
Cyclic Dipeptides 
 
Biological Activity 
Cyclo(Phe-Pro), cyclo(Tyr-Pro), 
cyclo(Trp-Pro) and cyclo(Trp-Trp)1, 
3 ,29 
 Calcium and sodium channel blocking 
activity 
 Antibacterial activity 
 Anticancer activity 
11 
 
• Cyclo(Phe-Pro), cyclo(Tyr-Pro) and 
cyclo(Trp-Pro) played a role in the 
induction of differentiation in cancer cell 
lines 
 
Cyclo(His-Pro) 2, 21, 22, 23, 24, 25, 26, 27, 28, 
29 
 
• Played an important role in the perception 
of pain induced by physical, mechanical, 
thermal and chemical stimuli 
• Inhibition of prolactin release from the 
pituitary gland 
• Decreased gastric mucosa blood flow 
• Production of hypothermia in mice 
• Suppression of stress induced eating, 
starvation induced eating and spontaneous 
eating over a ten hour period in mice 
• Antagonism of ethanol narcosis in mice 
• Modulation of glucose metabolism 
• Hormonal regulation 
 
Cyclo(Leu-Gly)2 Blocking of: 
• The development of physical 
dependence on morphine 
• The development of tolerance to the 
pharmacological effects of β-endorphin 
• The development of tolerance to 
haloperidol-induced catalepsy and 
hypothermia 
• Dopaminergic supersensitivity after long-
term morphine exposure 
Cyclo(Pro-Phe)2 
 
• Blocking the development of physical 
dependence on morphine 
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Cyclo(Tyr-Arg)2 
 
• Antinociceptive activity 
Cyclo(Asp-Pro)2, 29 • Inhibition of caloric and dietary fat intake 
Cyclo(Tyr-Pro)2 
 
• Phytotoxic action 
 
Cyclo(Pro-Gly)4 
 
• Antiamnesia properties 
 
Cyclo(Tyr-Tyr)5 
 
• Voltage dependent calcium channel 
blocking activity 
• Increased heart rate and coronary flow rate 
of isolated rat hearts 
• Mixed agonist/antagonist activity at μ-
opioid receptors 
Cyclo(Phe-Tyr)5 
 
• Inhibition of HT-29, HeLa and MCF-7 
tumour cell lines 
• Calcium channel blocking activity 
• Decreased heart rate, coronary flow rate 
and ventricular pressure of isolated rat 
hearts 
• Agonist activity at μ-opioid receptors 
Cyclo(Phe-Cys) and cyclo(Tyr-
Cys)6 
 
• Decreased heart rate and coronary flow 
rate, and increased ventricular pressure of 
isolated rat hearts 
• Inhibition of HT-29 and HeLa tumour cell 
lines 
• Inhibition of MCF-7 tumour cell lines 
(especially cyclo(Tyr-Cys)). 
• Deceleration of the rate of blood clot 
formation 
• Concentration dependant acceleration of 
thrombin substrate reaction 
• Concentration dependant change in rate of 
13 
 
platelet aggregation 
• Deceleration of initial fibrin formation 
Cyclo(Gly-Gly), cyclo(Gly-Trp), 
cyclo(Trp-Tyr), cyclo(Trp-Trp), 
cyclo(Phe-Trp), cyclo(Phe-Phe), 
cyclo(Pro-Gly), cyclo(Pro-Pro), 
cyclo(Phe-Pro), cyclo(Pro-Trp), 
cyclo(Ala-Pro), cyclo(Glu-Phe), 
cyclo(Tyr-Pro),      cyclo(Trp-Pro)7, 
29 
• Antifungal activity 
 
Cyclo(Gly-Gly), cyclo(Trp-Tyr), 
cyclo(Trp-Trp), cyclo(Phe-Trp), 
cyclo(Phe-Phe), cyclo(Pro-Gly), 
cyclo(Pro-Pro), cyclo(Phe-Pro), 
cyclo(Ser-Ser),         cyclo(Pro-Trp), 
cyclo(Ala-Pro), cyclo(Glu-Phe), 
cyclo(Tyr-Pro), cyclo(Phe-Leu), 
cyclo(Trp-Pro)7, 20, 29 
• Antibacterial activity 
• Cyclo(Pro-Pro) showed anticancer activity 
Cyclo(Met-Met) and cyclo(Met-
Gly)7, 8 
 
• Antifungal and antibacterial activity 
• Inhibition of adenosine diphosphate (ADP)- 
and thrombin induced platelet aggregation 
• Calcium and sodium channel blocking 
activity 
Cyclo(Gly-Tyr) and cyclo(Gly-Phe)9, 
29 
• Antibacterial activity 
• Inhibition of  ADP- and thrombin-induced 
platelet aggregation 
• Calcium channel blocking activity 
• Inhibition of HT-29, HeLa and MCF-7 
tumour cell lines 
• Anticonvulsant activity 
Cyclo(Trp-Tyr) and cyclo(D-Trp-L-
Tyr)10 
• Inhibition of ADP- and thrombin-induced 
platelet aggregation 
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 • Calcium channel agonistic activity 
• Increased coronary flow rate of isolated rat 
hearts 
Cyclo(Met-Trp) and cyclo(Met-
Tyr)11 
 
• Inhibition of ADP- and thrombin-induced 
platelet adhesion 
• Antibacterial and antifungal activity 
• Calcium and sodium channel blocking 
activity 
• Cyclo(Met-Trp) inhibited HT-29, HeLa and 
MCF-7 tumour cell lines 
Cyclo(His-Gly) and cyclo(His-Ala)12 
 
• Antifungal activity 
• Inhibition of  MCF-7 tumour cell lines 
• Cyclo(His-Ala) also inhibited HT-29 and 
HeLa tumour cell lines 
• Decreased coronary flow rate of isolated 
rat hearts 
• Inhibition of ADP- and thrombin-induced 
platelet aggregation 
• Inhibition of thrombin-substrate binding 
Cyclo(His-Phe) and cyclo(His-
Tyr)13 
 
• Inhibition of WHCO3, HeLa and MCF-7 
tumour cell lines 
• Calcium and sodium channel blocking 
activity and opening of inward rectifying 
potassium ion channels 
• Cyclo(His-Phe) decreased heart rate and 
coronary flow rate while increasing 
ventricular pressure of isolated rat hearts 
• Cyclo(His-Tyr) increased heart rate and 
ventricular pressure of isolated rat hearts 
• Cyclo(His-Tyr) prolonged blood clotting 
time, slowed clot lysis and inhibited ADP-
induced platelet adhesion and aggregation 
15 
 
• Antifungal activity 
• Cyclo(His-Tyr) also showed antibacterial 
activity 
Cyclo(Gly-Gly), cyclo(Trp-Trp) and 
cyclo(Gly-Trp)14 
 
• Inhibition of HT-29, HeLa and MCF-7 
tumour cell lines 
• Inhibition of ADP-induced platelet adhesion 
and aggregation 
• Cyclo(Trp-Trp) also inhibited thrombin-
induced platelet aggregation 
• Cyclo(Gly-Gly) and cyclo(Gly-Trp) showed 
calcium channel agonistic activity while 
calcium channel blocking activity was 
observed for cyclo(Trp-Trp) 
• Cyclo(Trp-Trp) showed antifungal activity 
Cyclo(L-Gly-L-Val) and cyclo(L-
Gly-D-Val)16 
 
• Antibacterial and antifungal activity 
• Inhibition of HT-29, HeLa and MCF-7 
tumour cell lines 
• Decreased heart rate, coronary flow rate 
and ventricular pressure of isolated rat 
hearts 
• Increased the rate and extent of thrombin 
formation 
Cyclo(Gly-Leu) and cyclo(Gly-Ile)17 
 
• Antibacterial and antifungal activity 
• Inhibition of HT-29, HeLa and MCF-7 
tumour cell lines 
• Inhibition of ADP-induced platelet 
aggregation and fibrinolysis 
• Decreased heart rate, coronary flow rate 
and ventricular pressure of isolated rat 
hearts 
 
Cyclo(L-Trp-L-Pro), cyclo(L-Trp-D- • Cyclo(L-Trp-D-Pro) and cyclo(D-Trp-L-Pro) 
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Pro), cyclo(D-Trp-L-Pro) and 
cyclo(D-Trp-D-Pro)15 
 
showed anticancer activity 
• Cyclo(L-Trp-L-Pro) and cyclo(D-Trp-L-Pro) 
inhibited Gram-positive bacteria, cyclo(L-
Trp-D-Pro) inhibited Gram-negative bacteria 
and cyclo(D-Trp-D-Pro) inhibited fungi 
• Cyclo(D-Trp-L-Pro) showed calcium 
channel blocking activity; cyclo(L-Trp-L-Pro), 
cyclo(L-Trp-D-Pro) and cyclo(D-Trp-D-Pro) 
showed calcium channel agonistic activity 
• Cyclo(L-Trp-D-Pro) showed positive 
chronotropic activity, while cyclo(D-Trp-L-
Pro) showed negative chronotropic activity of 
isolated rat hearts. Cyclo(L-Trp-D-Pro) and 
cyclo(D-Trp-L-Pro) also increased the 
coronary flow rate of isolated rat hearts 
• Cyclo(L-Trp-D-Pro) inhibited thrombin-
induced platelet aggregation. All the cyclic 
dipeptides increased ADP induced platelet 
adhesion, yet caused reduced adhesion 
when the platelets were stimulated by 
thrombin 
 
Cyclo(Gly-Thr) and cyclo(Gly-
Ser)18 
 
• Gram-negative antibacterial activity 
• Inhibition of HT-29 and HeLa tumour cell 
lines 
• Cyclo(Gly-Ser) also showed cytotoxic 
activity against MCF-7 cell lines 
• Increased fibrin and thrombin formation 
• Enhanced ADP-induced platelet 
aggregation 
• Decreased heart rate and ventricular 
pressure of isolated rat hearts 
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Cyclo(Trp-Pro) and cyclo(Pro-
Trp)19 
 
• Antifungal activity 
• Cyclo(Pro-Trp) also showed antibacterial 
activity 
• Anticancer activity 
• Cyclo(Trp-Pro) modulated delayed-rectifier 
potassium and calcium channels 
Cyclo(Leu-Ile)28 
 
• Antibacterial activity 
 
Cyclo(Arg-Lys) and cyclo(Asp-
Lys)29 
 
• Immunomodulation 
 
Cyclo(Ala-Phe)29 
 
• Anticonvulsive activity 
 
Cyclo(Phe-Phe)29 • Inhibition of cell division 
1
(Milne et al., 1998), 
2
(Prasad, 1995), 
3
(Graz et al., 1999), 
4
(Gudasheva et al., 1996), 
5
(Kilian, 
2002), 
6
(Van der Merwe, 2005), 
7
(Graz, 2002), 
8
(Pitchen, 2002), 
9
(Olivier, 2002), 
10
(Versluis, 
2002), 
11
(Jones, 2002), 
12
(Lucietto, 2004), 
13
(McCleland, 2003), 
14
(Grant, 2002), 
15
(Jamie, 2002), 
16
(Peterson, 2006), 
17
(Huang, 2006), 
18
(Cunningham, 2006), 
19
(Haywood, 2000), 
20
(Lautru et al., 
2002), 
21
(Prasad, 2001), 
22
(Prasad, 1995), 
23
(Jikihara et al., 1993), 
24
(Koskinen, 1986), 
25
(Kukla et 
al., 1985), 
26
(Morley et al., 1981), 
27
(Prasad, 1987), 
28
(Sammes, 1975), 
29
(Brauns, 2004). 
 
2.3.4. Cyclic dipeptides as drugs 
 
Even though diketopiperazines have been known for more than a century, only 
recently have 2,5-diketopiperazines attracted attention due to their biological 
properties. Their peculiar heterocyclic system found in several natural products 
constitutes a rich source of new biologically active compounds. The wide spectrum 
of their biological properties points to various therapeutic possibilities (Delaforge et 
al., 2001). 
 
Some of the most important biological activities of diketopiperazines are related to 
the inhibition of plasminogen activator inhibitor-1 (PAI-1) and alteration of 
cardiovascular and blood-clotting functions. In addition, these compounds also have 
activities as antitumour, antiviral, antifungal, antibacterial, and antihyperglycaemic 
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agents and affinities for calcium channels and opioid, GABAergic, serotoninergic 5-
HT1A and oxytocin receptors (Martins & Carvalho, 2007). 
 
Peptides are an interesting focus point for drug companies. Their role as mediators 
of key biological functions and their unique intrinsic properties make them particularly 
attractive therapeutic agents: peptides show high biological activity associated with 
low toxicity and high specificity. The benefits conferred by these characteristics 
include very little unspecific binding to molecular structures other than the desired 
target, minimization of drug-drug interactions and less accumulation in tissues 
reducing the risk of complications due to intermediate metabolites. Additionally, 
compared to small molecules, peptides offer valuable chemical and biological 
diversity on which intellectual property is still widely available. As a result, even the 
big pharmaceutical companies that traditionally focused on small molecules are 
increasingly considering peptides in their drug development strategies (Marx, 2005). 
 
Currently there are more than 40 marketed peptide drugs worldwide. There are also 
around 270 peptide drugs in clinical phase testing, and about 400 in advanced 
preclinical phases (Parmar, 2005).Table 2.3 below illustrates the advantages and 
disadvantages of peptides and proteins as therapeutic agents. 
 
Table 2.3: Advantages and disadvantages of peptides and proteins as drugs 
Advantages Disadvantages 
High activity Low oral bioavailability 
High specificity Injection required 
Little unspecific binding to molecular 
structures other than the desired target 
Less stable 
Minimization of drug-drug interactions Difficult delivery, challenge to transport 
across the membranes 
Less accumulation in tissues Challenging and costly synthesis 
Low toxicity Solubility challenges 
Often very potent Risk of immunogenic effects 
Biological and chemical diversity Cleared from body quicky 
(Adessi & Soto, 2002). 
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2.4. Halogenation of cyclic dipeptides 
 
Although recognized in small molecules for quite some time, the implications of 
halogen bonding in biomolecular systems are only now coming to light. Halogens do, 
however, play crucial roles in natural systems. The unusual chemical features of 
halogens render them very useful in designing protein inhibitors and drugs; about 
half of the molecules applied in high throughput screening are halogenated. 
Furthermore, the strength of the interactions attenuates in the order H-I > Br > Cl. A 
detailed analysis of the interactions reveals that halogen bonding interactions are 
responsible for the different conformations of the molecules at the active site 
(Yunxiang et al., 2009). 
 
Halogen bonding in biological systems seems to be weak, especially for the lighter 
halogens, while hydrogen bonding interactions of biological importance, indeed, 
have a wide range of stabilization energy (1-20 kcal/mol). However, the linear 
preference of this type of nonbonded interaction and the special chemical properties 
of halogen atoms should render halogen bonding very useful in drug design (Wang 
et al., 2007; Jurecka et al., 2006). 
 
Halogen substituents not only interact with the backbone or side chain oxygen atoms 
of peptides but also affect the conformations of parent compounds. These would 
make halogen bonding a novel or at least a potential tool for designing protein 
inhibitors and drugs. Nonetheless, the conclusions derived from the single system 
may cast some light on the important role of halogen bonds in rational drug design. 
In fact, the introduction of halogen atoms in ligands also causes many other factors 
that influence inhibitor recognition and binding, such as specificity surface and 
hydrophobic effects (Voth & Ho, 2007). 
 
2.4.1. Importance of iodine 
 
Iodine is a requisite substrate for the synthesis of thyroid hormones, the minimum 
daily requirement being about 50 micrograms. In addition to its role in reversing 
iodine deficiency, iodine is used as adjunctive therapy for hyperthyroidism. By 
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inhibiting the proteolytic release of thyronines from thyroglobulin, it induces a prompt 
slowing of thyroid hormone secretion. This effect is exploited in the treatment of 
thyrotoxic crisis or severe thyrocardiac disease. Iodine also reduces thyroid 
cellularity and vascularity and is therefore used in the preparation of the patient for 
thyroidectomy. Finally, by exploiting the failure of escape from the Wolff-Chaikoff 
effect, iodine may also be used in the early management of radioiodine-treated 
Graves' hyperthyroidism (Auffinger et al., 2004). It is therefore highly possible that 
the inclusion of iodine in cyclic dipeptides such as in cyclo(Phe-4I-Pro) may result in 
potential agents for the use against thyroid cancer. 
 
2.5. Motivation for the research 
 
No extensive studies have been undertaken to determine the biological activities 
(anticancer, antidiabetic, antimicrobial and haematological effects) of cyclo(D-Phe-4I-
Pro) and cyclo(L-Phe-4I-Pro), therefore this study will aim to investigate the 
prospective therapeutic and medicinal properties of cyclo(D-Phe-4I-Pro) and cyclo(L-
Phe-4I-Pro) as 2,5-diketopiperazines have several advantages over ordinary 
peptides i.e., higher binding affinities and a greater degree of specificity in peptide-
receptor interactions.  
 
 A possible advantage of the selected halogenated diketopiperazines, which the 
study aims to explore, is (1) improved cell membrane penetration and (2) receptor 
selectivity of the compounds. 
 
Other biological activities of phenylalanine- and proline-containing peptides are the 
following: Pro-Gly-Pro inhibited fibrin formation and blood clotting; cyclo(Pro-Trp) 
showed broad spectrum antibacterial effects against E. coli, K. pneumoniae, S. 
aureus; while cyclo(Pro-Trp) exhibited broad spectrum antifungal properties against 
B. subtilis (Graz et al., 1999). 
 
Iodine has some potential therapeutical activities which might synergise the potential 
therapeutic activities of cyclic dipeptides and it therefore necessitates the biological 
investigation of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro).  
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CHAPTER 3 
DIPEPTIDE SYNTHESIS 
 
3.1. Introduction 
 
According to literature, 2,5-diketopiperazines are useful in medicinal chemistry, 
combinatorial chemistry, and targeted organic synthesis.  In addition, these 
compounds possess interesting biological properties that need further investigation. 
2,5-diketopiperazines are synthesized by the coupling of an N-Boc-protected α-
amino acid with α-amino acid ester, followed by N-Boc deprotection (acid or base) 
and intramolecular cyclization under thermal conditions (Tom et al., 2004). 
 
Although many novel approaches have been developed to accomplish the head-to-
tial synthesis of peptides, one of the most commonly used methods is still the 
solution-phase synthesis using peptide-coupling reagents. A rational selection of 
coupling reagents can effectively improve the results of peptide cyclization (Li & 
Roller, 2002; Loughlin et al., 2000). Solution-phase cyclization of dipeptides can be 
achieved by utilising unprotected linear dipeptides or unprotected linear dipeptide 
esters (Lambert et al., 2001). 
 
Several research groups have reported an efficient method for the synthesis of DKPs 
from N-Boc-protected dipeptide esters using microwave conditions. Solvent-free 
conditions for cyclization of N-Boc-protected amino esters were used, and in few 
cases 10% silica gel was used to enhance the conversion. Tullberg et al. (2006) 
performed a comparative study between microwave and conventional heating with 
various solvents at different reaction conditions for the cyclization of dipeptide 
methylesters and found water to be an excellent solvent for the preparation of DKPs 
(Wang et al., 2009; Tullberg et al., 2006; Carlsson et al., 2006; López-Cobeñas et 
al., 2005). 
 
DKP rings may be produced without great difficulty and may also form without 
particular activation of the carboxyl groups of linear dipeptide precursors 
(Bodanszky, 1993). Kopple and Ghazarian (1968) reported an efficient method for 
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the cyclization of linear dipeptides without particular activation of their carbonyl 
groups. They described the formation of cyclic dipeptides by heating the unprotected 
linear dipeptides in phenol. This relatively fast three hour procedure produced a high 
yield of cyclic dipeptides, with little racemization. It is however necessary for at least 
one of the amino acid residues of the free linear dipeptide to be sensitive to phenol 
for the cyclization procedure to occur (Kopple and Ghazarian, 1968). Cyclization of 
some linear dipeptides may be an inherently improbable and slow process, and the 
exposure to reagents necessary for the cyclization may lead to extensive 
racemization when optically pure linear dipeptide precursors are utilized (Nitecki et 
al., 1968). This racemization can be avoided by protecting the amino and carboxyl 
terminals of the dipeptide precursors with blocking groups, which are capable of 
being selectively removed when necessary (Kopple, 1972).  
 
Among other blocking groups, tert-butyloxycarbonyl (t-Boc) has been used to protect 
the amino groups of linear dipeptide precursors (Han and Kim, 2004; Nitecki et al., 
1968; Anderson and McGregor, 1957). Nitecki et al. (1968) reported a method for the 
cyclization of the formate salts of dipeptide methyl esters. The formate salts were 
formed as a result of successful deblocking t-Boc dipeptides with formic acid (98%) 
at room temperature for 3 hours. Subsequent heating of the deblocked dipeptides in 
a neutral medium resulted in the formation of sterically pure cyclic dipeptides. This 
procedure decreased racemization and improved the yields of acid sensitive amino 
acids (Nitecki et al., 1968). 
 
3.2. Methodology 
 
The method developed by Milne et al. (1992) was adapted to generate a method to 
synthesize cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro). 
 
Three major steps are involved in the synthesis of 2,5-diketopiperazines. Firstly, the 
protected linear dipeptides are synthesized, which is followed by the removal of the 
protective t-Boc group. The final step involves the cyclization of the unprotected 
linear dipeptide in a neutral medium.  
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The protected linear dipeptides were synthesized using diethylphosphoryl cyanide 
(DEPC) as the coupling agent and triethylamine (TRI) as the base (Milne et al., 
1992). 
 
The materials used in the synthesis of the D and L isomers of cyclo(D-Phe-4I-Pro) 
and cyclo(L-Phe-4I-Pro) are tabulated in Table 3.1. 
 
The t-Boc protected 4-iodo-L/D-phenylalanine and L-Proline methyl ester 
hydrochloride were dissolved in 50 ml 1,2 dimethoxyethane (Fluka Chemika) at 0oC. 
The respective amounts of DEPC and TRI (Table 3.1) were added in a dropwise 
fashion. The entire reaction was carried out in a positive inert atmosphere. The 
reaction was stirred at 0oC for 1 hour, after which the reaction mixture was allowed to 
reach room temperature. The reaction mixture was then left at room temperature 
overnight to allow the reaction to run to completion. The reaction mixture was then 
diluted with 100 ml chloroform and isolated by successive washing with 5% HCl (50 
ml) and 5% NaHCO3 (50 ml) and saturated NaCl (50 ml). The organic phase was 
dried with Na2SO4 and protected from light.  
 
Removal of the Boc groups was achieved by the addition of 95% formic acid (20 ml) 
and 2% anisole. The solutions were stirred at room temperature for 4 hours, after 
which the reaction mixture was dried in vacuo. 
 
Table 3.1: The materials used in the synthesis of the D and L isomers of cyclo(D-Phe-4I-Pro) 
and cyclo(L-Phe-4I-Pro)   
Synthesis 
of cyclo- 
Starting 
materials 
Manufacturer Mr (g/mol) Starting 
mass (g) 
DEPC/TRI 
(ml) 
(D-Phe-4I-
Pro) 
Boc-D-Phe-
4I-OH 
Fluka 391.20 2 0.85/1.49 
 L-Proline 
methyl ester 
hydrochloride 
Fluka 165.62 0.85  
(L-Phe-4I-
Pro) 
Boc-L-Phe-
4I-OH 
Fluka 391.20 2 0.85/1.49 
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 L-Proline 
methyl ester 
hydrochloride 
Fluka 165.62 0.85  
 
 
3.2.1. Cyclization of the unprotected linear dipeptide precursors 
 
Sec-butanol and toluene (40 ml, 4:1) was added to the unprotected linear dipeptide 
esters. The mixtures were then boiled under reflux in an oil bath for 3 hours. After 3 
hours the solvent was evaporated off until about 10 ml was left. The concentrated 
solutions were then cooled to 0oC. This resulted in the precipitation of the cyclic 
dipeptides, which were then filtered off and successively washed with ether. The 
cyclic dipeptides were then recrystallized from chloroform: N-hexane (20:5). 
 
3.3. Results and discussion 
 
The percentage yields of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) are illustrated 
in Table 3.2 below. The two cyclic dipeptides were successfully synthesized and the 
method used produced high percentage yields for both cyclo(D-Phe-4I-Pro) (72%) 
and cyclo(L-Phe-4I-Pro) (70%). 
 
Table 3.2: Percentage yield of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
Isomer Yield (%) 
Cyclo(D-Phe-4I-Pro) 72 
Cyclo(L-Phe-4I-Pro) 70 
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CHAPTER 4 
PHYSICOCHEMICAL ANALYSIS 
 
The physicochemical properties of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
were determined using scanning electron microscopy, differential scanning 
calorimetry, thermogravimetric analysis and X-ray powder diffraction. High-
performance liquid chromatography and thin layer chromatography were used to 
determine their purity. 
 
4.1. Scanning electron microscopy 
 
4.1.1 Introduction 
  
Scanning electron microscopy (SEM) has long been recognized as a tool to give a 
simulated image of a surface, with a magnification range which is big enough for 
both macro- and micro-structures to be studied. The interaction of the primary 
electron beam with the surface is accompanied by the formation of a flux of 
secondary and back-scattered electrons, which are collected by detectors. 
Secondary electrons formed near the impact area of the primary electron beam are 
used to produce images with a spatial resolution closely related to the cross-
sectional area of the scanning beam of electrons. The intensity of the emitted 
electrons in a material of a given homogenous composition depends on the local 
angle of the surface to the scanning beam moderated by the probability of reaching 
the detector. The three dimensionality of a typical SEM micrograph is more 
subjective than real but there is scope for obtaining topographic information by the 
use of pairs of micrographs showing the surface from different angles or alternatively 
by using the images from differently placed detectors (Goldstein et al.,1992; Castle & 
Zhdan, 1997). 
 
4.1.2 Methodology 
 
The scanning electronmicrographs of cyclo(L-Phe-4I-Pro)) and cyclo(D-Phe-4I-Pro) 
were recorded on a Philips® XL30 Scanning Electron Microscope (Philips®, UK). A 
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portion of each respective cyclic dipeptide was mounted on carbon tags on a sample 
stub using conductive adhesive glue. The mounted specimens were then sputter 
coated with a thin layer of gold using a Novotech® SEMprep 2-sputter coater 
(Novotech®, Germany). Electronmicrographs were then recorded, showing the 
typical shape and the surface topography of the crystals (Skoog et al., 1996; Van der 
Merwe, 2005). 
 
4.1.3 Results and discussion 
 
The electronmicrographs of cyclo(L-Phe-4I-Pro) and cyclo(D-Phe-4I-Pro) are 
illustrated in Figures 4.1 to 4.4. The electronmicrographs show the shape and 
surface topography of the cyclic dipeptides. Six crystal systems are known, which 
are commonly referred to as cubic, tetragonal, orthorhombic, monoclinic, triclinic, 
and hexagonal. Crystal morphology occurs as a result of molecular arrangement. 
The molecular arrangements are predetermined for a specific polymorphic form, and 
cannot be changed provided that there are no changes in the polymorphic form. Five 
types of crystal habits are recognized, which can occur in any crystal system. The 
crystal habits are referred to as tabular (moderate expansion of two parallel faces), 
platy (plates), prismatic (columns), acicular (needle-like) and bladed (flat acicular) 
(Aulton, 2002). The crystal habit is the macromolecular appearance of a crystal. It 
depends on conditions of crystallization and can change without change in physical 
characteristics. The crystals of both cyclo(L-Phe-4I-Pro) and cyclo(D-Phe-4I-Pro) 
were obtained via identical synthetic pathways. Both cyclo(D-Phe-4I-Pro) cyclo(L-
Phe-4I-Pro) appear to form prismatic (columns) crystal habits. 
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Figure 4.1: Electronmicrograph of cyclo(D-Phe-4I-Pro) with magnification of 250x 
 
 
Figure 4.2: Electronmicrograph of cyclo(D-Phe-4I-Pro) with magnification of 2000x 
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Figure 4.3: Electronmicrograph of cyclo(L-Phe-4I-Pro) with magnification of 250x 
 
 
Figure 4.4: Electronmicrograph of cyclo(L-Phe-4I-Pro) with magnification of 2000x 
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4.2. Thermal analysis 
 
Thermal analysis means the analysis of a change in the properties of a sample, 
which is related to the imposed temperature alterations (Brown, 2001). The thermal 
analysis technique of thermogravimetry (TG) is one where the change in sample 
mass (loss or gain) is determined as a function of temperature or time (Wendlandt, 
1986). Derivative thermogravimetry (DTG) is a method of expressing the results of 
TG by giving the first derivative curve as a function of temperature or time (Dodd and 
Tonge, 1987). 
 
The development and manufacture of drugs require that close attention be paid to 
purity, quality, stability, and safety in order to ensure that the drug performs as 
intended. Pharmaceuticals or organic compounds have a propensity to exist in 
different structural or morphological forms and this gives rise to concerns over 
processing, long-term stability, aging, and biodelivery. Due to the complexity of the 
formulation of pharmaceutical materials, it becomes important to have a complete 
understanding of the properties of pharmaceutical materials. One of the best 
analytical techniques for characterization of pharmaceutical materials is thermal 
analysis. The two most widely used thermal analytical techniques for the 
characterization of pharmaceuticals are differential scanning calorimetry and 
thermogravimetric analysis (Sichina, 2001). 
 
4.2.1. Thermogravimetric analysis  
 
4.2.1.1. Introduction 
 
A simplified explanation of a thermogravimetric analysis (TGA) sample evaluation 
may be described as follows: (1) A sample is placed into a TGA sample pan which is 
attached to a sensitive microbalance assembly. (2) The sample holder portion of the 
TGA balance assembly is subsequently placed into a high temperature furnace. (3) 
The balance assembly measures the initial sample weight at room temperature and 
then continuously monitors changes in sample weight as heat is applied to the 
sample. TGA tests may be run in a heating mode at a controlled heating rate, or 
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isothermally. Dynamic TG, in which the sample is heated in an environment whose 
temperature is changing in a predetermined manner, preferably linear, is a common 
mode of TG (Brown, 2001 & Wendlandt, 1986). 
 
The resulting mass-change versus temperature curve, also known as a thermogram, 
provides information concerning the thermal stability and composition of the initial 
sample, the thermal stability and composition of any intermediate compounds that 
may be formed, and the composition of the residue, if any (Wendlandt, 1986). 
Typical weight loss profiles could therefore be analysed to determine the amount or 
percent of weight loss at any given temperature, the amount or percent of non-
combusted residue at some final temperatures, and the temperatures of various 
sample degradation processes (Brown, 2001). Mass changes which can be detected 
by TGA techniques are summarised in Figure 4.5 (Wendlandt, 1986). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Mass changes detected by TG 
 
 
         TGA 
Chemical changes Physical changes 
Sublimation 
Vaporization 
Absorption 
Desorption    
Adsorption      
 
 
 
 
Solid         Gas               
Solid1   Solid2 + Gas    
Gas + Solid1   Solid2   
Solid1 + Solid2   Gas 
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4.2.2. Differential scanning calorimetry  
 
4.2.2.1. Introduction 
 
Differential scanning calorimetry (DSC) is defined as the measure of the change of 
difference in heat flow rate of the sample and a reference sample when they are 
subject to a controlled temperature program. It measures the change of a heat flow 
rate difference, which is normally released due to an alteration of the sample 
temperature. When there is no alteration of sample temperature, no change of heat 
flow rate difference can be measured except for chemical reaction heat flow (Höhne 
et al., 2003). 
 
DSC is increasingly used in the field of quality assurance for many purposes: (1) for 
the inspection of raw materials, (2) as an accompanying measure in manufacturing 
and (3) for control of finished products (Höhne et al., 2003). 
 
DSC is one of the most widely used thermal analysis techniques for the 
characterization of pharmaceutical solids. Thermal events such as melting, 
recrystallization, decomposition, and glass transitions can be determined. 
Additionally, quantitative mixture analysis (e.g., to establish the presence of different 
polymorphs) can be performed utilising DSC. The use of modulated DSC expands 
the capabilities of DSC and allows one to measure heat capacities and characterize 
reversible/non-reversible thermal transitions (Sichina, 2001). 
 
DSC allows reaction heats and heats of transition, or heat flow rates and their 
changes at characteristic temperatures, to be quickly measured on small sample 
masses, over wide temperature ranges and with accuracy, which is usually 
sufficiently high for respective purposes. DSC is applied among others, in the 
following fields: 
• Characterization of materials 
• Comparison or relative measurement (quality control, identification of substances 
and mixtures) 
• Stability investigations 
32 
 
• Evaluation of phase diagrams 
• Purity determinations 
• Kinetic investigations 
• Safety investigations 
• Determination of heat capacity and complex heat capacity (Höhne et al., 2003). 
 
4.2.3. Methodology 
 
TGA and DSC thermograms of cyclo(L-Phe-4I-Pro) and cyclo(D-Phe-4I-Pro) were 
obtained by heating the samples in a TA instrument Q600 SDT (simultaneous DSC-
TGA) V8.1 (TA InstrumentsTM, USA). Because the samples generate large quantities 
of volatile decomposition products they were not run on the independent DSC and 
TGA instruments. The TA Instrument Q600 SDT was calibrated for temperature 
using the melting points of Indium and Tin.  Cyclo(L-Phe-4I-Pro) (5.9960 mg) and 
cyclo(D-Phe-4I-Pro) (5.4680 mg) were heated in open aluminium crucibles at a 
heating rate of 5°C per minute, over a temperature range of 50 to 400°C with 
nitrogen as the purging gas (flow rate of 50 ml per minute). 
 
4.2.4. Results and discussion 
 
The TGA thermogram (Figure 4.6) indicates a partial 100% decomposition of 
cyclo(D-Phe-4I-Pro), when heated to 400°C. Only carbon remains at 400°C, since 
the temperature required to vaporise it is too high to measure on a DSC (unless 
oxygen is present, which is not the case as nitrogen is used as the purging gas). A 
region of relative constant weight is observed for temperatures up to 200°C. The 
cyclic dipeptide is therefore stable, with no decomposition occurring, in this region. 
The region also indicates the absence of free water or waters of hydration in the 
sample, since water would have evaporated at 100°C, resulting in subsequent 
weight loss. Weight loss of the sample, however, commences just around ± 250°C 
and continues up to ± 360°C, indicating the decomposition of cyclo(D-Phe-4I-Pro). At 
± 350°C a second stage of decomposition occurs (step II). The weight loss may be 
due to physical or chemical changes which occurred at the relevant temperatures. 
Physical changes may include sublimation, vaporisation, and absorption and 
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desorption of the compound. A possible chemical change may be due to 
decomposition of the compound to yield a gas (solid1 → solid2 + gas). The purity of 
an organic substance can be estimated by DSC, based on the shape and 
temperature of the DSC melting endotherm. The melting endotherms for pure 
substances are very sharp, with a narrow overall melting range. The DSC 
thermogram for cyclo(D-Phe-4I-Pro) shows a sharp, narrow endotherm reaching a 
maximum at 196.58°C (the compound started to melt at 193.5ºC).  
 
The TGA thermogram (Figure 4.7) also indicates a partial ± 89% decomposition of 
cyclo(L-Phe-4I-Pro), when heated to 400°C. A similar region of relative constant 
weight is observed for temperatures up to 200°C. The compound is therefore also 
stable and free of water or waters of hydration throughout this region. Weight loss of 
cyclo(L-Phe-4I-Pro) commences just above 275°C and continues up to ± 347°C 
indicating decomposition of cyclo(L-Phe-4I-Pro). The DSC thermogram for cyclo(L-
Phe-4I-Pro) also shows a sharp, narrow endotherm reaching a maximum at 
203.26°C (the compound started to melt at 199.29°C). The endotherm indicates that 
cyclo(L-Phe-4I-Pro) is pure, since impurities would be evidenced by a lower and 
broader melting point. The second endotherm observed at about 348°C could be the 
result of decomposition, or a liquid to gas transition of the cyclic dipeptide that may 
occur at the higher temperature. 
 
Additionally, the TGA thermograms showed that decomposition of cyclo(D-Phe-4I-
Pro) and cyclo(L-Phe-4I-Pro) only occurred at temperatures in excess of their 
respective melting points. The high temperatures at which this decomposition was 
observed, suggests that the solid-state cyclic dipeptides have a high degree of 
thermostability. However, it is recommended that further modular thermal 
approaches should be explored to fully characterize the thermal characteristics of the 
cyclic dipeptides. 
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Figure 4.6: Simultaneous DSC-TGA thermogram of cyclo(D-Phe-4I-Pro) 
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Figure 4.7: Simultaneous DSC-TGA thermogram of cyclo(L-Phe-4I-Pro) 
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4.3. X-ray powder diffraction 
 
4.3.1. Introduction 
 
The X-ray powder diffraction (XRPD) experiment is the cornerstone of a truly basic 
materials characterization technique called diffraction analysis, and has been used 
for many decades with exceptional success to provide accurate information about 
the structure of materials (Pecharsky and Zavalij, 2005). 
 
While the broad definition of X-ray methods cover many techniques based on the 
scatter, emission and absorption properties of X-ray radiation, one of the most 
commonly used techniques are XRPD. XRPD material analysis involves 
characterization of the sample by means of atomic arrangements in the crystal 
lattice. XRPD uses single or multiphase specimens, comprising of a random 
orientation of small crystallites, each in the order of 1-50 mM in diameter. Each 
crystallite, in turn, is made up of a regular, ordered array of atoms. An ordered 
arrangement of atoms (the crystal lattice) contains planes of high atomic density. A 
monochromatic beam of X-ray photons will be scattered by these atomic electrons 
and if the scattered photons interfere with each other, diffraction maxima may occur. 
A diffraction pattern is typically in the form of a graph of diffraction angle (or 
interplanar spacing) against diffracted line intensity. The pattern is made up of a 
series of superimposed diffractograms, one for each unique phase in the specimen. 
Each of these unique patterns can act as an empirical „„fingerprint‟‟ for the 
identification of the various phases (Meyers, 2000). 
 
The possibility of using a diffraction pattern as a means of phase identification was 
recognized many years ago but it was not until the late 1930s that a systematic 
means of unscrambling the superimposed diffraction patterns was proposed. The 
technique was based on the use of a file of single phase patterns, characterized in 
the first stage by their three strongest reflections and a search technique based on 
matching strong lines in the unknown pattern with these standard pattern lines. A 
potential match was then confirmed by a check using the full pattern in question. The 
identified pattern was then subtracted from the experimental pattern and the 
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procedure repeated on the residue pattern until all lines were identified (Meyers, 
2000). 
 
Although powder data usually lack the three-dimensionality of a diffraction image, the 
fundamental nature of the method is easily appreciated from the fact that each 
powder diffraction pattern represents a one-dimensional snapshot of the three-
dimensional reciprocal lattice. The quality of the powder diffraction pattern is usually 
limited by the nature and the energy of the available radiation, by the resolution of 
the instrument and by the physical and chemical conditions of the specimen 
(Pecharsky and Zavalij, 2005). 
 
For phase identification of a sample, a powder diffraction database or at least its 
subset should thus be available in addition to a suitable search-and-match algorithm. 
The most complete and most often used powder diffraction database is the Powder 
Diffraction FileTM (PDF), which is maintained and periodically updated by the 
International Centre for Diffraction Data (ICDD®). Searches may also be carried out 
using several different existing databases that are, however, not as comprehensive 
as the PDF (Pecharsky and Zavalij, 2005). 
 
Of all the methods available to the analytical chemist, only X-ray radiation is capable 
of providing general purpose qualitative and quantitative information on the presence 
of phases in an unknown mixture. A diffraction pattern contains a good deal of 
information of which three parameters are of special interest:  
• The position of the diffraction maxima. 
• The peak intensities. 
• The intensity distribution as a function of diffraction angle. 
These three pieces of information can, in principle, be used to identify and quantify 
the contents of the sample, as well as to calculate the material‟s crystallite size and 
distribution, crystallinity, stress and strain (Meyers, 2000). 
 
The role of XRPD for identification of unknown chemicals is limited in the 
pharmaceutical industry, since there are numerous techniques available for 
determining the molecular structure of organic molecules. The techniques of mass 
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spectrometry and nuclear magnetic resonance are dominant in this role. On the 
other hand, due to its speed of data acquisition and sensitivity, XRPD exists as the 
primary tool for phase identification (Stephenson, 2005; Beckers, 2004). 
 
4.3.2. Methodology 
 
XRPD patterns of cyclo(L-Phe-4I-Pro) and cyclo(D-Phe-4I-Pro) were obtained by 
using an Bruker Advanced Solutions XRD Commander (DiffracPlus Version 2.3) 
diffractometer (Bruker Advanced Solutions, Germany), and the resultant diffraction 
patterns were interpreted using Bruker Advanced X-ray Solutions Eva software 
(DiffracPlus Version 10.0 Rev.1). n-Hexane (BDH Laboratory Supplies, England) 
was used as a wetting agent, which enabled small samples of the cyclic dipeptides 
to adhere to silicon plates, without causing dissolution of the compounds. The silicon 
plates were then placed within the X-ray powder diffractometer and scanned for 1 
hour. 
 
4.3.3. Results and discussion 
 
The XRPD patterns of cyclo(L-Phe-4I-Pro) and cyclo(D-Phe-4I-Pro) are illustrated in 
Figures 4.8 and 4.9, respectively. Determining the phase composition of the cyclic 
dipeptides was not possible, since none of the powder diffraction databases 
available included experimental diffraction patterns to which the compounds could be 
compared. Since the obtained Bragg angles and intensities of the cyclo(L-Phe-4I-
Pro) and cyclo(D-Phe-4I-Pro) have no known match, the collected data can 
potentially be used as a “fingerprint” to identify new crystalline substances. The 
identity of the cyclic dipeptides should, however, firstly be confirmed through 
structural elucidation to ensure that it is not a mixture of compounds. 
 
From the diffraction patterns of both cyclo(L-Phe-4I-Pro) and cyclo(D-Phe-4I-Pro)  it 
can be seen that it is not crystalline solids, since the curve of scattered intensity is 
not zero anywhere. The atoms in amorphous structures also show preference for a 
particular interatomic distance, resulting in X-ray diffractograms exhibiting various 
broad maxima. The curves of scattered intensity for cyclo(L-Phe-4I-Pro) showed 
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unmodified scaterring with almost the same wavelength in most of the curves, where 
as cyclo(D-Phe-4I-Pro) showed modified scattering with different wavelengths. 
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Figure 4.8: X-ray powder diffraction pattern of cyclo(L-Phe-4I-Pro) 
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Figure 4.9: X-ray powder diffraction pattern of cyclo(D-Phe-4I-Pro) 
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4.4. Purity determination of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
 
High-performance liquid chromatography (HPLC) and Thin layer chromatography 
(TLC) were used to determine the purity of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-
Pro). 
 
4.4.1. High-performance liquid chromatography 
 
4.4.1.1. Introduction 
 
High-performance liquid chromatography (HPLC) is now firmly established as the 
premier technique for analysis and purification of a wide range of molecules. HPLC 
in its various modes has become the central technique in the characterization of 
peptides and proteins and has therefore played a critical role in rapid advances in 
the biological and biomedical sciences over the last ten years (Aguilar, 2004). HPLC 
is the premier analytical technique in pharmaceutical analysis and is predominantly 
used in the pharmaceutical industry (Ahuja & Dong, 2005). 
 
The enormous success of HPLC can be attributed to a number of inherent features 
associated with reproducibility, ease of selective manipulation, and generally high 
recoveries. The most significant feature is the excellent resolution that can be 
achieved under a wide range of conditions for very closely related molecules as well 
as structurally quite distant molecules. This arise from the fact that all interactive 
modes of chromatography are based on recognition forces that can be subtly 
manipulated through changes in the elution conditions that are specific for particular 
modes of chromatography (Aguilar, 2004). 
 
HPLC is used in analytical development to quantitate the active pharmaceutical 
ingredient (API) and to evaluate impurity and degradation product profiles of drug 
substances and drug products. Additional uses of HPLC include the determination of 
content uniformity of dosage forms, monitoring of dissolution profiles, determination 
of antioxidant and microbial preservative content, and to support cleaning 
evaluations (Ahuja & Dong, 2005). 
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To understand the fundamentals of HPLC we must first look at what chromatography 
entails. Chromatography is a separation process in which the sample mixture is 
distributed between two phases in the chromatographic bed (column or plane). One 
phase is stationary whilst the other passes through the chromatographic bed. The 
stationary phase is either a solid, porous, surface active material in small-particle 
form or a thin film of liquid coated on a solid support or column wall. The mobile 
phase is a gas or liquid. If a gas is used, the process is known as gas 
chromatography (GC); the mobile phase is always liquid in all types of liquid 
chromatography (LC) (Meyer, 2004). 
 
The „inventors‟ of modern chromatography, Martin and Synge, were aware as far 
back as 1941 that, in theory, the stationary phase requires very small particles and 
hence a high pressure is essential for forcing the mobile phase through the column 
(Meyer, 2004). 
 
HPLC is thus a physical separation technique conducted in the liquid phase in which 
a sample is separated into its constituent components (or analytes) by distribution 
between the mobile phase (i.e., a flowing liquid) and a stationary phase (i.e., 
adsorbents packed inside a column). An online detector monitors the concentration 
of each separated component (or contaminant) in the column effluent and generates 
a chromatogram (Ahuja and Dong, 2005). 
 
Reverse phase chromatography (RPC) is a method in which molecules are bound 
via hydrophobic interactions to a very non-polar stationary phase in the presence of 
a relatively polar mobile phase. Thus, since the stationary phase (in RPC) is a non-
polar entity, the mobile phase must be more polar to allow retention of the analytes. 
RPC is arguably the most commonly used method for separation of peptides. The 
three-dimensional structure of proteins can be sensitive to often harsh conditions 
employed in RPC and as a consequence, RPC is employed less often for isolation of 
proteins where it is important to recover the protein in a biologically active form 
(Aguilar, 2004). 
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HPLC is extremely versatile for isolation of peptides and proteins from a wide variety 
of synthetic or biological sources. The number of applications of HPLC in peptides 
and protein purification continue to expand at an extremely rapid rate (Aguilar, 2004). 
 
4.4.1.2. Methodology 
 
2 mM stock solutions of cyclo(L-Phe-4I-Pro) and cyclo(D-Phe-4I-Pro) were prepared. 
All chemicals used were either of analytical or HPLC grade. Water required for 
analysis was obtained from an Ultra Clear TWF UF TM Reverse Osmotic water 
purification system SG®. The following mobile phases were used: (acetonitrile (32%) 
and water (68%)) for cyclo(L-Phe-4I-Pro) and (acetonitrile (31%) and water (69%)) 
for cyclo(D-Phe-4I-Pro). 
 
4.4.1.3. Results and discussion 
 
The HPLC chromatograms of both cyclo(L-Phe-4I-Pro) and cyclo(D-Phe-4I-Pro) are 
shown in Figures 4.10 and 4.11 respectively. The HPLC chromatograms of both 
cyclic dipeptides show single peaks with high resolution, indicating that the cyclic 
dipeptides were free from impurities. The observed retention time (tR) for cyclo(L-
Phe-4I-Pro) and cyclo(D-Phe-4I-Pro) was 5.4 and 7.4 minutes respectively, 
indicating different retention times. The (tR) for cyclo(D-Phe-4I-Pro) is much longer 
than that of cyclo(L-Phe-4I-Pro) indicating that cyclo(D-Phe-4I-Pro) is more 
hydrophobic than cyclo(L-Phe-4I-Pro) as cyclo(D-Phe-4I-Pro) associates more 
readily with the non-polar stationary phase. 
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Figure 4.10: HPLC chromatogram of cyclo(L-Phe-4I-Pro) (tR = 5.4 min) at a UV detection 
wavelength of 220 nm 
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Figure 4.11: HPLC chromatogram of cyclo(D-Phe-4I-Pro) (tR = 7.4 min) at a UV detection 
wavelength of 220 nm 
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4.4.2. Thin layer chromatography 
 
4.4.2.1. Introduction 
 
Thin layer chromatography (TLC) has been regarded traditionally as a simple, rapid 
and inexpensive method for separation, identification and visual semiqualification of 
a wide variety of substances. It is a method of liquid chromatography in which the 
sample is applied as a single spot to the origin of a thin sorbent layer supported by a 
glass, plastic or metal plate. The mobile phase moves through the stationary phase 
by capillary action, sometimes assisted by gravity or pressure. TLC separations take 
place in the “open” layer or (“open bed”), with each component having the same total 
migration time but different migration distances (Fried & Sherma, 2005). 
 
The mobile phase in TLC consists of a single solvent or a mixture of organic and/or 
aqueous solvents. A number of sorbents have been used, such as: silica gel, 
cellulose, alumina, polyamides, ion exchangers and chemically bonded polar or non-
polar phases. The sorbents are coated onto a suitable support such as: glass plate, 
polyester or aluminium sheets. The wide variety of available mobile and stationary 
phases provides a considerable versatility in choosing a system for resolution of 
virtually all types of compounds (Fried & Sherma, 2005). 
 
The basic procedure for TLC consists of the following steps: 
 The sample solution is applied to the TLC plate baseline (1 cm from the bottom of 
the plate (100 µL)) as a spot 
 The sample solvent is allowed to dry or evaporate 
 The plate is placed in a closed chamber containing a shallow pool of mobile 
phase on the bottom 
 The mobile phase rises by capillary action through the applied spot 
 Development is continued until the solvent front is about 10-15 cm from the top of 
the plate 
 The plate is removed from the chamber and the solvent front is marked 
 The mobile phase is removed from the plate by drying the plate in air or by using 
heat 
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 If the compounds are not naturally coloured or fluorescent, a detection reagent is 
applied to visualize the zones 
 The positions of the zones are used for qualitative identification of compounds 
and the size or intensity of the zones for quantification (Fried & Sherma, 2005). 
 
4.4.2.2. Methodology 
 
TLC of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) was performed on silica-gel 
plates (Silica gel 60 F254, Merck, Germany) using chloroform-methanol-acetic acid 
(C-M-A) (14:2:1) or chloroform-methanol (C-M) (7:3) as mobile phase. The TLC 
plates were then put  in tanks containing iodine (SAARCHEM (PTY) Ltd, SA) or read 
directly using UV light (254 nm). 
 
4.4.2.3. Results and discussion 
 
Table 4.1 illustrates the Rf values of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) in 
different solvent systems. The Rf values were 0.80 (C-M) and 0.91 (C-M-A) for 
cyclo(D-Phe-4I-Pro), and 0.78 (C-M) and 0.89 (C-M-A) for cyclo(L-Phe-4I-Pro). No 
signs of unwanted by-products were visualized. 
 
Table 4.1: The Rf values of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) in two different solvent 
systems  
Solvent system Cyclo(D-Phe-4I-Pro) Cyclo(L-Phe-4I-Pro) 
Chloroform:Methanol (7:3) 0.80 0.78 
Chloroform:Methanol:acetic 
acid (14:2:1) 
0.91 0.89 
 
 
 
 
 
 
 
47 
 
CHAPTER 5 
STRUCTURAL ELUCIDATION 
 
Structural and conformational analyses of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-
Pro) were performed using infrared spectroscopy, mass spectrometry, nuclear 
magnetic resonance spectroscopy and molecular modelling and computational 
chemistry. 
 
5.1. Infrared spectroscopy 
 
5.1.1. Introduction 
 
Infrared (IR) spectroscopy is one of the most important analytical techniques 
available to scientists. One of the great advantages of IR spectroscopy is that 
virtually any sample may be studied in any state. Liquids, solutions, pastes, powders, 
films, fibers, gases, and surfaces can all be examined with a judicious choice of 
sampling techniques. The sampling procedure used in IR spectroscopy depends 
very much on the type of sample to be examined. IR spectroscopy has been 
extensively used in both qualitative and quantitative pharmaceutical analysis. 
Although nuclear magnetic resonance spectroscopy and mass spectrometry are 
widely used in the pharmaceutical industry for the identification of drug substances, 
IR spectroscopy can provide valuable additional structural information, such as the 
presence of certain functional groups (Stuart, 2004). 
 
The basic theory of IR spectroscopy includes the vibrations of molecules that are 
crucial to the interpretation of IR spectra. An IR spectrum is commonly obtained by 
passing IR radiation through a sample and determining what fraction of the incidence 
radiation is absorbed at a particular energy. The energy at which any peak in an 
absorption spectrum appears corresponds to the frequency of a vibration of a part of 
a sample molecule (Stuart, 2004). 
 
Fourier-transform infrared (FTIR) spectroscopy is based on the idea of the 
interference of radiation between two beams to yield an interferogram. The latter is a 
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signal produced as a function of the change of pathlength between the two beams. 
The two domains of distance and frequency are interconvertible by the mathematical 
method of Fourier-transformation. The radiation emerging from a source is passed 
through an interferometer to the sample before reaching a detector. Upon 
amplification of the signal, in which high-frequency contributions have been 
eliminated by a filter, the data are converted to digital form by an analogue-to-digital 
converter and transferred to the computer for Fourier transformation. FTIR 
instruments have several significant advantages over older dispersive instruments. 
Two of these are the Fellgett (or multiplex) advantage and the Jacquinot (or 
throughput) advantage. The Fellgett advantage is due to an improvement in the 
signal-to-noise ratio (SNR) per unit time, proportional to the square root of the 
number of resolution elements being monitored simultaneously. In addition, due to 
the fact that FTIR spectroscopy does not require the use of a slit or other restrictive 
devices, the total source output can be passed through the sample continuously. 
This results in a substantial gain in energy at the detector, hence translating to 
higher signals and improved SNRs. This is known as the Jacquinot advantage. 
Another strength of FTIR spectroscopy is its speed advantage, making it possible to 
obtain spectra on a millisecond timescale (Stuart, 2004). 
 
The infrared spectrum can be divided into three main regions: the far-infrared (<400 
cm-1), the mid-infrared (400 – 4000 cm-1) and the near-infrared (4000 – 13000 cm-1). 
Many infrared applications employ the mid-infrared region, but the near- and far-
infrared regions also provide important information about certain materials. Generally 
there are less infrared bands in the 1800 – 4000 cm-1 region with many bands 
between 400 cm-1 and 1800 cm-1 (Stuart, 2004). 
 
5.1.2. Methodology 
 
The infrared spectra of cyclo(D-Phe-4I-Pro) and cyclo(L-D-Phe-4I-Pro) were 
recorded on a Shimadzu® Fourier-transform Infrared (FTIR-1800S) 
Spectrophotometer (Shimadzu® Corporation, Japan). Approximately 1 mg of each 
cyclic dipeptide, dried in a dessicator, was mixed with approximately 100 mg of dry, 
powdered, spectral grade potassium bromide (Merck, SA). The mixture was then 
49 
 
ground using an agate mortar and pestle. A Perkin Elmer® Bench Press, set at a 
pressure of 1 x 104 kg.cm-2, was then used to press the powder mixture into a thin 
transparent disc. The infrared spectra of the two cyclic dipeptides were then 
recorded within the frequency range of 4000 cm-1 to 400 cm-1. 
 
5.1.3. Results and discussion 
 
The IR spectra for cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) are illustrated in 
Figures 5.1 and 5.2, respectively. The main functional groups found in cyclo(D-Phe-
4I-Pro) and cyclo(L-Phe-4I-Pro) were identified by comparing the peaks obtained 
from the IR spectra with the observed reference values from literature, shown in 
Table 5.1. 
 
Table 5.1: IR absorption bands (cm
-1
) of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
Infrared 
absorption bands 
Observed bands 
according to 
literature 
Cyclo(D-Phe-4I-
Pro) 
Cyclo(L-Phe-4I-
Pro) 
Amide 1 (C=O 
stretch) 
cis 1670-16901 
trans  1650  
1656.9 1674.27 
Amide 11 (NH in-
plane vibration) 
cis 1420-14601 
trans 1480-1575 
1485.24 1437.02 
Amide 111 cis  1300-1350
1 1307.78 1330.93 
NH bending 14501 1452.45 1456.30 
NH stretching cis 3180-3195 
trans 3350 
3369.75 3161.43 
CN stretching 13501 1334.78 1342.50 
C=O (stretching) 
and NH 
(bending 
vibrations) 
31001 3095.85 3090.07 
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CH2 bending 1468
1 1452.45 1456.30 
CH2 wagging 1340
1 1334.78 1342.50 
CH2 rocking 998
1 1008.8* 987.59 
C=O in-plane 
bending 
8061 802.41 806.27 
C-H 2960-28502 2972.40 2972.40* 
C-N 1030-12301 1045.45 1120.68 
Cis or trans-amide 
bond 
 Trans  cis 
* 
Indicate the bands of modes that are indistinguishable from each other, due to Overlaysping of 
modes within the outlined regions. 1. Van der Merwe, 2005; McCleland, 2003; Sammes, 1975. 2. 
Ovchinnikov & Ivanov, 1975.  
 
The presence of secondary amide and carbonyl groups together with the absence of 
carboxylic acid groups was necessary to confirm that the diketopiperazine (DKP) 
rings were present in the structure of the cyclic dipeptides and that cyclization 
therefore had occurred during the synthesis of the compounds. 
 
According to literature, secondary amide functional groups will show N-H stretching 
absorption bands between 3180 – 3195 cm-1 (cis) and 3350 cm-1 (trans), with 
carbonyl stretching (Amide I) absorption bands being observed between 1650 cm-1 
(trans) and 1670 – 1690 cm-1 (cis) (Stuart, 2004; Sammes, 1975). The amide II band 
for secondary amide groups is due to the coupling of N-H bending and C-N 
stretching and appears between 1420 – 1460 cm-1 (cis) and 1480 – 1575 cm-1 (trans) 
(Ovchinnikov and Ivanov, 1975). A weak band which is an overtone of the amide II 
band also appears between 650 cm-1 and 750 cm-1 (Stuart, 2004). 
 
The presence of secondary amide groups in cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-
4I-Pro) are confirmed by the presence of N-H stretching absorption bands at 3369.75 
cm-1 for cyclo(D-Phe-4I-Pro) and 3161.43 cm-1 for cyclo(L-Phe-4I-Pro). CN stretching 
was observed at 1334.78 cm-1 for cyclo(D-Phe-4I-Pro) and 1342.50 cm-1 for cyclo(L-
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Phe-4I-Pro), while the amide II bands occurred at 1485.24 cm-1 for cyclo(D-Phe-4I-
Pro) and 1437.02 cm-1 for cyclo(L-Phe-4I-Pro).  
 
The CH2 bending vibration is also present within the amide II mode, and since only a 
single absorption band appears in this range, it is difficult to determine the presence 
of each mode. CH2 rocking is observed at 1008.8 cm
-1 and 987.59 cm-1 for cyclo(D-
Phe-4I-Pro) and for cyclo(L-Phe-4I-Pro) respectively. 
 
IR spectroscopy allows for the discrimination betweem cis- and trans-amide bonds 
(Ovchinnikov & Ivanov, 1975). The absence of the 1420-1460 cm-1 and 1676-1690 
cm-1 bands of cyclo(D-Phe-4I-Pro) gives a strong indication that cyclo(D-Phe-4I-Pro) 
is in the trans-conformation. 
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Figure 5.1: Infrared spectrum of cyclo(D-Phe-4I-Pro) 
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Figure 5.2: Infrared spectrum of cyclo(L-Phe-4I-Pro) 
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5.2. Mass spectrometry 
 
5.2.1. Introduction 
 
Over the past decade, mass spectrometry (MS) has undergone tremendous 
technological improvements, allowing for its application to proteins, peptides, 
carbohydrates, DNA, drugs, and many other biologically relevant molecules 
(Siuzdak, 2005). 
 
MS has a strong history in drug-metabolite analysis and has recently emerged as the 
foremost technology in endogenous metabolite research. The advantages of mass 
spectrometry include a wide dynamic range, the ability to observe a diverse number 
of molecular species, and reproducible quantitative analyses. These attributes are 
important in addressing the issue of metabolite profiling, as the dynamic range easily 
exceeds nine orders of magnitude in biofluids, and the diversity of species ranges 
from simple amino acids to lipids to complex carbohydrates. The goals of the 
application of mass spectrometry range from basic biochemistry to clinical biomarker 
discovery but the challenges faced are in generating a comprehensive profile, data 
analysis, and structurally characterizing physiologically important metabolites (Want 
et al., 2005). 
 
MS is a technique for measuring the mass, and therefore the molecular weight 
(MW), of a molecule. In addition, it is often possible to gain structural information 
about a molecule by measuring the masses of the fragments produced when 
molecules are broken apart (McMurry, 2000).  
 
Fast atom ion bombardment, or FAB, is an ionisation source that uses a matrix and a 
highly energetic beam of particles to desorb ions from a surface. FAB is a soft 
ionisation source that requires the use of a direct insertion probe for sample 
introduction and a beam of xenon neutral atoms or cesium ions to sputter the sample 
and matrix from the direct insertion probe surface. It is common to detect matrix ions 
in the FAB spectrum as well as the protonated or cationised molecular ion of the 
analyte of interest. The FAB matrix is typically a nonvolatile liquid material that 
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serves to constantly replenish the surface with new samples as it is bombarded by 
the continuous incident ion beam. By absorbing most of the incident energy, the 
matrix also minimises sample degradation from the high-energy particle beam. Two 
of the most common matrices used with FAB are m-nitrobenzyl alcohol and glycerol. 
The fast atoms or ions impinge on or collide with the matrix causing the matrix and 
analyte to be desorbed into the gas phase. The sample may already be charged and 
get transferred into the gas phase by FAB, or it may become charged during FAB 
desorption through reactions with surrounding molecules or ions. Once in the gas 
phase, the charged molecules can be propelled electrostatically to the mass 
analyser (Siuzdak, 2005). 
 
Because of the emerging importance of small peptides and peptidomimetics as novel 
pharmacotherapeutics, establishing the mechanisms of fragmentation is an 
important experimental objective for pharmacological and toxicity studies with these 
classes of compounds (Henczi & Weaver, 1995). The possible fragmentation 
pathway for both cyclic dipeptides and protonated DKPs are shown in Figures 5.3 
and 5.4 respectively. 
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Figure 5.4: Possible fragmentation pathways for protonated DKPs (Sammes, 1975) 
 
 
5.2.2. Methodology 
 
The FAB mass spectra for cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) were 
recorded on a VG-7070E spectrometer (Biotech, UK) equipped with a VG2035 data 
system. All samples were run under positive ion operating conditions. The cyclic 
dipeptides were disolved in deuterated dimethylsulphoxide (DMSO-d6) and 3-
Nitrobenzyl alcohol was used as the matrix.  
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5.2.3 Results and discussion 
 
The mass spectra of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) are illustrated in 
Figures 5.5 and 5.6, respectively. Cyclic dipeptides are simple DKPs which 
consistently produce characteristic mass spectral fragmentation pathways (Sammes, 
1975).  
 
Possible fragmentation pathways of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) are 
illustrated in Figure 5.7. 
 
Table 5.2: Summary data of molecular formulas, observed and calculated mass for cyclo(D-
Phe-4I-Pro) and cyclo(L-Phe-4I-Pro). 
Compound Mol. Formula Calculated Mass Observed mass 
Cyclo(D-Phe-4I-Pro) C14H15IN2O2 371.02566 371.025601 
Cyclo(L-Phe-4I-Pro) C14H15IN2O2 371.02566 371.025713 
 
The parent ion of m/e 371 is indicative of the protonated molecular mass of cyclo(D-
Phe-4I-Pro) and cyclo(L-Phe-4I-Pro), i.e., [C14H16N2O2I]
+. The parent ion has a 
calculated saturation index of 8. The saturation index gives the number of rings 
and/or double bonds that the molecule possesses and is calculated from the 
molecular formula. The saturation index can be calculated as follows: working from 
the general formula CxHyNzOn, the total number of rings and/or double bonds = x - ½ 
y + ½ z + 1, where x represents the number of carbons, y the number of hydrogens 
and z the number of nitrogens. The number of oxygens present plays no part in 
determining the saturation index (Van der Merwe, 2005). Thus for cyclo(L-Phe-4I-
Pro)/cyclo(D-Phe-4I-Pro) (C14H16N2O2I)
+, the saturation index will therefore equals 
14 - ½(16) + ½(2) + 1, which calculates to 8 and corresponds to the total number of 
rings and double bonds in the structure. 
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Figure 5.5: Mass spectrum of cyclo(D-Phe-4I-Pro) 
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Figure 5.6: Mass spectrum of cyclo(L-Phe-4I-Pro) 
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5.3. Nuclear magnetic resonance spectroscopy 
 
5.3.1. Introduction 
 
Nuclear magnetic resonance (NMR) spectroscopy is a powerful, nondestructive 
technique capable of complete structural and conformational analyses of complex 
molecules, quantitative analysis of complex mixtures, and noninvasive measurement 
of reaction rates of chemical systems in the test tube and in intact living organisms, 
including humans (Smith & Blandford, 1995). 
 
NMR refers to the absorption and release of radio frequency (rf) energy by a nucleus 
in a magnetic field. Possession of both charge and spin renders some nuclei 
magnetic and confers various properties on them which affect their behaviour in an 
external magnetic field. One such property is a magnetic moment (µ). In an external 
magnetic field (B0), the magnetic moment of a spinning nucleus will describe a cone, 
around the direction of the field. The precessional frequency of a particular nucleus 
is proportional to the strength of the magnetic field (Smith & Blandford, 1995). 
 
Nuclear magnetic resonance (NMR) spectroscopy has long been an important tool in 
the pharmaceutical sciences. Its initial role, which began soon after NMR 
spectrometers became commercially available, was to identify and characterize 
chemically synthesized drugs, or biologically active molecules derived from a variety 
of natural sources. Today, NMR remains a premier method for the structural 
characterization of pharmaceutical compounds. The development of methodologies 
for assigning and determining the structures of peptides and proteins by two-
dimensional NMR has made possible, a variety of new applications in the field of 
drug design (Abraham and Mobli, 2004; Craik, 1996; Günther, 1995). 
 
1H NMR spectra offer three important parameters which can be extracted, the 1H 
chemical shift (δ), the 1H-1H coupling constants (nJH,H; n = number of intervening 
bonds, generally 2-4), and the signal intensity (integral) (Duddeck et al., 1989). 
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The 13C DEPT spectrum contains only signals arising from carbons. In more 
advanced applications, the 13C DEPT experiment can be used to separate the 
signals arising from carbons in CH3, CH2 and CH groups (Field et al., 1995). 
 
For 1H and 13C NMR spectroscopy tetramethylsilane (TMS) is the usual standard 
reference solvent for establishing the zero point of the δ scale (internal or external 
standard) (Hesse et al., 1997). 
 
The availability of high-quality shielded gradients for high resolution NMR has 
provided new approaches to attain coherence selection and water suppression. 
Gradient techniques hold promise particularly for heteronuclear 1H detected 
experiments e.g., Heteronuclear Multiple Quantum Coherence (HMQC) (shows 
correlation between carbons and protons directly bonded to each other) and 
Heteronuclear Single Quantum Coherence (HSQC), where coherence of protons not 
bound to the heteronucleus is usually canceled by subtraction in consecutive scans. 
Gradient techniques can select the desired coherence-transfer (Vuister et al., 1991). 
 
The Heteronuclear Multiple Bond Correlation (HMBC) experiment is the most 
powerful NMR technique for structural studies of complex natural occurring products 
and it is highly sensitive if the 1H signals to be observed are sharp. HMBC 
experiments provide correlations between protons and carbons over two and three 
bonds (Furihata & Seto, 1995). 
  
The two-dimensional correlated spectroscopy (COSY) is used for measurements of 
proton-proton spin-spin coupling constants in protein 1H NMR spectra. Compared to 
other techniques used for studies of spin-spin coupling constants, COSY provides 
greatly improved spectral resolution (Marion & Wüthrich, 2004). 
 
5.3.2. Methodology 
 
The 1H (300.13 MHz) and 13C (75.48 MHz) NMR spectra for cyclo(D-Phe-4I-Pro) and 
cyclo(L-Phe-4I-Pro) were recorded on a Bruker AMS 300 spectrometer (Bruker, 
Germany). COSY, HSQC, and HMQC spectra were also recorded for the 
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assignment of the proton to proton, and proton to carbon couplings within the 
respective cyclic dipeptides. Cyclic dipeptide solutions were prepared using DMSO-
d6 (Merck, Germany) as the solvent. TMS was used as the internal standard, 
specified at 0 parts per million (ppm), for the determination of chemical shifts.  
 
5.3.3. Results and discussion 
 
The assignment of the 1H and 13C data for the cyclic dipeptides, are illustrated in 
Tables 5.3 and 5.4. NMR results were recorded as shifts in ppm and the recorded 
NMR spectra are presented in Figures 5.8 to 5.19. 
 
Table 5.3: NMR data of cyclo(D-Phe-4I-Pro) (DMSO-d6) 
1H NMR  (chemical shift-ppm) 13C NMR  (chemical shift-ppm) 
1.50 (t) Pro-β 22.4 (t) Pro-γ 
1.75 (m) Pro-γ 28.3 (t) Pro-β 
2.04 (m) Pro-β 35.0 (t) Phe-β 
3.00 (m) Phe-β 45.1 (t) Pro-δ 
3.28 (m) Pro-δ 55.9 (d) Phe-α 
3.39 (m) Pro-δ 58.9 (d) Pro-α 
4.09 (distorted t) Pro-α 92.8 (s) Phe-Ar 
4.36 (t) Phe-α 132.8 (q) Phe-Ar 
7.10 (d) Phe-Ar 137.1 (d) Phe-Ar 
7.62 (d) Phe-Ar  137.6 (dd) Phe-Ar 
8.09 (s) Phe-NH) 165.4 (s) Pro-C=O 
 169.7 (s) Phe-C=O 
s = singlet, d = doublet, t = triplet, m = 
multiplet, quartet = q, dd = doublet of 
doublets 
 
 
From the 1H-NMR spectrum of cyclo(D-Phe-4I-Pro) (Figure 5.8), the Pro-β and Pro-δ 
protons are non-equivalent as they resonate at 1.50 ppm and 2.04, 3.28 ppm and 
3.39 ppm respectively indicating that the one β-proton and one δ-proton are more 
shielded (Table 5.3). The Pro-γ and Phe-β protons resonate at 1.75 ppm and 3.00 
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ppm respectively. The Pro-α proton resonates upfield at 4.09 ppm compared with the 
Phe-α proton which resonate at 4.36 ppm, indicating greater deshielding of the Phe-
α proton. The aromatic protons (Phe-Ar) and the Phe-NH proton resonate far 
downfield at 7.10, 7.62 and 8.09 ppm respectively (Figure 5.8 and Table 5.3). 
 
From the 13C-NMR spectrum of cyclo(D-Phe-4I-Pro), (Figures 5.9 & 5.10), the Pro-α 
carbon resonates downfield at  58.9 ppm compared with the Phe-α carbon which 
resonates at 55.9 ppm. The Pro-γ, Pro-β, Phe-β and Pro-δ carbons resonate at 22.4 
ppm, 28.3 ppm, 35.0 ppm and 45.1 ppm respectively (Figure 5.10 and Table 5.3). 
 
The carboxyl groups resonate far downfield at 165.4 ppm and 169.7 ppm, while the 
aromatic carbons also resonate downfield at 92.8 ppm, 132.8 ppm, 137.1 ppm and 
137.6 ppm respectively. 
 
Table 5.4: NMR data of cyclo(L-Phe-4I-Pro) (DMSO-d6) 
1H NMR  (chemical shift-ppm) 13C NMR  (chemical shift-ppm) 
1.65 (m) Pro-β, Pro-γ 21.9 (t) Pro-γ 
1.81 (m) Pro-γ  29.0 (t) Pro-β 
2.03 (m) Pro-β 39.2 (t hidden under DMSO peak) Phe-β 
2.67 (dd) Phe-β 45.3 (t) Pro-δ 
2.95(dd) Phe-β 57.8 (d) Phe-α 
3.25 (m) Pro-δ 58.3 (d) Pro-α  
3.35 (m) Phe-α 93.3 (s) Phe-Ar 
3.45 (m) Pro-δ 132.6 (q) Phe-Ar 
3.93 (dd) Pro-α 136.6 (m) Phe-Ar 
6.57 (d ) Phe-Ar 137.5 (dd) Phe-Ar 
7.65 (d) Phe-Ar  165.1 (s) Pro-C=O 
8.17 (d) Phe-NH) 168.8 (s) Phe-C=O 
s = singlet, d = doublet, t = triplet, m = 
multiplet, dd = doublet of doublet, q = 
quartet 
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The 1H-NMR spectrum of cyclo(L-Phe-4I-Pro) (Figure 5.14) shows that the Pro-β and 
Pro-δ protons are non-equivalent as they resonate at 1.65 ppm and 2.03 ppm; 3.25 
ppm and 3.45 ppm respectively indicating that the one β-proton and one δ-proton are 
more shielded. The Pro-γ and Phe-β protons resonate at 1.65 ppm and 1.81 ppm; 
2.67 ppm and 2.95 ppm respectively. The Pro-α proton resonates downfield at 3.93 
ppm compared with the Phe-α proton which resonate at 3.35 ppm, indicating greater 
shielding of the Phe-α proton. The aromatic protons and the one Phe-NH proton 
resonate far downfield at 6.57, 7.65 ppm and 8.17 ppm respectively (Figure 5.14 and 
Table 5.4). 
 
From the 13C-NMR spectrum of cyclo(L-Phe-4I-Pro) (Figures 5.15 & 5.16), the Pro-α 
carbon resonates downfield at  58.3 ppm compared with the Phe-α carbon which 
resonates at 57.8 ppm. The Pro-γ, Pro-β, Phe-β and Pro-δ carbons resonate at 21.9 
ppm, 29.0 ppm, 39.2 ppm and 45.3 ppm respectively (Figure 5.16 and Table 5.4). 
 
The carboxyl groups resonate far downfield at 165.1 ppm and 168.8 ppm, while the 
aromatic carbons also resonate  downfield at 132.6 ppm, 136.6 ppm and 137.5 ppm 
respectively (Figure 5.16 and Table 5.4). 
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Figure 5.8: 
1
H (300.13 MHz) NMR spectrum of cyclo(D-Phe-4I-Pro) 
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Figure 5.9:
 13
C (75.48 MHz) coupled NMR spectrum of cyclo(D-Phe-4I-Pro) 
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Figure 5.10: 
13
C (75.48 MHz) decoupled NMR spectrum of cyclo(D-Phe-4I-Pro) 
69 
 
 
Figure 5.11: HMQC spectrum of cyclo(D-Phe-4I-Pro) 
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Figure 5.12: COSY spectrum of cyclo(D-Phe-4I-Pro) 
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Figure 5.13: HMBC spectrum of cyclo(D-Phe-4I-Pro) 
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Figure 5.14: 
1
H (300.13 MHz) NMR spectrum of cyclo(L-Phe-4I-Pro) 
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Figure 5.15:
 13
C (75.48 MHz) coupled NMR spectrum of cyclo(L-Phe-4I-Pro) 
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Figure 5.16: 
13
C (75.48 MHz) decoupled NMR spectrum of cyclo(L-Phe-4I-Pro) 
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Figure 5.17: HSQC spectrum of cyclo(L-Phe-4I-Pro) 
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Figure 5.18: COSY spectrum of cyclo(L-Phe-4I-Pro) 
 
77 
 
 
Figure 5.19: HMBC spectrum of cyclo(L-Phe-4I-Pro) 
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5.4. Molecular modeling and computational chemistry 
 
5.4.1. Introduction 
 
Molecular modeling is the science and art of studying molecular structures and their 
functions through model building and computation (Schlick, 2010). Molecular 
modeling has appeared as a popular methodology for drug design and it can 
combine computational chemistry and computer graphics. Molecular modeling can 
be implemented as a master-worker parallel application. It has benefits because 
firstly, it can take advantage of High performance computing (HPC) technologies 
such as clusters and secondly, it grids for large-scale data exploration (Buyya et al., 
2003). 
 
Computational chemistry is used in number of different ways. Firstly, it can model a 
molecular system prior to synthesizing the molecule in the laboratory. Although 
computational models may not be perfect, they are most of the time good enough to 
rule out 90% of possible compounds as being unsuitable for their intended use. 
Secondly, it helps in understanding a problem completely because there are some 
properties of a molecule that can be determined computationally but not 
experimentally. It also gives some insight into molecular bonding which can be 
obtained only from results of computations but not from experimental methods 
(Young, 2001) 
 
There are many levels of theory at which computational models of three-dimensional 
molecular structures can be constructed. Generally, the plan of modeling methods 
will often be to try to relate biological activity to structure. This plan will be capable of 
computing the potential energy of the molecule as a function of the positions of the 
constituent atoms (Foster, 2002). 
 
5.4.2. Methodology 
 
The HyperChem® (Professional Version 7.0) molecular modeling package was used 
to determine the energetically favourable conformation distributions of cyclo(D-Phe-
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4I-Pro) and cyclo(L-Phe-4I-Pro) in the gas phase, water phase and in DMSO. Local 
minima conformations were obtained for each cyclic dipeptide by the use of 
molecular mechanics (AMBER force field) optimization methods, due to the fact that 
it does not consider hydrogens explicitly (Wishart and Case, 2001). 
 
The cyclic dipeptides cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) were initially built 
by using the Hyperchem®, the amino acid data base. A step-wise approach to 
energy minimization was then followed. Geometrical optimization was achieved by 
an initial Steepest-Descent run, which was run for at least 200 cycles or until the root 
mean square (RMS) of 0.1 kcal.mol-1 Å-1 was achieved. The calculation was 
performed in vacuum N2. The conjugate gradient method (Polak-Ribier method) was 
then used to further minimise the structures in repeated runs of 32650 cycles until 
the lowest energy conformations was 0.0001 kcal.mol-1 Ǻ-1. The calculation was 
performed in vacuum N2. 
 
5.4.3. Results and discussion 
 
The results obtained from the conformational investigations for cyclo(D-Phe-4I-Pro) 
and cyclo(L-Phe-4I-Pro) are illustrated in Tables 5.5 to 5.8. For both compounds, 
conformer 1 matches the structure with the lowest energy, therefore conformer 1 is 
the most stable structure which is most likely to be found under standard conditions. 
No results were obtained for the compounds in DMSO. The experiment was run 
several times and every time the following message was received “failure to convert 
error”. 
 
Table 5.5: Conformation results of cyclo(D-Phe-4I-Pro) in the gas phase 
Conformer E (kJ/mol) Rel. E (kJ/mol) Boltzmann Dist 
1 369.76 0 0.792 
2 373.24 3.47 0.195 
3 379.89 10.13 0.013 
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Table 5.6: Conformation results of cyclo(D-Phe-4I-Pro) in the aqueous phase 
Conformer E (kJ/mol) Rel. E (kJ/mol) Boltzmann Dist 
1 289.36 0 0.765 
2 292.41 3.04 0.224 
3 299.9 10.54 0.011 
 
 
 
  
Figure 5.20: Conformation of conformer 1 of cyclo(D-Phe-4I-Pro) in the gas phase 
 
 
  
Figure 5.21: Conformation of conformer 2 of cyclo(D-Phe-4I-Pro) in the gas phase 
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Figure 5.22: Conformation of conformer 3 of cyclo(D-Phe-4I-Pro) in the gas phase 
 
 
  
Figure 5.23: Overlays of conformer 1 and 2 of cyclo(D-Phe-4I-Pro) in the gas phase 
 
  
 
Figure 5.24: Overlays of conformer 1 and 3 of cyclo(D-Phe-4I-Pro) in the gas phase 
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Figure 5.25: Overlays of conformer 2 and 3 of cyclo(D-Phe-4I-Pro) in the gas phase 
 
 
  
Figure 5.26: Overlays of conformer 1, 2 and 3 of cyclo(D-Phe-4I-Pro) in the gas phase 
 
 
  
Figure 5.27: Conformation of conformer 1 of cyclo(D-Phe-4I-Pro) in the aqueous phase 
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Figure 5.28: Conformation of conformer 2 of cyclo(D-Phe-4I-Pro) in the aqueous phase 
 
 
  
Figure 5.29: Conformation of conformer 3 of cyclo(D-Phe-4I-Pro) in the aqueous phase 
 
 
  
Figure 5.30: Overlays of conformer 1 and 2 of cyclo(D-Phe-4I-Pro) in the aqueous phase 
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Figure 5.31: Overlays of conformer 1 and 3 of cyclo(D-Phe-4I-Pro) in the aqueous phase 
 
 
   
Figure 5.32: Overlays of conformer 2 and 3 of cyclo(D-Phe-4I-Pro) in the aqueous phase 
 
 
  
Figure 5.33: Overlays of conformer 1, 2 and 3 of cyclo(D-Phe-4I-Pro) in the aqueous phase 
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Table 5.7: Conformation results of cyclo(L-Phe-4I-Pro) in the gas phase 
Conformer E (kJ/mol) Rel. E (kJ/mol) Boltzmann Dist 
1 365.36 0 0.939 
2 373.36 7.9 0.039 
3 374.73 9.27 0.022 
 
 
Table 5.8: Conformation results of cyclo(L-Phe-4I-Pro) in the aqueous phase 
Conformer E (kJ/mol) Rel. E (kJ/mol) Boltzmann Dist 
1 285.8 0 0.954 
2 294.82 9.02 0.025 
3 295.3 9.5 0.021 
 
 
 
 
 
Figure 5.34: Conformation of conformer 1 of cyclo(L-Phe-4I-Pro) in the gas phase 
 
 
  
Figure 5.35: Conformation of conformer 2 of cyclo(L-Phe-4I-Pro) in the gas phase 
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Figure 5.36: Conformation of conformer 3 of cyclo(L-Phe-4I-Pro) in the gas phase 
 
 
  
Figure 5.37: Overlays of conformer 1 and 2 of cyclo(L-Phe-4I-Pro) in the gas phase 
 
 
 
 
Figure 5.38: Overlays of conformer 1 and 3 of cyclo(L-Phe-4I-Pro) in the gas phase 
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Figure 5.39: Overlays of conformer 2 and 3 of cyclo(L-Phe-4I-Pro) in the gas phase 
 
 
  
Figure 5.40: Overlays of conformer 1, 2 and 3 of cyclo(L-Phe-4I-Pro) in the gas phase 
 
 
 
 
Figure 5.41: Conformation of conformer 1 of cyclo(L-Phe-4I-Pro) in the aqueous phase 
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Figure 5.42: Conformation of conformer 2 of cyclo(L-Phe-4I-Pro) in the aqueous phase 
 
  
 
Figure 5.43: Conformation of conformer 3 of cyclo(L-Phe-4I-Pro) in the aqueous phase 
 
 
  
Figure 5.44: Overlays of conformer 1 and 2 of cyclo(L-Phe-4I-Pro) in the aqueous phase 
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Figure 5.45: Overlays of conformer 1 and 3 of cyclo(L-Phe-4I-Pro) in the aqueous phase 
 
 
  
Figure 5.46: Overlays of conformer 2 and 3 of cyclo(L-Phe-4I-Pro) in the aqueous phase 
 
 
  
Figure 5.47: Overlays of conformer 1, 2 and 3 of cyclo(L-Phe-4I-Pro) in the aqueous phase 
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The structural geometry of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) is mainly 
influenced by the substituents on their respective side chains at the α-carbons. They 
both contain carbonyl groups in the DKP structure. 
 
The chemistry of an organic molecule is not only established by the size and 
complexity but also by the functional groups it contains (McMurray, 2000). When 
studying the structures of both cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro), it can 
be established that the biological activity of these cyclic dipeptides is mainly due to 
the C=O functional groups located in the DKP structure, that binds to a receptor by 
means of the Emil Fisher‟s “lock and key” principle (Kessler, 1982). The extended 
conformation of the aromatic side chain was observed for all the different 
conformers. This can be attributed to the steric hinderance caused by the halogens. 
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CHAPTER 6 
HAEMATOLOGICAL STUDIES 
 
6.1. Introduction 
 
Blood is a connective tissue composed of a liquid portion called plasma and a 
cellular portion consisting of various cells and cell fragments. Blood, the only liquid 
connective tissue, has three general functions: (1) transportation, (2) regulation and 
(3) protection. Blood is denser and more viscous than water. The temperature of 
blood, in the body, is about 38°C and it has a slightly alkaline pH ranging from 7.35 
to 7.45 and constitutes about 8% of the total body weight. The blood volume is 5 to 6 
litres in an average-sized adult male and 4 to 5 litres in an average-sized adult 
female. Blood is composed of two portions: (1) blood plasma, a watery liquid that 
contains dissolved substances and (2) formed elements, which are cells and cell 
fragments (Tortora and Grabowski, 2000). 
 
6.1.1. Blood coagulation 
 
Blood coagulation and platelet-mediated primary haemostasis have evolved as 
important defence mechanisms against bleeding. The coagulation system is 
triggered in response to rupture of the endothelium, which allows exposure of blood 
to the extravascular tissue. The responses of the coagulation system are 
coordinated with the formation of the platelet plug that initially occludes the vascular 
lesion. Anticoagulant mechanisms ensure careful control of coagulation and, under 
normal conditions prevail over the procoagulant forces. Disturbances of the natural 
balance between the procoagulant and anticoagulant systems due to genetic or 
acquired factors may result in bleeding or thrombotic diseases (Dahlback, 2000). 
 
6.1.1.1. Blood coagulation pathway 
 
Thrombin is the key effector enzyme of the coagulation system, having many 
biologically important functions such as the activation of platelets, conversion of 
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fibrinogen to a fibrin network, and feedback amplification of coagulation. The precise 
and balanced generation of thrombin at sites of vascular injury is the result of an 
ordered series of reactions collectively referred to as blood coagulation. The system 
is triggered on the surface of extravascular cells by the exposure of tissue factor to 
blood. 
 
 
Figure 6.1: The blood coagulation cascade (Vogler and Siedlecki, 2009).   
 
 The blood coagulation system is composed of inactive precursors of coagulation 
enzymes and cofactors that are sequentially activated to functional coagulation 
factors. Activation of tissue factor activates factor VII (FVII) of the extrinsic system 
and this activates factor IX of the intrinsic system, which in turn activates factor X. 
Platelet aggregation and release reactions accelerate the coagulation process by 
providing abundant membrane phospholipids. Thrombin generated at the injury site 
converts soluble plasma fibrinogen into fibrin and also potentiates platelet 
aggregation and secretion. Thrombin also activates factor XI which amplifies the 
intrinsic pathway activity. Furthermore, it activates factor XIII which covalently cross-
links the fibrin meshwork, a meshwork of fibrin anchors, and extends the platelet 
plug. The fibrin component of the haemostatic plug increases as the fused platelets 
autolyze and after a few hours the entire haemostatic plug is transformed into a solid 
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mass of cross-linked fibrin (Dahlback, 2000). The blood coagulation cascade is 
shown in Figure 6.1 above. 
 
6.1.1.2 Fibrinolysis 
 
Coagulation and fibrinolysis are processes that form and dissolve fibrin, respectively. 
These processes are exquisitely regulated and protected from excessive blood loss 
or excessive fibrin deposition. Regulation of these cascades is accomplished by a 
variety of mechanisms involving cellular responses, flow, and protein-protein 
interactions. With respect to regulation mediated by protein-protein interaction, the 
coagulation cascade appears to be more complex than the fibrinolytic cascade 
because it has more components (Bajzar, 2000). Figure 6.2 shows the link between 
blood coagulation and fibrinolysis. 
 
 
Figure 6.2: Diagram showing a link between blood coagulation and fibrinolysis (Heiligenhaus 
et al., 1998). 
 
6.1.1.3. Platelet aggregation 
 
The physiological role that platelets play in haemostasis is the maintenance of vessel 
integrity and the stopping of bleeding upon vessel injury. However, in 
pathophysiological conditions, platelet activity can lead to various responses that 
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play a role in atherosclerosis. Platelets play a role in the pathogenesis of 
cardiovascular, cerebrovascular, and peripheral vascular diseases. They also play a 
role in thrombosis and bleeding via platelet adhesion, activation and aggregation. 
When platelets are activated, they change shape, aggregate, and secrete contents 
of their intracellular granules via various intracellular biochemical pathways. Platelet 
aggregation is induced by various agonists, such as adenosine diphosphate (ADP), 
collagen and thrombin and is dependent on the release of ADP and prostaglandin 
(PG) H2/thromboxane TXA2. When platelets are activated, they change shape and 
secrete pro-activator substances that activate and recruit more platelets to the site of 
injury. The central component in the platelet response is TXA2. TXA2 is an 
eicosanoid which is formed via a cyclo-oxygenase-TXA2 synthase pathway. It is 
considered as a powerful agonist for platelet activation and greatly contributes to 
thrombus formation. The binding of TXA2 to a G-protein-coupled receptor induces 
phospholipase Cβ activation. An increase in [Ca2+]i and Protein kinase C (PKC) 
activation occurs due to the activation of phospholipase Cβ. The change in platelet 
shape and eventually the adhering of platelets to the site of injury is caused by this 
increase in [Ca2+]i and PKC activation. The increase in [Ca2+]i as a result of either 
(1) influx of Ca2+ or (2) secretion from intracellular stores, play a major role in the 
response of platelets to various agonists. [Ca2+]i release is through: (1) the activation 
of the G-protein-coupled receptor, (2) the protease-activated receptors [PARs] and 
(3) an integrin-type receptor, α2β1. Therefore, the inhibition of cyclo-oxygenase-1 
(COX-1) enzyme activity or TXA2 and/or the inhibition of cystolic Ca
2+ mobilization in 
platelets may inhibit platelet aggregation (Jin et al., 2005; Jin et al., 2007; Xiang et 
al., 2008, Kim et al., 2008 (a) & Kim et al., 2008 (b)). 
 
6.1.1.4. Drugs affecting coagulation 
 
Drugs that affect the coagulation process at all four coagulation stages are the 
following: 
Drugs preventing fibrin formation 
• Coumarin derivatives (e.g., warfarin) 
• Indirect thrombin inhibitors (e.g., heparin) 
• Direct thrombin inhibitors (e.g., hirudin) 
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Antiplatelet drugs 
• Cyclo-oxygenase inhibitors (e.g., aspirin) 
• Glycoprotein IIa and IIA receptor inhibitors (e.g., abciximab) 
• Inhibitors of ADP binding (e.g., clopidogrel) 
Fibrinolytic drugs 
• Plasminogen activators (e.g., streptokinase) (Pleuvry, 2004). 
 
One of the most important activities of cyclic dipeptides is inhibition of plasmonogen 
activator inhibitor (PAI-1). PAI-1 is the main physiological inhibitor of serine 
proteases, urokinase plasminogen activator (uPA) and tissue plasminogen activator 
(tPA). tPA is ana essential element of fibrinolytic system regulating formation and 
degradation of clots while uPA is linked to extracellular proteolytic homeostasis 
(Martins & Carvalho 2007). The haematological study will determine whether 
cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) affect the blood coagulation pathways. 
 
6.1.2. Heparin 
 
Heparin is used as a positive control for this assay. It is a rapidly acting anticoagulant 
and is used to interfere with the formation of thrombi. It normally occurs as a 
micromolecule complexed with histamine in the mast cells and it is extracted for use 
from porcine intestines (Richard et al., 2009). 
 
Heparin is used in the prevention of venous thrombosis and for the treatment of 
various thrombotic diseases such as pulmonary embolism and myocardial infarction. 
Its anticoagulant effects are due to binding to antithrombin III resulting in subsequent 
rapid inactivation of the coagulation factors. Without heparin, antithrombin III 
interacts very slowly with thrombin and factor Xa. Heparin therefore acts as a 
catalyst allowing antithrombin to rapidly combine with and inhibit circulating thrombin 
and factor Xa (Richard et al., 2009). 
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6.2. Methodology 
 
A coagulation assay for prothrombin (PT) and activated partial thromboplastin time 
(APTT), a fibrinolysis assay (D-Dimer and Fib-C) and a platelet aggregation assay 
were utilized to investigate the effects of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-
Pro) on haemostasis. Water required for experimentation was obtained from an Ultra 
Clear TWF UF TM Reverse Osmotic water purification system SG®. To ensure 
reproducibility, all assays were performed in triplicate. 
 
Calibration plasma was used to conduct the coagulation studies (PT, APTT) and 
fibrinolysis studies (D-Dimer and Fib-C). Healthy donors were used to prepare 
calibrated plasma. A CL coagulation analyser S/N 217 (Instrumental Laboratory 
Corporation, Beckman) and ACL-assay reagent kit (Instrumental Laboratory 
Corporation, Beckman) were used to perform the assays. The Clinical and 
Laboratory Standards Institute (CLSI) guidelines and manufacturer‟s package insert 
guidelines were used to perform the in vitro tests. 
 
6.2.1. Preparation of test solutions 
 
6.2.1.1. Cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) solutions 
3.70 mg of both cyclic dipeptides were initially dissolved in 5% dimethyl sulphoxide 
(DMSO) (Associated Chemical Enterprises (Pty) Ltd, SA) with the help of vortex 
agitation (Vortex Mixer BM300) to give a stock solution of 100 mM. The cyclic 
dipeptide solutions were diluted to final concentrations of 50 mM, 25 mM and 12.5 
mM. The solutions were then filter-sterilized through 0.22 µm sterile acetate filters. 
 
6.2.1.2. Positive control 
 
Heparin was used as the positive control for the assay at a concentration of 0.1 U/ml. 
Water required to prepare the positive control was obtained from an Ultra Clear TWF 
UF TM Reverse Osmotic water purification system SG®. The solution was then filter-
sterilized through a 0.22 μm sterile acetate filter. 
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6.2.1.3. Calibration 
 
A CL coagulation analyser S/N 217 (Instrumental Laboratory Corporation, Beckman) 
was calibrated prior to use with the calibration plasma (0020003700) (Beckham). 
The calibration plasma is prepared by using citrated plasma plasmapherezed from 
healthy donors. The plasma is designed for calibration of coagulation assays on IL 
and ELECTRATM coagulation systems to determine PT, APPT, fibrinogen, vWF, 
plasminogen, plasmin inhibitor, protein C and protein S. It is also used as reference 
plasma for APTT. 
 
6.2.1.4. Prothrombin Time Test 
 
The PT test, defined as the coagulation time (seconds) of a mixture of platelet-poor 
plasma, tissue factor (thromboplastin) and calcium chloride was developed by A.J. 
Quick in 1935 as a means to investigate the coagulopathy associated with 
obstructive jaundice. Being responsive to the deficiencies of many coagulation 
factors (VII, X, V, II and fibrinogen), PT became over the years the test of choice to 
investigate congenital or acquired coagulopathies as well as to monitor the treatment 
of vitamin K antagonists (VKA). The key component for the PT test is thromboplastin 
which may be extracted or recombinant. The variable reagent composition makes 
coagulation times dependent on the reagent used for testing, thus making inter-
laboratory comparability of results difficult (Tripodi et al., 2007). 
 
The PT test was performed according to the manufacturer‟s instructions. A 
RecombiPlastin kit (Beckman) was used in the assay. The thromboplastin reagent 
(phospholipid/tissue factor preparation) included in the RecombiPlastin kit, is a 
liposomal preparation which consists of recombinant human tissue factor in a 
phospholipid mixture with calcium chloride, buffer and a preservative. The calibration 
plasma (cal plasma) was first diluted (1: 40) and 25 µL of cal plasma was then 
diluted with 1000 µL of factor diluent. 200 µL RecombiPlastin was incubated at 37˚C 
for 180 sec on the CL Analyser (IVD, Beckman Coultier). 100 μL of diluted plasma 
and 50 µL of either the diluent factor, heparin (0.1 U/ml) (Bodene) or cyclic dipeptide 
solutions were premixed and incubated in separate cuvettes for 180 sec at 37˚C. 150 
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μL of the premixed solutions were added to the RecombiPlastin (200 μL) and the 
clotting time was measured. 
 
6.2.1.5. Activated partial thromboplastin time 
 
Activated partial thromboplastin time (APTT) is a laboratory test for the diagnosis of 
blood coagulation disorders. The test consists of two stages: the first one is the 
preincubation of a plasma sample with negatively charged materials (kaolin, ellagic 
acid etc.) to activate factors XII and XI; the second stage begins after the addition of 
calcium ions that triggers a chain of calcium-dependent enzymatic reactions resulting 
in fibrinogen clotting (Kogan et al., 2001). 
 
Prolonged clotting times may be observed in the following situations: deficiency of 
factor XII, XI, X, IX, VIII, V, II, fibrinogen, liver disease, vitamin K deficiency, 
presence of heparin, lupus anticoagulant or other inhibitors (Kogan et al., 2001). 
 
To evaluate the effect of the cyclic dipeptides on APTT, 100 μL of the APTT reagent 
was added to cuvettes containing 100 μL of plasma and either the diluent factor, 
cyclic dipeptide solutions, or heparin (0.1 U/mL). The premixed solutions were 
incubated at 37˚C for 180 sec on the CL Analyser, after which 100 μL of 0.025 M 
CaCl2 solution was added to initiate the activation of the intrinsic pathway. The 
clotting time was determined, and the anticoagulatory activity of the test samples 
evaluated relative to the untreated control. 
 
6.2.1.6. Fibrinogen-C 
 
Plasma levels of fibrinogen have been identified as independent risk predictors of 
cardiovascular disease. This has greatly increased interest in the regulation of 
plasma fibrinogen levels. Many demographic and environmental factors are known to 
affect fibrinogen levels, such as diet, use of several drugs, age, smoking, body mass, 
gender, physical exercise, race, and different seasons. Impairment in the conversion 
of fibrinogen to fibrin occurs during the coagulation process when there are 
abnormalities in fibrinogen. Fibrinogen levels are used as a diagnostic marker to 
99 
 
determine disease states that include disseminated intravascular coagulation (DIC), 
liver disease, inflammatory diseases and malignancies. An increased risk in 
cardiovascular disease is directly associated with high levels of fibrinogen. 
Thrombolytic therapy reduces the fibrinogen levels (De Maat, 2001). 
 
The fibrinogen-C assay was performed according to the manufacturer‟s instructions. 
200 µL of diluted plasma (1: 9 dilution, 200 µL of plasma was diluted with 1800 µL of 
diluent factor) was incubated with 50 μL of either the diluent factor, cyclic dipeptide 
solutions, or heparin (0.1 U/mL) at 37˚C on the CL Analyser for 180 sec. After the 
incubation period, a thrombin (Beckman) solution of 100 μL was added and the 
effect on the conversion of fibrinogen to fibrin was determined by comparing the 
fibrin levels of the treated plasma with that of the untreated plasma control. 
 
6.2.1.7. D-Dimer 
 
D-Dimer, a breakdown product of cross-linked fibrin has been extensively used as a 
diagnostic test for acute venous thromboembolism. Rapid, highly sensitive D-Dimer 
assays are now available that are suitable for testing in emergency settings. 
Preliminary studies suggest that when a highly sensitive D-Dimer assay is used, a 
negative test result may be sufficient to exclude the diagnosis of venous 
thromboembolism without the need for further testing. Less sensitive, but more 
specific D-Dimer assays are also available. High levels of D-Dimer are found during 
the occurence of deep vein thrombosis and pulmonary oedema (Anderson & Wells, 
2000).   
 
When the plasma containing D-Dimer is mixed with the Latex Reagent and Reaction 
buffer, also included in the D-Dimer kit (0020008500) (Beckman), the degree of 
agglutination is directly proportional to the concentration of D-Dimer in the solution.  
 
The D-Dimer assay (Beckman) was performed according to the manufacturer‟s 
instructions. The buffer (150 μL) was added to 42 μL of plasma containing 8 μL of 
either the diluent factor, cyclic dipeptide solutions, or heparin (0.1 U/mL). The 
mixtures were then incubated at 37˚C in the CL Analyser for 15 minutes and 
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thereafter the Latex D-Dimer was added. The rate of fibrinolysis was determined by 
comparing the protein levels of the treated plasma with that of the untreated plasma 
control.  
 
6.2.2. Platelet aggregation 
 
6.2.2.1. Isolation of platelets 
 
Ethical clearance was obtained prior to initiating the studies in accordance with the 
guidelines set by the Human Ethics Committee of the Nelson Mandela Metropolitan 
University. The study was conducted in May, 2010 so the clearance was still valid at 
that time. Blood was drawn by venipuncture from the forearm of healthy human 
subjects. Sodium citrate (0.105 M, 10 µL) was used as an anticoagulant to prevent 
the blood from clotting. The healthy subjects used were individuals who have not 
been sick in the past three months and who had not taken any medication. Platelet 
rich plasma (PRP) was obtained by centrifugation (Eppendorf centrifuge 5804R) at 
300 x g for 10 minutes while Platelet poor plasma (PPP) was obtained by 
centrifugation (Eppendorf centrifuge 5804R) at 900 x g for 15 minutes. The PRP and 
PPP were then gently suspended in a buffer composed of 145 mM NaCl, 5 mM KCl, 
10 mM HEPES, 0.5 mM Na2HPO4, 6 mM glucose and 0.2% bovine serum albumin 
(BSA), (pH 7.4) (buffer A). The platelet suspension was kept at room temperature 
and utilized within an hour. Prior to use, the platelet suspension was warmed at 37ºC 
(Bellavite et al., 1994).  
 
6.2.2.2. Platelet count 
 
Volumes of 200 µL of platelet suspension were pipetted into 96-well microtiter plates 
for measurement of turbidity (Bio TekPower Wave XS) at 600 nm. Each sample was 
also used to obtain triplicate platelet counts using a haemocytometer chamber. A 
standard curve correlating absorbance to the number of platelets was obtained. The 
method of determining the number of platelets in a suspension was developed by 
Walkowiak et al. (1997). 
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Figure 6.3: A standard curve illustrating the correlation between platelet count numbers and 
absorbance (R
2
 = 0.9976) 
 
Flow cytometry uses the principles of light scattering, light excitation, and emission of 
fluorochrome molecules to generate specific multi-parameter data from particles and 
cells in the size range of 0.5-40 mM in diameter. One unique feature of flow 
cytometry is that it measures fluorescence per cell or particle. This is in contrast with 
spectrophotometry in which the percent absorption and transmission of a specific 
wavelength of light is measured for a given sample volume. Platelet activity, 
circulating activated platelets, platelet-platelet aggregates, leukocyte-platelet 
aggregates, procoagulant platelet-derived microparticles, and calcium flux can be 
measured by aggregometry but this method cannot determine whether a particular 
condition directly activates platelets, since it only shows results with regard to 
changes in platelet reactivity. Activation of platelets by a clinical condition can be 
indirectly determined in plasma assays, but these assays cannot measure changes 
in platelet reactivity associated with the condition. Measurement of platelet 
aggregation by such assays is semi-quantitative and is prone to standardization 
problems. Previous aggregation studies only investigated platelet-platelet interaction 
for the development of thrombosis, whereas recent developments in flow cytometric 
analysis have made it possible to detect specific markers of platelet activation. The 
most studied markers are P-selectin, a marker for platelet degranulation, and PAC-1, 
a marker for GPIIb/IIIa activation. Flow cytometry can be used to determine both the 
activation state of circulating platelets and the reactivity of circulating platelets 
(Michelson et al., 2000). 
 
The method for the platelet aggregation was adapted from Michelson et al. (2000). A 
platelet rich plasma suspension containing a platelet count of 30 x 106 platelets/ml 
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was used. A volume of 40 µL of PRP was pipette into tubes containing a saturated 
concentration of fluorescein isothiocyanate (FITC)-PAC1 (BD Bioscience) (10 µL). 2 
µL of 2,5 mmol/L of peptide glycyl-L-propyl-L-arginyl-L-proline (GPRP) (Sigma) was 
added to inhibit polymerization of fibrin. A thrombin stock solution of 50 U/ml was 
added to the tubes to give a final concentration of 10 U/ml. The same volume of 
buffer was added to the untreated control and cyclic dipeptide solutions. Unstained 
cells were used to determine background staining. The tubes were incubated at 
room temperature for 15 minutes and thereafter mixed with a 2:1 ratio of 1% 
formaldehyde and buffer A (145 mM NaCl, 5 mM KCl, 10 mM HEPES, 0.5 mM 
Na2HPO4, 6 mM glucose, 0.2% bovine serum albumin) (BSA), (pH 7.4) and then 
incubated for 30 minutes at room temperature. A threefold volume of Tyrode‟s buffer 
(140 mmol/L NaCl, 10 mmol/L glucose and 15 mmol/L Tris/HCl, pH 7.4) was added 
and the cells were analyzed with a Beckman flow cytometer (Beckman Coultier, 
Cytomics FC 500). Twenty thousand events were counted to measure fluorescent 
light scattering with each analyzed sample. The parameters were collected in list 
mode files and analyzed. 
 
6.3. Statistical analysis 
 
Results were obtained in triplicate values and represented as a mean ± standard 
deviation. Microsoft Excel® (version 2007) software was used to graphically 
represent the data. Student t-tests were performed in order to determine if the mean 
response of each cyclic dipeptide concentration was statistically significant in 
inhibiting or accelerating a particular coagulation pathway. Calculated P-values of 
less than 0.05 were defined as an indication of statistical significance. 
 
6.4. Results and discussion 
 
6.4.1. Prothrombin time test  
 
The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on PT clotting 
time are illustrated in  Table 6.1 and Figure 6.4. 
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Table 6.1: The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on PT clotting 
time  
Concentration Cyclo(D-Phe-4I-Pro) 
Clotting time (sec) 
Cyclo(L-Phe-4I-Pro) 
Clotting time (sec) 
Control  14.7 ± 0.15 14.7 ± 0.15 
Positive control (0.1 U/ml) 21.6 ± 0.25 21.6 ± 0.25 
12.5 mM 23.8 ± 0.15 23.6 ± 0.26 
25 mM 26.4 ± 0.15 25.5 ± 0.21 
50 mM 29.4 ± 0.25 28.5 ± 0.25 
 
 
Figure 6.4: The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on the PT 
clotting time 
 
The positive control (heparin 0.1 U/ml) prolonged the clotting time to 21.6 ± 0.25 
seconds while cyclo(D-Phe-4I-Pro) significantly prolonged the clotting time to 23.8 ± 
0.15  seconds (P = 0.0003) at 12.5 mM, 26.4 ± 0.15 seconds (P = 0.0005) at 25 mM 
and 29.4 ± 0.25 seconds (P < 0.0001) at 50 mM when compared with the control 
(14.7 ± 0.15). The effects of cyclo(D-Phe-4I-Pro) on the clotting time are greater than 
that shown by the positive control and are concentration dependent. 
 
Cyclo(L-Phe-4I-Pro) significantly prolonged the PT clotting time which is also greater 
than that produced by the positive control. It prolonged the clotting time to 23.6 ± 
0.26 seconds (P = 0.0001), 25.5 ± 0.21 seconds (P = 0.0001), 28.5 ± 0.25 seconds 
(P = 0.0001) at screening concentrations of 12.5 mM, 25 mM and 50 mM 
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respectively. The effects of cyclo(L-Phe-4I-Pro) on the clotting time are also 
concentration dependent. 
 
6.4.2. Activated partial thromboplastin time 
 
The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on APTT 
clotting time are illustrated in Table 6.2 and Figure 6.5. 
 
Table 6.2: The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on APTT clotting 
time  
Concentration Cyclo(D-Phe-4I-Pro) 
Clotting time (sec) 
Cyclo(L-Phe-4I-Pro) 
Clotting time (sec) 
Control  21.4 ± 0.25 21.4 ± 0.25 
Positive control (0.1 U/ml) 70.5 ± 0.31 70.5 ± 0.31 
12.5 mM 29.7 ± 0.15 31.9 ± 0.53 
25 mM 38.8 ± 0.10 44.4 ± 0.21 
50 mM 47.5 ± 0.20 55.5 ± 0.31 
 
 
 
 
Figure 6.5: The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on the APTT 
clotting time 
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The positive control significantly prolonged the APTT clotting time to 70.5 ± 0.31 
seconds while cyclo(D-Phe-4I-Pro) prolonged the APTT clotting time to 29.7 ± 0.15 
(P < 0.0001), 38.8 ± 0.10 (P < 0.0001) and 47.5 ± 0.20 seconds (P < 0.0001) at 
screening concentrations of 12.5 mM, 25 mM and 50 mM respectively when 
compared with the control, 21.4 ± 0.25. The effects of cyclo(D-Phe-4I-Pro) on APTT 
clotting time are concentration dependent. 
 
Cyclo(L-Phe-4I-Pro) prolonged the APTT clotting time to 31.9 ± 0.53 (P < 0.0001), 
44.4 ± 0.21 (P < 0.0001) and 55.5 ± 0.31 (P < 0.0001) seconds at screening 
concentrations of 12.5 mM, 25 mM and 50 mM respectively. The effects of cyclo(L-
Phe-4I-Pro) on the APTT clotting time are also concentration dependent. 
 
6.4.3. Fibrinogen-C  
 
The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on fibrin 
formation are illustrated in  Table 6.3 and Figure 6.6. 
 
 
Table 6.3: The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on fibrin 
formation  
Concentration Cyclo(D-Phe-4I-Pro) 
fibrin formation (mg/dl) 
Cyclo(L-Phe-4I-Pro) 
fibrin formation (mg/dl) 
Control 560.3 ± 1.3 560.3 ± 1.3 
Positive control (0.1 U/ml) 88.0 ± 1.0 88.0 ± 1.0 
12.5 mM 487.3 ± 3.1 492.3 ± 5.5 
25 mM 461.7 ± 6.5 466.3 ± 1.5 
50 mM 242.3 ± 4.6 394.7 ± 6.5 
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Figure 6.6: The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on fibrin 
formation 
 
The positive control decreased fibrin formation by 88.0 ± 1.0. Cyclo(D-Phe-4I-Pro) 
signifigantly decreased fibrin formation, in a dose dependent manner, to 487.3 ± 3.1 
mg/dl (P < 0.0001), 461.7 ± 6.5 mg/dl (P < 0.0001) and 242.3 ± 4.6 mg/dl (P = 
0.0002) at screening concentrations of 12.5 mM, 25 mM and 50 mM respectively 
when compared with the control (560.3 ± 1.5). Cyclo(L-Phe-4I-Pro) also decreased 
fibrin formation in a dose dependent manner. It decreased fibrin formation to 492.3 ± 
5.5 mg/dl (P < 0.0001), 466.3 ± 1.5 mg/dl (P < 0.0001) and 394.7 ± 6.5 mg/dl (P < 
0.0001) at screening concentrations of 12.5 mM, 25 mM and 50 mM respectively. 
 
6.4.4. D-Dimer 
 
The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on D-Dimer 
formation are illustrated in Table 6.4 and Figure 6.7. The addition of the Latex D-
Dimer Reagent to the negative control (untreated plasma) formed 99.0 ± 1.0 ng/ml of 
D-Dimer.  
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Table 6.4: The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on D-Dimer 
formation  
Concentration Cyclo(D-Phe-4I-Pro) D-
Dimer  formation (ng/ml) 
Cyclo(L-Phe-4I-Pro) D-
Dimer  formation (ng/ml) 
Control 99.0 ± 1.0 99.0 ± 1.0 
Positive control (0.1 U/ml) 22.0 ± 1.0 22.0 ± 1.0 
12.5 mM 43.3 ± 1.5 48.0 ± 1.0 
25 mM 28.0 ± 1.0 38.0 ± 1.0 
50 mM 21.3 ± 1.5 33.7 ± 1.5 
 
 
 
Figure 6.7: The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on D-Dimer 
formation 
 
The positive control significantly decreased the D-Dimer formation to 22.0 ± 1.0 
ng/ml while cyclo(D-Phe-4I-Pro) decreased D-Dimer formation to 43.3 ± 1.5 ng/ml (P 
= 0.002), 21.3 ± 1.5 ng/ml (P = 0.001) and 28.0 ± 1.0 ng/ml (P = 0.02) at at screening 
concentrations of 12.5 mM, 25 mM and 50 mM respectively, when compared with 
the negative control (99.0 ± 1.0 ng/ml). Cyclo(L-Phe-4I-Pro) also significantly 
decreased D-Dimer formation to 48.0 ± 1.0 ng/ml (P = 0.0002), 38.0 ± 1.0 ng/ml (P = 
0.002) and 33.7 ± 1.5 ng/ml (P = 0.005) at screening concentrations of 12.5 mM, 25 
mM and 50 mM respectively. 
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6.4.5. Platelet aggregation 
 
The flow cytometry histograms and cell density plots for the untreated control (PRP), 
treated control (PRP with 50 U/ml thrombin), cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-
4I-Pro) at screening concentrations of 12.5 mM, 25 mM and 50 mM are illustrated in 
Figures 6.8 to 6.15. To obtain the percentage of the cells that stained positive, a 
region (gate) was drawn around a population of the intact cells to exclude cell debris 
and clumped cells. 
 
The untreated control showed platelet aggregation of 6.4%. The positive control 
showed platelet aggregation of 10.3%. Cyclo(D-Phe-4I-Pro) at screening 
concentrations of 12.5 mM, 25 mM and 50 mM showed platelet aggregation of  
20.3%, 18.7% and 12.9% respectively. Cyclo(L-Phe-4I-Pro) at screening 
concentrations of 12.5 mM, 25 mM and 50 mM showed platelet aggregation of 
31.8%, 30.6% and 17.7% respectively. Both cyclic dipeptides showed less platelet 
aggregation at higher concentrations which shows that they exhibit antiplatelet 
activity at high concentrations. 
 
 
 
Figure 6.8: Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by the untreated control (PRP) 
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Figure 6.9: Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by the positive control (PRP with thrombin 50 U/ml) 
 
  
Figure 6.10: Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by 12.5 mM cyclo(D-Phe-4I-Pro) 
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Figure 6.11: Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by 25 mM cyclo(D-Phe-4I-Pro) 
 
  
Figure 6.12: Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by 50 mM cyclo(D-Phe-4I-Pro) 
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Figure 6.13: Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by 12.5 mM cyclo(L-Phe-4I-Pro) 
 
  
Figure 6.14: Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by 25 mM cyclo(L-Phe-4I-Pro) 
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Figure 6.15: Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by 50 mM cyclo(L-Phe-4I-Pro) 
 
 
6.5. Summary 
 
The effects of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on coagulation were 
determined by conducting APTT and PT assays. The effect of both cyclic dipeptides 
on prolonging clotting time was significant when compared with heparin (0.1 U/ml). 
Both cyclic dipeptides prolonged the clotting time in a concentration dependent 
manner whereby the highest screening concentration of 50 mM showed the longest 
clotting time. It can therefore be concluded that both compounds exhibited no 
anticoagulant activity. 
 
The fibrinolytic activity of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) was 
determined by conducting D-Dimer and fib-C assays. Both cyclic dipeptides showed 
a significant reduction of fibrin formation and D-Dimer formation when compared with 
heparin (0.1 U/ml). It can therefore be concluded that both compounds showed 
fibrinolytic activity.The results of platelet aggregation showed that both cyclo(D-Phe-
4I-Pro) and cyclo(L-Phe-4I-Pro) enhanced platelet aggregation at lower 
concentrations. Both cyclic dipeptides showed less platelet aggregation at higher 
concentrations. It can therefore be concluded that both compounds showed 
antiplatelet activity at high concentrations.  
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Martins & Carvalho, 2007 in their study showed thaty cyclic peptides have the 
function of inhibiting blood coagulation and cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-
Pro) also showed significant effects on blood coagulation. This increased activity is 
usually seen in cyclic dipeptides of hydrophobic nature because of their ability to 
cross the lipid membrane. The ability to cross the lipid membrane may be enhanced 
by the halogen present in the cyclic dipeptide structure as the halogen bonding 
interactions are responsible for the different conformations of the molecules at the 
active site (Yunxiang et al., 2009). 
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CHAPTER 7 
ANTIMICROBIAL STUDIES 
 
7.1. Introduction 
 
A wide variety of organisms produce antimicrobial peptides as part of their first line of 
defence. Antimicrobial peptides are typically relatively short (12 to 100 amino acids), 
are positively charged, are amphiphilic, and have been isolated from single-celled 
microorganisms, insects and other invertebrates, plants, amphibians, birds, fish, and 
mammals, including humans. These peptides exhibit broad-spectrum activity against 
a wide range of microorganisms including Gram-positive and Gram-negative 
bacteria, protozoa, yeast, fungi and viruses (Reddy et al., 2004). 
 
In the early 1970s, it was believed that virtually any bacterial infection could be 
treated, as a wide range of antimicrobial agents were available. These agents 
generally known as antibiotics were products isolated from a few fungal and bacterial 
species. The belief was soon proved false when pathogens became resistant to the 
conventional antibiotics routinely used to treat bacterial infections. This event has 
resulted in the identification of novel molecules which can resist pathogens 
developing resistance. One such group of compounds explored for such novel 
properties are the antimicrobial peptides (Reddy et al., 2004; Haversen et al., 2000). 
 
The continuous use of antibiotics has resulted in the emergence of multi-resistant 
bacterial strains all over the world and as expected, hospitals have become breeding 
grounds for human associated microorganisms. It‟s widely accepted among 
clinicians, medical researchers, microbiologists and pharmacologists, that antibiotic 
resistance will, in the very near future, leave healthcare professionals without 
effective therapies for bacterial infections. For example, it is now estimated that 
about half of all S. aureus strains found in many medical institutions are resistant to 
antibiotics such as methicillin. The emerging resistance of enterococci to another 
useful and widely effective antibiotic, vancomycin, might accelerate the spread of 
vancomycin-resistant genes, eventually limiting the efficacy of this drug. The priority 
for the next decades should be to focus on the development of alternative drugs 
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and/or the recovery of natural molecules that would allow the consistent and proper 
control of pathogen-caused diseases. Ideally, these molecules should be as natural 
as possible, with a wide range of action against several pathogens, easy to produce, 
and not prone to induce resistance (Marshall & Arenas, 2003). 
 
Even though piperazine have been known for more than a century, only recently 
have 2,5 diketopiperazines attracted attention because of their selectivity, their 
speed of action and because bacteria may not easily develop resistance against 
them. Some antimicrobial peptides are already in clinical and commercial use, 
including ambicin (nisin), polymixin B and gramicidin S. There have been several 
attempts to develop peptides making them more suitable for clinical use. For 
peptides that act against bacterial membranes, it is possible to differentiate between 
those structural features that contribute to the specificity of initial membrane binding 
and those that contribute to the subsequent breach of membrane integrity. The 
design of novel antimicrobial peptides would necessitate the optimization of multiple 
parameters, a problem that has proved difficult to solve (Bradshaw, 2003). 
 
The selectivity of these peptides appears to relate to differences between the 
external membranes of prokaryotic and eukaryotic cells. The action of the peptides 
may involve the formation of „barrel-stave‟ or „torroidal‟ pores, the introduction of 
packing defects in the membrane phospholipids, or large-scale disruption of the 
membrane by dense aggregation of the parallel-oriented peptide, called the „carpet‟ 
(Bradshaw, 2003). 
 
Many different types of organisms use antimicrobial peptides, typically 20-40 amino 
acids in length, for defense against infection. Most antimicrobial peptides are 
capable of rapidly killing a wide range of microbial cells. Epand & Vogel (1999) have 
classified antimicrobial peptides according to their structures into six general groups. 
The groups are classified as: (1) amphipathic and hydrophobic helices, (2) β-sheet 
peptides and small proteins, (3) peptides with irregular amino acid composition, (4) 
peptides with thioether rings, (5) peptaibols and (6) macrocyclic cystine knot 
peptides (Bradshaw, 2003; Epand and Vogel, 1999). The classification and features 
of antimicrobial peptides are illustrated in Table 7.1.  
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Table 7.1: Classification and features of antimicrobial peptides 
Group Features Example 
Amphipathic and 
hydrophobic helices 
Form membrane pores by 
end-to-end association 
(gramicidin A) or „toroidal‟ 
pores (alamethicin, 
magainin) 
Gramicidin A 
Magainin 
Alamethicin 
β-Sheet peptides and 
small proteins 
Often cyclical, ring 
structure formed by 
disulphide 
bonds or by cyclization of 
the peptide backbone 
Tachyplesin 
Protegrin 
Gramicidin S 
Polymixin B 
Tyrocidine 
Defensins 
Thionines 
Peptides with 
irregular amino acid 
composition 
Frequently found to 
contain high levels of a 
single 
amino acid 
Histatin 
PR-39 
Prophenin 
Tritripticin 
Indolicidin 
Peptides with 
thioether rings 
(lantibiotics) 
Contain the unusual amino 
acids lanthionine and 
β-methyl lanthionine, as 
well as dehydrated 
residues 
Nisin Z 
Cinnamycin 
Peptaibols Conformationally 
restricted, frequently as α- 
or 310- 
helix. Have a high 
proportion of α-amino-
isobutyric 
acid residues. Derive their 
name from the 1,2- 
amino alcohol at the C-
Trichogin 
Alamethicin 
117 
 
terminus 
Macrocyclic cystine 
knot peptides 
Contain a cystine knot 
motif in which a disulphide 
bond is threaded through 
two others 
Circulin A 
Circulin B 
Cyclopsychotride 
Kalata 
(Epand & Vogel, 1999). 
 
7.1.1. Bacterial and fungal cultures 
 
Cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) were tested against a broad spectrum 
of Gram-positive (Staphylococcus aureus and Bacillus subtilis)  and Gram-negative 
(Escherichia Coli and Pseudomonas aeruginosa)  bacteria, as well as a fungus 
(Candida albicans)  in order to determine their potential antimicrobial activity. The 
bacterial and fungal microorganisms were selected because they are the causative 
organisms of a wide variety of infectious diseases. The microoganisms were 
obtained from Nelson Mandela Metropolitan University microbiology department, 
north campus. 
 
7.1.1.1. Gram-positive bacteria 
 
7.1.1.1.1. Staphylococcus aureus 
 
Staphylococci are Gram-positive bacteria about 1 µm in diameter and occur in 
grape-like clusters (Greenwood et al., 2007). Nasal colonization provides a natural 
reservoir that facilitates maintenance and propagation of S. aureus in human 
populations (Alexander et al., 2011; Baumann et al., 2004). Diagnosis of 
staphylococcal infections involves the detection of Gram-positive bacteria in 
grapelike arrangements isolated from pus, blood, or other fluids. Several toxins such 
as cytolytic toxins, exfoliative toxin A and B, toxic shock syndrome (TSS) toxin and 
enzymes such as cell-free coagulase, hyaluronidase and beta-lactamases facilitate 
the invasion of S. aureus to cause diseases such as: (1) pneumoniae, (2) wound 
infection, (3) food poisoning, (4) TSS and (5) infection of joints, bones and blood 
(Baumann et al., 2004). 
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The organisms are usually non-sporing, non-motile and non-capsulated. Individual 
colonies are usually circular, 2-3 mm in diameter with a smooth, shiny surface and 
the colonies appear opaque and are pigmented (golden-yellow). These 
characteristics are seen when grown on many types of agar for 24 hours at 37ºC 
(Greenwood et al., 2007). 
 
7.1.1.1.2. Bacillus subtilis 
 
The genus Bacillus contains Gram-positive, endospore-forming, chemoheterotrophic 
rods that are usually motile and peritrichously flagellated (Baumann et al., 2004). 
Bacillus subtilis is commonly found in wounds and tissues of immunocompromised 
or burned patients (Greenwood et al., 2007). 
 
7.1.1.2. Gram-negative bacteria 
 
7.1.1.2.1. Escherichia coli 
 
Eschericia coli (E. coli) are Gram-negative bacteria which are motile and often 
fimbriate. They grow over a wide range of temperatures usually between 15-45ºC 
and some of the strains are heat resistant to survive at 60ºC for 15 minutes or 55ºC 
for 60 minutes (Greenwood et al., 2007). 
 
E. coli can be identified from other enteric Gram-negative bacteria firstly, by the 
ability to utilize sugars, and secondly, by a range of other biochemical reactions 
(indole production, formation of acid and gas from lactose and other carbohydrates). 
It is the most common cause of urinary tract infection, neonatal meningitis and 
sepsis in wounds (Greenwood et al., 2007). 
 
7.1.1.2.2. Pseudomonas aeruginosa 
 
Pseudomonas aeruginosa (P. aeruginosa) is a non-sporing, non-capsulated Gram-
negative bacillus; it is motile due to one of two desirable polar flagella. It is aerobe 
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but can grow anaerobically if nitrate is available as a terminal electron acceptor. It 
grows over wide ranges of culture media and temperature and releases a sweet 
grape-like scent that is easily recognized. It infects almost all external sites or organs 
and most community infections are mild and superficial but hospital infections are 
more common and severe (Greenwood et al., 2007). 
 
7.1.1.3. Fungus 
 
7.1.1.3.1. Candida albicans 
 
Candida albicans strains are round or oval cells of 3 to 8 mm in diameter. They grow 
predominantly in yeast medium. Candida species are found in small numbers in the 
commensal flora (mouth, gastrointestinal tract, vagina and skin) of about 20% of 
normal population (Greenwood et al., 2007). 
 
7.1.2. Antimicrobials used as controls for the assays 
 
7.1.2.1. Amoxicillin  
 
Amoxicillin belongs to a family of penicillins. Penicillins are among the most widely 
effective antibiotics and also the least toxic drugs known, but increased resistance 
has limited their use. Members of this family differ from one another with regard to 
the R substituent attached to the 6-aminopenicillanic acid residue. The nature of this 
side chain affects the antimicrobial spectrum, stability to stomach acid, and 
susceptibility to bacterial degradative enzymes (β-lactamases) (Richard et al., 2009). 
 
The penicillins interfere with the last step of bacterial cell wall synthesis 
(transpeptidation or cross-linkage), resulting in exposure of the osmotically less 
stable membrane. Cell lysis can then occur, either through osmotic pressure or 
through the activation of autolysins. These drugs are thus bactericidal. The success 
of a penicillin antibiotic in causing cell death is related to the antibiotic's size, charge, 
and hydrophobicity. Penicillins are only effective against rapidly growing organisms 
that synthesize a peptidoglycan cell wall. Consequently, they are inactive against 
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organisms of different structures, such as mycobacteria, protozoa, fungi, and viruses 
(Richard et al., 2009). Amoxicillin was used as a positive control because it is the 
commonly used for gram-positive microorganisms and also the fact that it is cheap 
and readily available. 
 
7.1.2.2. Chloramphenicol 
 
Chloramphenicol was first discovered in 1947 as an antibiotic from cultures of 
Streptomyces venezuelae and is now synthesized chemically (Izard &Ellis, 2000). 
Chloramphenicol inhibits protein biosynthesis by binding reversibly to the 50S 
ribosomal subunits at a site that blocks the peptidyl transferase step in bacterial 
protein biosynthesis (Katzung, 2001). Chloramphenicol is a broad-spectrum, mainly 
bacteriostatic antibiotic, active against many Gram-positive and Gram-negative 
bacteria, as well as mycoplasma, chlamydia, rickettsia and larger viruses (Gibbon, 
2000; Volk et al., 1996). It is particularly effective against H. influenzae, S. 
pneumoniae, S. typhi and Neisseria species. Resistance to chloramphenicol due to 
enzymatic inactivation of the antibiotic is normally because of chloramphenicol 
acetyltransferase (CAT) activity. (Izard and Ellis, 2000). Chloramphenico was used 
as a positive control because it is the commonly used for gram-negative 
microorganisms and it is also cheap and readily available. 
 
 
7.2. Methodology 
 
The methods employed by Stevens & Olsen (1993), Freimoser et al. (1999), Kilian 
(2002) and Janse van Rensburg (2006) were adapted to develop a method to test 
the antimicrobial activity of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) against 
selected microorganisms. 
 
The Gram-positive and Gram-negative bacteria were plated onto nutrient agar 
(Merck, Germany), and C. albicans was plated onto potato dextrose agar medium 
(Merck, Germany). This was done to maintain the integrity and viability of the 
cultures that were used. The organisms were then incubated overnight at 37ºC and  
121 
 
28ºC respectively with subsequent sub-culturing to ensure growth of pure colonies. 
Mueller-Hinton broth was used for overnight activation of microbial cultures. 
 
7.2.1. Preparation of solutions 
 
7.2.1.1. Cyclic dipeptide solutions 
 
The preparation of cyclic dipeptide solutions was done in accordance with a standard 
aseptic technique. The cyclic dipeptides were solubilized in 5% dimethyl sulphoxide 
(DMSO) (Associated Chemical Enterprises (Pty) Ltd, SA) with the aid of vortex 
agitation (Vortex Mixer BM300) and made up to volume with reverse osmosis water 
to give a stock concentration of 2 mM. The 2 mM stock solutions were diluted 
accordingly. Both solutions were filter sterilized through 0.22 µm sterile acetate 
filters. The solutions were then stored at 4°C prior to use. 
 
7.2.1.2. Negative control 
 
The negative control representing 100% viability of test organism growth was 
required in order to compare the test organism in the presence of drug solutions. The 
negative control consisted of the relevant test organism and 5% dimethyl sulphoxide 
(DMSO). 
 
7.2.1.3. Positive control 
 
Amoxicillin at final concentrations of 1 mg/ml and 0.5 mg/ml was selected as the 
positive control for Gram-positive organisms. Chloramphenicol at concentrations of 
0.5 mg/ml and 0.25 mg/ml was used as a positive control for Gram-negative 
organisms. Both control solutions included 5% v/v dimethyl sulphoxide (DMSO) and 
were made up using Mueller-Hinton broth. The control solutions were then filter-
sterilized through 0.22 μm sterile acetate filters (Cameo 25AS acetate filter 
(Millipore®) into sterile Eppendorf tubes and stored at 4ºC prior to use.  
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7.2.1.4. MTT dye solution 
 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) is a water soluble 
tetrazolium salt, which is converted to insoluble purple formazan crystals by 
cleavage of the tetrazolium ring by succinate dehydrogenase within the 
mitochondria. The purple formazan crystals are not soluble in aqueous solution. MTT 
is always added to facilitate the measurement of microbial cell viability and is used 
as a growth indicator (O‟Brien et al., 2000; Fotakis & Timbrell 2006). 
 
MTT solution was made up in sterile phosphate buffer saline (PBS) (pH 7.4) to give a 
stock concentration of 0.5 mg/ml. The solution was sterilized by filtration through a 
sterile 0.22 μm acetate filter and stored at 4ºC prior to use. 
 
7.2.1.5. Mueller-Hinton broth solution 
 
Mueller-Hinton broth solution was made by dissolving 23 g of Mueller-Hinton broth in 
1000 ml reverse osmosis water. The solution was sterilized at 121ºC for 15 minutes 
and stored in the fridge until further use. 
 
7.2.2. Standardization of the bacterial cultures 
 
The test organisms were scraped off from the relevant agar plates using a flame 
sterilized platinum loop. The organisms were inoculated into 15 ml sterile Mueller-
Hinton broth and incubated at 37°C (for bacteria) or 28°C (for C. albicans) in an 
orbital shaker at 100 rpm for 24 hours. The cultures were then sub-cultured by 
transferring 100 μL of the test organism into 15 ml sterile Mueller-Hinton broth and 
the cultures were then incubated for 16 hours at 37ºC for bacteria and 28ºC for C. 
albicans, in an orbital shaker at 100 rpm. The turbidity of the test cultures was 
measured at 540 nm (for Gram-positive and Gram-negative bacteria) and 600 nm 
(for C. albicans) using sterile Mueller-Hinton broth as the blank.  
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7.2.3. Standardization of colony numbers 
 
Following the initial adjustment of the test cultures to an absorbance reading of 0.22 
AU, further dilutions of each test culture were made as follows:  
0.1 ml standardized culture (0.22 AU) into 9.9 ml of sterile water = A  
0.1 ml of A into 9.9 ml of sterile water = B  
0.1 ml of B into 9.9 ml of sterile water = C   
0.1 ml of each of the dilutions were placed onto sterile nutrient agar plates for 
bacteria and potato dextrose agar plates for C. albicans.  Plating and counting were 
done in triplicate and the number of microorganisms per mililiter in the standardized 
culture was subsequently calculated. 
 
7.2.4. MTT linearity assay 
 
An MTT linearity assay was conducted using the test organisms to determine the 
existence of a linear relationship between the number of viable organisms and the 
intensity of the formazan product. 50 µl of the respective serial dilutions were 
pipetted into 96-well microplates containing 40 µl MTT dye. The microplates were 
incubated at 37ºC for 2 hours, and thereafter centrifuged (Eppendorf 5894R, 
Germany) at 3000 rpm for 7 minutes to pellet the insoluble formazan precipitate 
(Freimoser et al., 1999). The supernatant was aspirated off and discarded. The 
precipitate was dissolved by adding 90 µl of DMSO to each well. Turbidity was read 
at 540 nm for bacteria and 600 nm for C. albicans. Experiments were performed in 
triplicate. 
 
7.2.5. Antimicrobial assay 
 
50 μl of each test organism was aseptically transferred into sterile 96-well 
microplates, thereafter 50 μl of cyclic dipeptides at concentrations of 1 mM and 2 mM 
were added which resulted in final concentrations of 0.5 mM and 1 mM in each well. 
50 μL of each of the positive controls were pipetted into the respective cells 
according to the test organism cultures giving final concentrations of 0.25 mg/ml and 
0.5 mg/ml (chloramphenicol) and 0.5 mg/ml and 1 mg/ml (amoxicillin) in the 
124 
 
respective wells. 50 μL of the negative control was pipette to the separate wells to 
indicate 100% viability of test organism growth. The 96-well microplates were 
incubated at 37°C for bacteria and 28ºC for C. albicans in an orbital shaker at 100 
rpm for 24 hours. After incubation, 40 μl of MTT dye (0.5 mg/ml) was added to each 
well. Absorbance was immediately measured on a microplate reader to obtain zero 
reading time at 540 nm for bacteria and 600 nm for C. albicans. The plates were 
again incubated at 37°C in an orbital shaker at 100 rpm for 4 hours to allow for the 
metabolic reduction of MTT. The plates were subsequently removed from the 
incubator and centrifuged at 3000 rpm (Eppendorf 5804R, Germany) for 7 minutes to 
pellet the insoluble formazan product (Freimoser et al., 1999). The supernatant of 
each well was aspirated off and discarded. The formazan product present was 
dissolved in 90 μl DMSO and placed on a plate shaker for four minutes. Absorbance 
was then read at 540 nm for bacteria and 600 nm for C. albicans. Experiments were 
conducted in triplicate. Results are reported as the percentage relative to the 
respective control. Percentage growth inhibition was calculated as follows: 
% inhibition = (Negative control absorbance – organism absorbance obtained) x 100 
  __________________________________________________ 
    Negative control absorbance 
 
Negative control absorbance was calculated as follows:  
Negative (t-24) – Negative (t-0) 
 
Inhibition of growth of the organisms by the positive controls and cyclic dipeptides 
after incubation was calculated as follows: 
 
Organism absorbance (t-24) – organism absorbance (t-0) 
 
Where (t-24) represents absorbance at 540 nm after 24 hours incubation and (t-0) 
represents absorbance before incubation. 
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7.3. Statistical analysis 
 
Results were obtained in triplicate values and represented as mean ± standard 
deviation (SD). Percentage growth inhibition after 24 hours exposure to the cyclic 
dipeptides was calculated with reference to the negative control. Data was 
represented graphically with the aid of Microsoft Excel® and GraphPad Prism 5®. To 
determine if the cyclic dipeptides under study caused a statistically significant 
inhibition in cell viability relative to the negative control, student t-tests were 
conducted for each concentration of the cyclic dipeptides. Calculated P-values of 
less than 0.05 were defined as an indication of statistical significance. Linear 
regression analysis was utilized to determine MTT linearity. This was defined as a 
correlation coefficient (R2) of between 0.9 and 1 with a y-intercept of less than 10% 
of the maximum absorbance value. 
 
7.4. Results and discussion 
 
7.4.1. MTT linearity assay 
 
A linear relationship between the number of viable organisms and the intensity of the 
MTT-formazan at 540 nm (for bacteria) and 600 nm (for C. albicans) was observed 
for all organisms tested (Figures 7.1 to 7.5). Linearity is evidenced by the fact that all 
organisms have correlation values exceeding 0.95.  
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Figure 7.1: P. aeruginosa linearity of MTT vs. bacteria count (R
2
 = 0.982) 
 
 
Figure 7.2: E. coli linearity of MTT vs. bacteria count (R
2
 = 0.974)  
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Figure 7.3: B. subtilis linearity of MTT vs. bacteria count (R
2
 = 0.958)  
 
 
Figure 7.4: S. aureus linearity of MTT vs. bacteria count (R
2
 = 0.976)  
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Figure 7.5: C. albicans linearity of MTT vs. fungus count (x 10
6
) (R
2
 = 0.969)  
 
 
7.4.2. Antimicrobial assay 
 
7.4.2.1. Gram-positive bacteria 
 
7.4.2.1.1. Growth inhibition of S. aureus 
 
Percentage growth inhibitions of S. aureus after 24 hours exposure to different 
concentrations of cyclo(D-Phe-4I-Pro), cyclo(L-Phe-4I-Pro), chloramphenicol and 
amoxicillin are illustrated in Figure 7.6 and Table 7.2. Percentage inhibitions shown 
by the cyclic dipeptides at all concentrations were compared with that exhibited by 
chloramphenicol and amoxicillin. Cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
showed greater percentage growth inhibitions than the effects exhibited by 
chloramphenicol and amoxicillin. Amoxicillin at screening concentrations of 0.5 
mg/ml and 1 mg/ml showed growth inhibitions of 28.25 ± 0.02% (P-value < 0.0001) 
and 31.78 ± 0.02% (P-value < 0.0001) respectively. Chloramphenicol at screening 
concentrations of 0.25 mg/ml and 0.5 mg/ml showed growth inhibitions of 63.64 ± 
0.39% (P-value < 0.0001) and 71.14 ± 1.07% (P-value = 0.002) respectively. 
Cyclo(D-Phe-4I-Pro) at screening concentrations of 0.5 mM and 1 mM showed 
growth inhibitions of 96.66 ± 0.03% (P-value < 0.0001) and 96.72 ± 0.03% (P-value 
< 0.0001) respectively. Cyclo(L-Phe-4I-Pro) at screening concentrations 0.5 mM and 
129 
 
1 mM showed growth inhibitions of 92.90 ± 0.02% (P-value < 0.0001)  and 93.38 ± 
0.02% (P-value < 0.0001) respectively. 
 
The effects of chloramphenicol, amoxicillin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-
Pro) are represented in Table 7.2.  
 
 
Table 7.2: Percentage growth inhibitions of S. aureus after 24 hours exposure to cyclo(D-Phe-
4I-Pro), cyclo(L-Phe-4I-Pro), chloramphenicol and amoxicillin 
Agent Concentration % inhibition  
Amoxicillin 0.5 mg/ml 28.25 ± 0.02 
 1 mg/ml 31.78 ± 0.02 
Chloramphenicol 0.25 mg/ml 63.64 ± 0.39 
 0.5 mg/ml 71.14 ± 1.07 
Cyclo(D-Phe-4I-Pro) 0.5 mM 96.66 ± 0.03 
 1 mM 96.72 ± 0.03 
Cyclo(L-Phe-4I-Pro) 0.5 mM 92.90 ± 0.02 
 1 mM 93.38 ± 0.02 
 
 
 
Figure 7.6: Percentage growth inhibitions of S. aureus after 24 hours exposure to cyclo(D-Phe-
4I-Pro), cyclo(L-Phe-4I-Pro), chloramphenicol and amoxicillin 
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7.4.2.1.2. Growth inhibition of B. subtilis 
 
Percentage growth inhibitions for B. subtilis after 24 hours exposure to different 
concentrations of cyclo(D-Phe-4I-Pro), cyclo(L-Phe-4I-Pro), chloramphenicol and 
amoxicillin are illustrated in Figure 7.7 and Table 7.3. Percentage growth inhibitions 
shown by the cyclic dipeptides at all concentrations were compared with that 
exhibited by chloramphenicol and amoxicillin. Cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-
4I-Pro) showed significantly greater percentage growth inhibitions than the effects 
exhibited by both chloramphenicol and amoxicillin. Amoxicillin at screening 
concentrations of 0.5 mg/ml and 1 mg/ml showed growth inhibitions of 77.64 ± 
0.48% (P-value < 0.0001) and 88.97 ± 0.31% (P-value < 0.0001) respectively. 
Chloramphenicol at screening concentrations of 0.25 mg/ml and 0.5 mg/ml showed 
percentage growth inhibitions of 12.14 ± 0.02 (P-value < 0.0001) and 25.86 ± 0.04 
(P-value < 0.0001) respectively. Cyclo(D-Phe-4I-Pro) at screening concentrations of 
0.5 mM and 1 mM showed growth inhibitions of 94.07 ± 0.02% (P-value < 0.0001) 
and 94.37 ± 0.02% (P-value < 0.0001) respectively. Cyclo(L-Phe-4I-Pro) at 
screening concentrations 0.5 mM and 1 mM showed percentage growth inhibitions of 
93.55 ± 0.03% (P-value < 0.0001) and 95.71 ± 0.02% (P-value < 0.0001) 
respectively.  
The effects of chloramphenicol, amoxicillin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-
Pro) are represented in Table 7.3.  
 
Table 7.3: Percentage growth inhibitions of B. subtilis after 24 hours exposure to cyclo(D-Phe-
4I-Pro), cyclo(L-Phe-4I-Pro), chloramphenicol and amoxicillin 
Agent Concentration % inhibition  
Amoxicillin 0.5 mg/ml 77.64 ± 0.48 
 1 mg/ml 88.97 ± 0.31 
Chloramphenicol 0.25 mg/ml 12.14 ± 0.02 
 0.5 mg/ml 25.86 ± 0.04 
Cyclo(D-Phe-4I-Pro) 0.5 mM 94.07 ± 0.02 
 1 mM 94.37 ± 0.02 
Cyclo(L-Phe-4I-Pro) 0.5 mM 93.55 ± 0.03 
 1 mM 95.71 ± 0.02 
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Figure 7.7: Percentage growth inhibitions of B. subtilis after 24 hours exposure to cyclo(D-
Phe-4I-Pro), cyclo(L-Phe-4I-Pro), chloramphenicol and amoxicillin 
 
 
7.4.2.2. Gram-negative bacteria 
 
7.4.2.2.1. Growth inhibition of E. coli 
 
Percentage growth inhibitions of E. coli after 24 hours exposure to different 
concentrations of cyclo(D-Phe-4I-Pro), cyclo(L-Phe-4I-Pro), chloramphenicol and 
amoxicillin are illustrated in Figure 7.8 and Table 7.4. Percentage growth inhibitions 
showed by the cyclic dipeptides at all concentrations were compared with that shown 
by chloramphenicol and amoxicillin. Cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
showed significantly greater percentage growth inhibitions than the effects exhibited 
by both chloramphenicol and amoxicillin. Amoxicillin at screening concentrations of 
0.5 mg/ml and 1 mg/ml showed growth inhibitions of 2.37 ± 0.01% (P-value < 
0.0001) and 12.37 ± 0.02% (P-value < 0.0001) respectively. Chloramphenicol at 
screening concentrations of 0.25 mg/ml and 0.5 mg/ml showed growth inhibitions of 
56.39 ± 0.16% (P-value = 0.0008) and 60.44 ± 0.78% (P-value < 0.003) respectively. 
Cyclo(D-Phe-4I-Pro) at screening concentrations of 0.5 mM and 1 mM showed 
growth inhibitions of 94.09 ± 0.01% (P-value < 0.0001) and 94.78 ± 0.02% (P-value 
< 0.0001) respectively. Cyclo(L-Phe-4I-Pro) at screening concentrations 0.5 mM and 
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1 mM showed growth inhibitions of 90.26 ± 0.02% (P-value < 0.0001) and 91.03 ± 
0.02% (P-value < 0.0001) respectively.  
 
The effects of amoxicillin, chloramphenicol, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-
Pro) are represented in Table 7.4. 
 
Table 7.4: Percentage growth inhibitions of E. coli after 24 hours exposure to cyclo(D-Phe-4I-
Pro), cyclo(L-Phe-4I-Pro), chloramphenicol and amoxicillin 
Agent Concentration % inhibition  
Amoxicillin 0.5 mg/ml 2.37 ± 0.01 
 1 mg/ml 12.37 ± 0.02 
Chloramphenicol 0.25 mg/ml 56.39 ± 0.16 
Chloramphenicol 0.5 mg/ml 60.44 ± 0.78 
Cyclo(D-Phe-4I-Pro) 0.5 mM 94.09 ± 0.01 
 1 mM 94.78 ± 0.02 
Cyclo(L-Phe-4I-Pro) 0.5 mM 90.26 ± 0.02 
 1 mM 91.03 ± 0.02 
 
 
Figure 7.8: Percentage growth inhibitions of E. coli after 24 hours exposure to cyclo(D-Phe-4I-
Pro), cyclo(L-Phe-4I-Pro), chloramphenicol and amoxicillin 
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7.4.2.2.2. Growth inhibition of P. aeruginosa 
 
Percentage growth inhibitions of P. aeruginosa after 24 hours exposure to different 
concentrations of cyclo(D-Phe-4I-Pro), cyclo(L-Phe-4I-Pro), amoxicillin and 
chloramphenicol are illustrated in Figure 7.9 and Table 7.5. Percentage growth 
inhibitions caused by the cyclic dipeptides at all concentrations were compared with 
that of chloramphenicol and amoxicillin. Cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-
Pro) showed significantly greater percentage growth inhibitions than the effects 
exhibited by both amoxicillin and chloramphenicol. Amoxicillin at screening 
concentrations of 0.5 mg/ml and 1 mg/ml showed growth inhibitions of 52.66 ± 
0.28% (P-value < 0.0001) and 55.68 ± 0.21% (P-value < 0.0001) respectively. 
Chloramphenicol at screening concentrations of 0.25 mg/ml and 0.5 mg/ml showed 
growth inhibitions of 45.42 ± 0.37% (P-value < 0.0001) and 47.80 ± 0.25% (P-value 
< 0.0001) respectively. Cyclo(D-Phe-4I-Pro) at screening concentrations of 0.5 mM 
and 1 mM showed growth inhibitions of 88.87 ± 0.02% and 89.97 ± 0.01% (P-value < 
0.0001) respectively. Cyclo(L-Phe-4I-Pro) at screening concentrations of 0.5 mM and 
1 mM showed growth inhibitions of 92.64 ± 0.02% and 93.13 ± 0.02% (P-value < 
0.0001) respectively.  
 
The effects of amoxicillin, chloramphenicol, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-
Pro) are represented in Table 7.5. 
 
Table 7.5: Percentage growth inhibitions of P. aeruginosa after 24 hours exposure to cyclo(D-
Phe-4I-Pro), cyclo(L-Phe-4I-Pro), chloramphenicol and amoxicillin 
Agent Concentration % inhibition  
Amoxicillin 0.5 mg/ml 52.66 ± 0.28 
 1 mg/ml 55.68 ± 0.21 
Chloramphenicol  0.25 mg/ml 45.42 ± 0.37 
Chloramphenicol 0.5 mg/ml 47.80 ± 0.25 
Cyclo(D-Phe-4I-Pro) 0.5 mM 88.87 ± 0.02 
 1 mM 89.97 ± 0.01 
Cyclo(L-Phe-4I-Pro) 0.5 mM 92.64 ± 0.02 
 1 mM 93.13 ± 0.02 
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Figure 7.9: Percentage growth inhibitions of P. aeruginosa after 24 hours exposure to cyclo(D-
Phe-4I-Pro), cyclo(L-Phe-4I-Pro), chloramphenicol and amoxicillin 
 
 
7.4.2.3. Fungus 
 
7.4.2.3.1. Growth inhibition of C. albicans 
 
Percentage growth inhibitions of C. albicans after 24 hours exposure to different 
concentrations of cyclo(D-Phe-4I-Pro), cyclo(L-Phe-4I-Pro) chlorampenicol and 
amoxicillin are illustrated in Figure 7.10 and Table 7.6. Percentage growth inhibitions 
produced by the cyclic dipeptides at all concentrations were compared with that of 
chloramphenicol and amoxicillin. Cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
showed significantly greater percentage growth inhibitions than the effects exhibited 
by chloramphenicol and amoxicillin. Amoxicillin at screening concentrations of 0.5 
mg/ml and 1 mg/ml showed growth inhibitions of 23.41 ± 0.04% (P-value < 0.0001) 
and 30.97 ± 0.03% (P-value < 0.0001) respectively. Chloramphenicol at screening 
concentrations of 0.25 mg/ml and 0.5 mg/ml showed growth inhibitions of 79.39 ± 
0.83% (P-value < 0.0001) and 83.25 ± 0.93% (P-value = 0.0005) respectively. 
Cyclo(D-Phe-4I-Pro) at screening concentrations of 0.5 mM and 1 mM showed 
growth inhibitions of 92.12 ± 0.03% (P-value < 0.0001) and 94.06 ± 0.03% (P-value 
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< 0.0001) respectively. Cyclo(L-Phe-4I-Pro) at screening concentrations of 0.5 mM 
and 1 mM showed growth inhibitions of 90.47 ± 0.03% (P-value < 0.0001) and 99.13 
± 0.03% (P-value < 0.0001) respectively.  
 
The effects of chloramphenicol, amoxicillin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-
Pro) are represented in Table 7.6. 
 
Table 7.6: Percentage growth inhibitions of C. albicans after 24 hours exposure to cyclo(D-
Phe-4I-Pro), cyclo(L-Phe-4I-Pro), chloramphenicol and amoxicillin 
Agent Concentration % inhibition  
Amoxicillin 0.5 g/ml 23.41 ± 0.04 
 1 mg/ml 30.97 ± 0.03 
Chloramphenicol 0.25 mg/ml 79.39 ± 0.83 
 0.5 mg/ml 83.25 ± 0.93 
Cyclo(D-Phe-4I-Pro) 0.5 mM 92.12 ± 0.03 
 1 mM 94.06 ± 0.03 
Cyclo(L-Phe-4I-Pro) 0.5 mM 90.47 ± 0.03 
 1 mM 99.13 ± 0.03 
 
 
 
Figure 7.10: Percentage growth inhibitions of C. albicans after 24 hours exposure to cyclo(D-
Phe-4I-Pro), cyclo(L-Phe-4I-Pro), chloramphenicol and amoxicillin 
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7.5. Summary 
 
Peptide antibiotics have become very important and have been under investigation 
for a number of years (Edwards et al., 1999). The increasing resistance to microbial 
antibiotics demands the development of antibiotics with novel modes of action. 
Reports of bacteria that have developed resistance to established drugs are 
appearing with increasing frequency. In order to address this threat of microbial 
antibiotic resistance, researchers have pursued several strategies, one being the 
development of peptide-based antibiotics (Coppins, 2001; Edwards et al., 1999). 
 
The mechanism of action for most of the peptide antibiotics is membrane disruption, 
leading to cell leakage and cell death (Mor, 2000). Membrane disruption is achieved 
by the peptide antibiotics forming tubes in the lipid bacterial membrane and 
subsequent depolarisation of the cell membrane. 
 
Both cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) showed excellent antibacterial 
and antifungal activity against the Gram-positive bacteria (B. subtilis and S. aureus) 
and the Gram-negative bacteria (E. coli and P. aeruginosa) and fungus (C.albicans).  
 
Proline (Pro) peptides act by entering the cell through the lipid membrane and once 
into the cytoplasm, they bind to and inhibit activities of specific molecular targets 
essential to bacterial growth thereby causing cell death (Gennaro et al.,2002). The 
increased activity is usually seen in cyclic dipeptides of hydrophobic nature because 
of their ability to cross the lipid membrane of the microorganism. The ability to cross 
the lipid membrane may be enhanced by the halogen present in the cyclic dipeptide 
structure as the halogen bonding interactions are responsible for the different 
conformations of the molecules at the active site. The strength of halogens 
interaction and activity at the active site attenuate in the order I > Br > H (Yunxiang 
et al., 2009). The antimicrobial activity of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-
Pro) is significant as compared to unhalogenated cyclo(Phe-Pro). Graz et al, 1999 
showed that cyclo(Phe-Pro) exhibited a broad antimicrobial activity. Cyclo(L-Phe-L-
Pro) also showed to have antimicrobial activity against E.coli, P. aeruginosa, K. 
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pneumoniae, S. aureus and B. subtilis (Milne et al., 1998).This study showed the 
increased activity with the halogenated cyclic dipeptides. 
 
It can be concluded that cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) showed good 
antibacterial activity. It is recommended that these two compounds must be tested 
against other organisms as well to establish their potential as future antibacterial 
agents. 
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CHAPTER 8 
ANTICANCER STUDIES 
 
8.1. Introduction 
 
Cancer is defined as an abnormal cell growth which originates from one cell. 
Scientifically, a cancer or a tumour is defined as a malignant neoplasm (a relatively 
autonomous growth of tissue not subject to rules and regulations of a normal 
growing cell). There are two types of tumours: (1) benign and (2) malignant tumours. 
A benign tumour is characterized by slow growth, encapsulation and non-invasive 
growth surrounding the tissue. Benign tumours or growths usually have a normal 
complement of chromosomes, demonstrate good differentiation and have rare cell 
division whereas malignant tumours have the opposite characteristics. A malignant 
tumour is characterized by rapid growth, non-encapsulation and invasive growth 
surrounding the tissue and metastases (Warshawsky & Landolph, 2006). The types 
of cancer are classified in Table 8.1.  
 
Table 8.1: Types of cancer 
Tissue Benign Malignant 
Epithelial 
Glands or ducts e.g., breast, 
gut, uterus or lungs 
Adenoma  
Carcinoma- in situ 
Adenocarcinoma 
Stratified squamous tissue 
e.g., skin, lungs 
Squamous cell 
papilloma 
Squamous cell or epidermoid 
carcinoma 
Basal cells (skin) - Basal cell carcinoma 
Melanocytes (skin) Nevus Malignant melanoma 
Renal epithelium Renal tubular 
adenoma 
Renal cell carcinoma 
Liver cells Liver cell 
carcinoma 
Hepatocellular carcinoma 
Connective tissue and derivatives  
Fibroblasts  Fibroma  Fibrosarcoma 
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Cartilage  Chondroma  Chondrosarcoma 
Bone  Osteoma  Osteogenic sarcoma 
Striated muscle Rhabdomyoma  Rhabdomyosarcoma  
Blood vessels Haemangioma  Angiosarcoma  
Bone marrow, spleen 
Haematopoietic (blood 
forming) cells 
- Leukemias, erythroleukemia, 
myeloma, lymphomas 
Nerves  
Peripheral nervous system - Neuroblastomas 
Central nervous system - Gliomas, astrocytomas, 
medulloblastomas 
 
Cancer is the second major cause of disease-associated death, the first being 
cardiovascular diseases. 5-10% of cancer is hereditary whereas the remaining 
percentage is due to damage of genes that occur throughout the life time, either due 
to external factors or internal factors. Most of the cancer deaths, approximately 80%, 
are due to external factors that can be prevented or avoided. Those external factors 
include: (1) the use of tobacco and tobacco products, (2) diet and (3) lifestyle factors 
that can induce occupational cancer (Warshawsky & Landolph, 2006). 
 
The critical goal of chemotherapy is to cure (long term or disease free survival), 
which requires eradication of all neoplastic cells, but if cure is not achieved, then the 
goal becomes control of the disease (stop the cancer from spreading) and to extend 
and improve the quality of life. In both cases, the neoplastic cell burden is initially 
reduced but in advance stages of cancer, controlling or curing is imposible and the 
goal in this case is palliative care. This means chemotheraphy or anticancer drugs 
can be used to alleviate symptoms and improve the quality of life even though they 
might not lengthen life (Richard et al., 2009). 
 
An understanding of the cancer cell growth cycle is essential for proper use of 
anticancer drugs. Figure 8.1 illustrate the cancer cell growth cycle and interaction of 
drugs at different stages. 
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Figure 8.1: Cancer cell growth cycle indicating all the phases and main sites of action of 
anticancer drugs (Koda-Kimble et al., 2001). 
 
The cancer cell cycle is divided into four phases, phase G1, G2, S and M. Phase G1 
is the gap period between mitosis and the beginning of DNA synthesis. Resting cells 
(cells that are not preparing for cell division) are in a phase of G1. Phase S 
represents the period of DNA synthesis, phase G2 shows the premitotic interval, and 
phase M illustrates the period of mitosis (Richard et al., 2009). 
 
Proliferation of normal cells (cell renewal) is excellently controlled to balance the loss 
of mature functional cells with the production of new cells. Proto-oncogenes and 
tumour-suppressor genes provide the stimulatory and inhibitory signals that regulate 
the cell cycle, respectively. The messages are conveyed to the cell by the cell cycle 
„clock‟ (Koda-Kimble et al., 2001; Dipiro et al., 2002). 
 
In a normal cell, the clock decides whether the cell should undergo cell division by 
collecting the inhibitory signals. The clock consists of interacting proteins found in the 
nucleus, including cyclins and cyclin-dependant kinases (CDKs). The cyclins 
combine with the CDKs to form complexes that act as a molecular switch. The 
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molecular switch allows a cell to move through the restriction point that occurs late in 
the G1 phase to the S phase. If insufficient amounts of cyclins and CDKs are present 
during the G1 phase, the cell will not enter the S phase to start cell division. The 
complexes generate phosphate groups from molecules of adenosine triphosphate 
(ATP) and transfer them to a protein called a retinoblastoma protein (pRB). If the 
pRB acquires enough phosphate groups, the protein will release the transcription 
factors that the cell needs to make proteins essential for cell division. New evidence 
suggests that the function of cyclins, CDKs and inhibitory proteins may be disrupted 
by a malignant transformation, or these proteins could undergo changes that cause a 
malignant transformation (Koda-Kimble et al., 2001). 
 
8.1.1. Carcinogenesis 
 
Carcinogenesis involves different phases, the first phase being initiation which 
involves exposure of normal cells to carcinogenic substances. Carcinogenic 
substances or agents are categorized into three classes: (1) physical agents 
(radiation), (2) viruses and (3) chemicals. The first carcinogenic agent, radiation 
(ionising or ultraviolet), has shown to cause cancer in humans and experimental 
animals, whereas the role of viruses in the etiology of human cancer is not clear but 
there are some correlations between human cancers and some viruses. Those 
viruses are the following: HIV and AIDS virus, hepatitis B virus, Epstein-Barr virus, 
human papilloma virus and human T-cell lymphotropic virus type 1 (Warshawsky & 
Landolph, 2006). Carcinogenic agents are also classified based on their mechanism 
of action. They are direct acting alkylation agents and chemicals that require 
activation. Direct acting alkylation agents are chemically and biologically active due 
to their structures and electrophilic character whereas chemicals that require 
activation are chemically and biologically inert and therefore named 
procarcinogenics. Procarcinogenics are converted to either proximal or intermediate 
carcinogens and ultimately to electrophilic carcinogens. Therefore exposure to these 
carcinogens may cause a change in DNA, RNA or proteins and if not repaired, can 
result in irreversible cellular mutations (Warshawsky & Landolph, 2006). 
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The second phase of carcinogenesis which is called the promotion phase results in 
the formation of latent tumour cells which lead to neoplastic growth and finally the 
formation of tumours. This phase can be reversible up to a certain point 
(Warshawsky & Landolph, 2006). While in this stage, carcinogens and other factors 
such as age, sex, species, strain, diet, health status, intestinal flora conditions 
chronic irritation and inflammation disturb the environment and favour the growth of a 
mutated cell population over normal cells (Dipiro et al., 2002). 
 
The final stage of carcinogenesis is called progression and involves further genetic 
changes leading to increased cell proliferation. This phase is critical because it 
involves the invasion of a tumour into local tissue leading to metastasis development 
(malignant cells detach from primary tumour and invade the body cavity or enter the 
blood or lymph system). Secondary tumours are established if these cells survive, 
becoming vascularised to provide nutrients for further growth (Dipiro et al., 2002). 
 
8.1.2. Chemotherapy 
 
Successful cancer therapy involves the removal or destruction of tumours. 
Unfortunately, there are no drugs meeting that criterion to date. The use of 
chemotherapy involves weighing benefits over risks to explore favourable outcomes. 
The treatment of cancer involves three main methods: radiation therapy, surgical 
removal of the tumour and chemotherapy (Koda-Kimble et al., 2001; Dipiro et al., 
2002). 
 
8.1.2.1. Radiation therapy 
 
Radiation therapy utilizes ionizing radiation to activate apoptosis that will cause cell 
death. This method is administered via three routes: (1) external beam radiation, (2) 
branchytherapy, which involves placement of radioactive sources on or within a 
tumour and (3) internal isotope treatment, which involves administering radioactive 
isotopes systematically to the target tissues (Sambrook et al., 1950; Joslin, 1982). 
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8.1.2.2. Surgery 
 
John Hunter, a Scottish surgeon, (1728-1793), suggested surgery as one of the 
oldest cancer treatments. He suggested that some cancers might be cured by 
surgery and he provided a protocol that helps to decide which cancers are operable 
and those that are not operable. He also advised that cancers that had not invaded 
nearby tissues should not be surgically removed (Thun et al. 2010). 
 
The primary aim of surgery is to physically remove the tumour mass confined to 
specific locations. The challenge with this procedure is to completely remove the 
primary tumour without disseminating and circulating the detached cancerous cells 
(Olson, 1989; Almeida & Barry, 2009). 
 
8.1.3. Agents used as controls in the assay 
 
Melphalan (L-phenylalanine mustard) was used as the positive control in this study. 
It is an alkylating agent with two functional groups that cause cross-linking of two 
DNA strands thus interfering with the synthesis of DNA, RNA and proteins in 
proliferating cells. Melphalan is active at any phase of the cancer cell cycle but its 
effects are more prominent at phase S where it blocks the cell cycle progress at the 
G2 checkpoint. A dose of 1 mg/kg is administered over 5 days and repeated every 3 
to 4 weeks in the treatment of multiple myeloma, malignant melanoma, breast and 
ovary carcinoma (Dollery, 1999). Melphan activity against these types of cancer 
made it suitable to be used as a positive control for this study. 
 
Polyethylene glycol (PEG), a well known polymer, is usually used to increase the 
bioavailability of anticancer agents. It is widely used as a carrier for drugs with low 
molecular weight and low solubility in order to improve the solubility of the drugs and 
therefore enhancing their therapeutic efficacy. Conjugation of PEG with paclitaxel, 
camptothecin, methotrexate and doxorubicin has improved water solubility, plasma 
clearance and bioavailability of these agents (Greenwald, 2001; Youk et al., 2005). 
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8.2. Methodology 
 
Methods employed by Huq et al. (2004) and Cunningham (2006) were adapted to 
develop a method to test the anticancer activity of cyclo(D-Phe-4I-Pro) and cyclo(L-
Phe-4I-Pro). 
 
8.2.1. Cell cultures 
 
Three cancerous cell lines, namely MCF-7 (breast cancer), HT-29 (colon cancer) 
and HeLa (cervical cancer), were used in the experiments. All primary cell cultures 
were of human origin. Primary cell cultures were obtained from Highveld Biologicals, 
South Africa (SA), and stored in liquid nitrogen until needed. 
 
8.2.2. Cell line maintenance and routine culture 
 
All experiments were done in accordance with standard sterile culture techniques 
and all procedures were carried out under aseptic conditions in laminar flow units to 
prevent the infection of cell cultures. MCF-7, HT-29 and HeLa cell cultures were 
maintained in RPMI 1640 growth medium (Sigma-Aldrich) in culture flasks 
(Corningware, Cambridge, USA) containing 10% heat-inactivated foetal calf serum 
(FCS) (Adcock Ingram, SA) at 37ºC with 5% humidification (Labotec® 
ThermoForma®, SA). The RPMI 1640 (Sigma-Aldrich) growth medium was replaced 
every 48 hours by aspirating the old medium, washing twice with sterile phosphate 
buffered saline (PBS) and adding fresh medium. Cell lines were cultured until they 
achieved approximately 80% confluence and were then sub-cultured by aspirating 
medium from the confluent flasks, and washed twice with 1 ml of 0.25% trypsin in 
ethylenediaminetetraacetic acid (EDTA), pre-warmed to 37°C. The cells were 
dissociated by adding 1 ml trypsin/EDTA for approximately 5 minutes at 37°C. The 
cells were incubated in a Labtec® humidified CO2 incubator (Labcon
®, SA) for 10 
minutes and resuspended in 9 ml growth medium and incubated at 37°C. Portions 
from each sub-cultured generation were stored in liquid nitrogen for preservation of 
the cell lines. 
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Prior to use, the cells were dissociated from the culture flask by adding 1 ml of 
0.25% trypsin (Highveld Biologicals, SA). Trypsin was deactivated by adding 10 ml of 
RPMI 1640 (Sigma-Aldrich) growth medium. The cells were gently agitated to 
disperse and suspend them into single-cell suspensions. The concentration of the 
cells was determined with a haemocytometer by utilizing tryphan-blue staining. The 
cell suspensions were then diluted with culture medium to contain a standard of 
6000 cells/ml.   
 
8.2.3. Preparation of solutions 
 
8.2.3.1. Negative control 
 
A negative control representing 100% viability of cell line growth was necessary for 
comparing the cell line growth in the presence of drug solutions. The negative control 
which was aseptically prepared consisted of 0.25% or 0.5% dimethyl suphoxide 
(DMSO) which aided in solubilization of the respective cyclic dipeptide solutions. 
This was then made up to volume with RPMI 1640 (Sigma-Aldrich) containing 10% 
FCS which was then pre-warmed to 37°C. The solution was filter-sterilized through a 
sterile 0.22 µm acrodisc filter. 
 
8.2.3.2. Positive control 
 
A 100 mM solution of the positive control, melphalan (Chemistry Department, 
NMMU) was prepared by dissolving 3.052 g in 100 ml of 1% ethanol. The stock 
solution was diluted to give a final concentration of 0.5 mM (152.6 µg/l) with RPMI 
medium containing 10% FCS, which was pre-warmed to 37°C. The solution was 
then sterilized through sterile 0.22 µm acrodisc filters prior to use. Special 
precautions like wearing musks and gloves as well as well ventilated cabins were 
considered when using melphalan. Melphan was convalently bond to PEG by 
hydrolysis via a urethane or urea bond to get a conjugate of PEG-end capped with 
melphalan (Ouchi et al., 1992).  
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8.2.3.3. Cyclic dipeptide solutions 
 
The stock solutions of 0.75 M cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) were 
prepared by adding 0.25% DMSO for the 1 mM concentration and 0.5% DMSO for 
the 2 mM concentration and the mixtures were then sonicated to aid in complete 
solubilization of the cyclic dipeptides. The solutions were then made up to volume 
with RPMI 1640 (Sigma-Aldrich) medium supplemented with 10% foetal calf serum 
(FCS). The cyclic dipeptide solutions were filter-sterilised through 0.22 mM sterile 
acrodisc filters prior to use. 
 
8.2.3.4. MTT dye solution 
 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) is a water soluble 
tetrazolium salt, which is converted to insoluble purple formazan crystals by 
cleavage of the tetrazolium ring by succinate dehydrogenase within the 
mitochondria. The purple formazan crystals are not soluble in aqueous solution. MTT 
is always added to facilitate the measurement of microbial cell viability and is used 
as a growth indicator (O‟Brien et al., 2000; Fotakis & Timbrell 2006). 
 
MTT (Sigma Chemicals Co., USA) was made up with PBS (pH 7.4) to give a 
concentration of 5 mg/ml. The solution was filter-sterilized through a sterile 0.22 µm 
acrodisc filter and stored at 4°C until needed. 
 
8.2.4. Cytotoxicity assay utilizing MTT 
 
200 µL of each cell suspension  containing 6000 cells/ml was transferred to the wells 
of 96-well flat bottom microtitre plates and were incubated at 37ºC with 5% CO2 
humidification for 24 hours to allow the cells to attach to the bottom of the well. After 
incubation, the growth medium was aspirated off and there after 200 µl aliquots of 
the negative control, positive control and cyclic dipeptide solutions were added to the 
wells such that each concentration yielded results in triplicate. To each well, 50 µL of 
MTT solution was added. The microtitre plates were then incubated again at 37ºC 
with 5% CO2 humidification for 3 hours to allow for metabolic reduction of MTT which 
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forms insoluble formazan precipitates. Incubation allowed the drug compound to 
interact with particular cell lines. MTT supernatant was aspirated off and 200 μL 
aliquots of DMSO were added to each well to dissolve the formazan precipitates. 
The microtitre plates were placed on a plate shaker for 5 minutes and the 
absorbance was read immediately at 540 nm on a microtitre plate spectrophotometer 
(Multiscan MS®, (version 4.0) Labsystem® type 352, England) (Huq et al., 2004). The 
results were reported as percentage inhibition relative to the negative control. 
 
8.3. Statistical analysis 
 
All results were obtained in triplicate and represented as mean ± SD. The 
percentage inhibition was calculated with reference to 100% cell line viability. This 
was then represented graphically as percentage inhibition as a function of drug 
concentration with the aid of Microsoft Excel® and Graphpad Prism 5®. Student t-
tests were conducted to determine whether means of the cyclic dipeptides caused a 
statistically significant reduction in cell viability relative to the negative control. 
Statistical significance was defined as P-value < 0.05. 
 
8.4. Results and discussion 
 
The percentage inhibitions of the HeLa, MCF-7 and HT-29 cell lines caused by 
melphalan, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) are illustrated on Figures 
8.2 to 8.5. To establish if the growth inhibition effects exhibited by melphalan and the 
cyclic dipeptides were statistically different compared with the negative control, 
student t-tests for both cyclic dipeptides and melphalan were conducted. 
 
8.4.1. Cyclo(D-Phe-4I-Pro) 
The percentage growth inhibition of the HeLa, MCF-7 and HT-29 cancer cell lines 
caused by cyclo(D-Phe-4I-Pro) and melphalan, with and without PEG, are illustrated 
in Figure 8.2 and 8.3 respectively. The conjugation of melphalan with PEG showed 
growth inhibitions of 86.88 ± 1.12 % (P-value = 0.0001), 82.39 ± 0.32 % (P-value < 
0.0001) and 71.30 ± 0.94 % (P-value < 0.0001) against the HeLa, MCF-7 and HT-29 
cell lines. 
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Figure 8.2: The percentage inhibition of growth of the HeLa, MCF-7 and HT-29 cell lines caused 
by melphalan (0.5 mM) and cyclo(D-Phe-4I-Pro) at screening concentrations of 1 mM and 2 
mM, all conjugated with PEG 
 
Cyclo(D-Phe-4I-Pro) at concentrations of 1 mM and 2 mM showed growth inhibitions 
of 41.48 ± 5.50% (P-value = 0.0028) and 62.32 ± 2.73% (P-value = 0.0004) against 
the HeLa cell line respectively. Growth inhibitions of 72.87 ± 1.19% (P-value = 
0.0001) and 60.97 ± 1.05% (P-value = 0.0004) against the MCF-7 and HT-29 cell 
lines were observed at a screening concentration of 2 mM. Cyclo(D-Phe-4I-Pro) at a 
screening concentration of 1 mM caused growth inhibitions of 60.97 ± 4.47% (P-
value = 0.321) and 53.85 ± 0.91% (P-value < 0.0001) against the MCF-7 and HT-29 
cell lines respectively. 
 
 The results obtained showed decreased growth inhibitions of the HeLa, MCF-7 and 
HT-29 cell lines by melphalan and cyclo(D-Phe-4I-Pro) without PEG. Mephalan 
showed growth inhibitions of 54.47 ± 1.12% (P-value = 0.0002), 56.06 ± 0.32% (P-
value < 0.0001) and 58.87 ± 0.94% (P-value < 0.0001) against the HeLa, MCF-7 and 
HT-29 cell lines respectively when compared with the results obtained with PEG. 
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Figure 8.3: The percentage inhibition of growth of the HeLa, MCF-7 and HT-29 cell lines caused 
by melphalan (0.5 mM) and cyclo(D-Phe-4I-Pro) at screening concentrations of 1 mM and 2 
mM, all without PEG 
 
Cyclo(D-Phe-4I-Pro) at a screening concentration of 2 mM showed growth inhibitions 
of 31.12 ± 0.08% (P-value < 0.0001), 41.92 ± 2.52 (P-value = 0.0004) and 36.12 ± 
3.43% (P-value = 0.0021) against the HeLa, MCF-7 and HT-29 cell lines 
respectively. At the screening concentration of 1 mM, cyclo(D-Phe-4I-Pro) caused 
growth inhibitions of 46.52 ± 0.03% (HeLa cell line) (P-value < 0.0001), 9.92 ± 0.12% 
(MCF-7 cell line) (P-value < 0.0001) and 20.52 ± 1.18 (HT-29 cell line) (P-value = 
0.0001). 
 
The results obtained confirm that the conjugation with PEG enhances the anticancer 
activity of melphalan. It was also shown that the activity of cyclo(D-Phe-4I-Pro) was 
also affected by conjugation with PEG. Higher inhibitions of the HeLa, MCF-7 and 
HT-29 cell lines were seen with cyclo(D-Phe-4I-Pro) conjugated with PEG than 
cyclo(D-Phe-4I-Pro) without PEG. Cyclo(D-Phe-4I-Pro) showed a concentration-
dependent percentage inhibitions with the exception of activity against the HeLa cell 
line where the lower concentration of 1 mM (without PEG) had a higher percentage 
growth inhibition that that of the 2 mM concentration. 
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8.4.2. Cyclo(L-Phe-4I-Pro)  
 
The percentage growth inhibition of the HeLa, MCF-7 and HT-29 cancer cell lines 
caused by cyclo(L-Phe-4I-Pro) and melphalan, with and without PEG, are illustrated 
in Figures 8.4 and 8.5 respectively. The conjugation of melphalan with PEG showed 
growth inhibitions of 86.88 ± 1.12 % (P-value = 0.0001) against the HeLa cell line, 
82.39 ± 0.32 % (P-value < 0.0001) against the MCF-7 cell line and 71.30 ± 0.94 % 
(P-value < 0.0001) against the HT-29 cell line. 
 
 
 
 
Figure 8.4: The percentage inhibition of growth of the HeLa, MCF-7 and HT-29 cell lines caused 
by melphalan (0.5 mM) and cyclo(L-Phe-4I-Pro) at screening concentrations of 1 mM and 2 mM, 
all conjugated with PEG 
 
Cyclo(L-Phe-4I-Pro) at concentrations of 1 mM and 2 mM showed growth inhibitions 
of 29.82 ± 2.83% (P-value = 0.001) and 58.88 ± 2.73% (P-value = 0.001) against the 
HeLa cell line respectively. Growth inhibitions of 61.26 ± % 0.45 (P-value = 0.0001) 
and 61.39 ± 2.18% (P-value = 0.0204) were observed for the MCF-7 and HT-29 cell 
lines at a screening concentration of 2 mM. Cyclo(L-Phe-4I-Pro) at screening 
concentration of 1 mM caused growth inhibitions of 43.85 ± 1.21% (P-value = 0.008) 
and 40.05 ± 0.41% (P-value < 0.0001) against the MCF-7 and HT-29 cell lines 
respectively. 
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The results obtained showed a decrease in growth inhibitions against the HeLa, 
MCF-7 and HT-29 cell lines by melphalan and cyclo(L-Phe-4I-Pro) without PEG. 
Mephalan showed growth inhibitions of 54.47 ± 1.12% (P-value = 0.0002), 56.06 ± 
0.32% (P-value < 0.0001) and 58.87 ± 0.94% (P-value < 0.0001) against the HeLa, 
MCF-7 and HT-29 cell lines respectively when compared with the results obtained 
with PEG. 
 
 
Figure 8.5: The percentage inhibition of growth of the HeLa, MCF-7 and HT-29 cell lines caused 
by melphalan (0.5 mM) and cyclo(L-Phe-4I-Pro) at screening concentrations of 1 mM and 2 mM, 
all without PEG 
 
 
Cyclo(L-Phe-4I-Pro) at a screening concentration of 2 mM showed growth inhibitions 
of 19.19 ± 0.27% (P-value = 0.0002), 51.43 ± 2.52 (P-value = 0.0012) and 49.84 ± 
3.43% (P-value = 0.0421) against the HeLa, MCF-7 and HT-29 cell lines 
respectively. At the screening concentration of 1 mM, cyclo(L-Phe-4I-Pro) caused 
growth inhibitions of 40.63 ± 0.09% (P-value < 0.0001) against the HeLa cell line, 
14.6 ± 0.17% (P-value < 0.0001) against the MCF-7 cell line and 7.01 ± 1.92 (P-
value = 0.0002) against the HT-29 cell line. 
 
The results obtained confirm that the conjugation with PEG enhances the anticancer 
activity of melphalan. It was also shown that the activity of cyclo(L-Phe-4I-Pro) was 
also affected by conjugation with PEG. Higher inhibitions of the HeLa, MCF-7 and 
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HT-29 cell lines were seen with cyclo(L-Phe-4I-Pro) conjugated with PEG than 
cyclo(L-Phe-4I-Pro) without PEG. 
 
8.5. Summary 
 
The discovery of new peptides has become increasingly important as they exhibit 
some therapeutic benefits. Peptides such as cecropins, defensins and mellitin, 
induced cell death in prokaryotic and eukaryotic cells due to increased membrane 
permeability. This increased permeability may lead to cell lysis or, may produce 
subtle changes in membrane barrier function and promote cell death (Sharom et al., 
1998). It has also been shown that natural and synthetic peptides exhibit therapeutic 
anticancer activity against human tumours (Lee et al., 2005). 
 
Milne et al. (1998) demonstrated that selected cyclic dipeptides have the capability of 
decreasing the growth of the HT-29 cells, a human colon carcinoma cell line. The 
qualitative findings were in accord with the mutual exclusivity of proliferation and 
differentiation. Initial screening showed that selected cyclic dipeptides were capable 
of enhancing the expression of the biochemical differentiation marker, alkaline 
phosphatase, in HT-29 human colon carcinoma cell lines (Milne et al., 1998). 
 
The results obtained confirmed that conjugation of PEG with anticancer agents 
enhances their activity as higher percentage inhibition was observed in such cases. 
Conjugation of PEG with the cyclic dipeptides also appeared to be beneficial as it 
has also shown to increase their activity. 
 
Both the cyclic dipeptides showed anticancer activity against the HeLa, MCF-7 and 
HT-29 cell lines. The potential of these two compounds as anticancer agents must 
be thoroughly investigated and taken to a higher level. It has been postulated that 
the hydrophobicity of peptides, not the number of hydrophobic amino acids, play an 
important role in anticancer activity or membrane transport (Lee et al., 2005).  
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This increase in anticancer activity is usually seen in cyclic dipeptides of hydrophobic 
nature because of their ability to cross the lipid membrane of the cell. The ability to 
cross the lipid membrane may be enhanced by the halogen present in the cyclic 
dipeptide structure as the halogen bonding interactions are responsible for the 
different conformations of the molecules at the active site (Yunxiang et al., 2009). 
 
Comparing the growth inhibitions produced by the cyclic dipeptides with regard to 
one another, cyclo(D-Phe-4I-Pro) showed greater inhibitory effects against the HeLa, 
MCF-7 and HT-29 cell lines than cyclo(L-Phe-4I-Pro), with PEG at both screening 
concentrations.  
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CHAPTER 9 
ANTIDIABETIC STUDIES 
 
9.1. Introduction 
 
Diabetes mellitus is not a single disease but rather a group of disorders 
characterized by elevation in blood sugar (hyperglycaemia) caused by: (1) relative or 
absolute deficiency in insulin, (2) change in metabolism of lipids, proteins and 
carbohydrates and (3) an increase in complications resulting from vascular diseases. 
There are two types of diabetes: Type 1 and type 2, while gestational diabetes is 
also very common (Richard et al., 2009; Brunton & Parker, 2008). 
 
Studies done had not extensively investigated the activity of cyclic dipeptides on 
diabetes mellitus. Martins & Carvalho, 2007 perfomed a study that showed cyclic 
peptides to have antidiabetic through binding to glycogen phosphorylase active site 
and inhibited glucose production. This study explored the antidiabetic activity of 
cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) through other mechanisms like 
inhibition of α-glucosidase and α-amylase enzymes. 
 
Table 9.1: Characteristics of type 1 and type 2 diabetes 
Characteristics Type 1 Type 2 
Age of onset Usually during childhood 
or puberty 
Often over 35 years 
Nutritional status at 
time of onset 
Often undernourished Obesity commonly present 
Prevalence  5-10% of diagnosed 
diabetics 
90-95% of diagnosed diabetics 
Genetic 
predisposition 
Moderate Very strong 
Defect or deficiency β cells are destroyed, 
inhibiting the production of 
insulin 
Inability of β cells to produce 
enough quantities of insulin; 
insulin resistance and other 
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defects 
(Richard et al., 2009) 
 
9.1.1. Type 1 diabetes 
 
Type 1 diabetes commonly occurs in the early stages of life, childhood or puberty. It 
is characterized by a total deficiency of insulin caused by massive β cell necrosis. 
The loss of β cell functions is usually associated with the autoimmune mediated 
processes directed at the β cells which may be due to invasion of viruses or the 
exposure to chemical toxins. As a consequence of the destruction of β cells, the 
pancreas cannot respond to glucose, that is why type 1 diabetes is characterized by 
an insulin deficiency. Type 1 diabetics require exogenous insulin to control 
hyperglycaemia and to avoid ketoacidosis and long term complications associated 
with elevated blood glucose (Richard et al., 2009). 
 
9.1.2. Type 2 diabetes 
 
Most diabetics are type 2. It is influenced by factors such as age, obesity, genetic 
factors and peripheral insulin resistance. In this type, the pancreas still retains the β 
cell functions but the unpredictable insulin secretion is not sufficient to maintain 
glucose homeostasis and the β cells are gradually reduced with time. Type 2 
diabetes is also accompanied by a lack of sensitivity to exogenous or endogenous 
insulin by target organs and this resistance to insulin is considered to be the major 
cause of this type of diabetes. The major goal in the treatment of type 2 diabetes is 
to keep blood glucose within normal limits to prevent complications. Weight loss, 
exercise and dietary modification can help reduce the resistance to insulin (Richard 
et al., 2009). 
 
9.1.3. Enzymes used for the study 
 
Blood glucose levels are mainly controlled by hormones that regulate the rate of 
production and consumption of glucose. High blood glucose levels lead to 
hyperglycaemia while low blood glucose levels lead to hypoglycaemia. Persistent 
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cases of hyperglycaemia justify diabetes mellitus diagnosis. The normal blood 
glucose concentration range is 55-140 mg/dL (3.1-7.8) during fasting. Insulin and 
glucagon are the major hormones that regulate the production and consumption of 
glucose. Elevation of blood glucose stimulates the release of insulin from the β-cells. 
Insulin in turn stimulates (1) the uptake of glucose by muscle and adipose tissue, (2) 
glycolysis, (3) the synthesis of triglycerides and (4) protein synthesis (Koda-Kimple et 
al., 2011) 
 
9.1.3.1. α-Glucosidase 
 
α-Glucosidase is an enzyme that is responsible for catalysing the final step in the 
digestive process of carbohydrates, and the use of alpha-glucosidase inhibitors 
could delay the use of dietary carbohydrates to suppress postprandial 
hyperglycaemia (PPHG). α-Glucosidase inhibitors such as acarbose, miglitol and 
voglibose are known to reduce PPHG primarily by interfering with the enzyme that is 
responsible for digesting carbohydrates therefore delaying glucose absorption (Kim 
et al., 2000). 
 
9.1.3.2. α-Amylase 
 
α-Amylase is an endoglucanase, i.e., an enzyme responsible for catalysing 
hydrolysis of the internal alpha-1,4-glycosidic linkages found in starch and other 
related polysaccharides. It also targets the suppression of PPHG. α-Amylase 
inhibitors are better suppressors of PPHG because they do not result in abnormal 
accumulation of maltose, which is responsible for undesirable effects such as 
abdominal pain, flatulence and diarrhoea (Kim et al., 2000).  
 
9.2. Methodology 
 
The antidiabetic potential of the compounds was determined by conducting the 
following assays: (1) an α-amylase assay and (2) an α-glucosidase assay. 
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9.2.1. Preparation of solutions 
 
9.2.1.1. Positive control solution 
 
0.321 g/ml of acarbose was dissolved in reverse osmosis water to produce a stock 
solution of 500 mM. The stock solution was diluted with reverse osmosis water to 
give a final screening concentration of 50 mM. The positive control solution was 
filter-sterilised through a 0.22 mM sterile acetate filter before it was used. 
 
9.2.1.2. α-Glucosidase solution 
 
100 mg of rat intestine acetone powder was suspended in 3 ml of 0.01 M phosphate 
buffer (pH 7.0) and sonicated for 30 seconds, twelve times in an ice bath. The 
solution was then centrifuged at 3000 rpm at 4ºC for 20 minutes. The crude enzyme 
solution was removed and the pellets were discarded. The supernatant solution was 
kept on ice prior to use. 
 
9.2.1.3. Sodium carbonate solution 
 
1.06 g of sodium carbonate was dissolved in 50 ml of reverse osmosis water to give 
a stock concentration of 0.2 M sodium carbonate solution. The solution was filter-
sterilized with a 0.22 mM acetate filter prior to use. 
 
9.2.1.4. 4-Nitrophenyl-α-D-glucopyranoside 
 
1.5065 mg 4-nitrophenyl-α-D-glucopyranoside was dissolved in 10 ml of 0.1 M 
phosphate buffer (pH 7.0) to give a stock concentration of 0.5 mM. The solution was 
then filter-sterilized with a 0.22 μM acetate filter prior to use. 
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9.2.2. α-Amylase assay 
 
The method developed by Fuwa (1954) and modified by Xiao et al. (2006) was 
adapted to determine the effects of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on 
α-amylase activity. 
 
The microplate-based starch-iodine assay is based on the reduced staining value of 
blue starch-iodine complexes, where starch forms a deep blue complex with iodine. 
When iodine binds to starch polymers, it results in the development of colour 
because hydrolysis of the starch in the presence of iodine causes a colour change 
i.e., from deep blue to red brown. 
 
40 μl of starch (Sigma) solution and 40 μl of the α-amylase enzyme (in 0.1 M 
phosphate buffer, pH 7.0) was pipette into microplate wells and incubated at 50ºC for 
30 minutes. After incubation, 20 μl of 1 M HCl was added to terminate the enzymatic 
reaction. 100 μl of iodine reagent (5 mM iodine and 5 mM potassium iodine) was 
then added. After colour development, 150 μl of the iodine-treated sample was 
transferred to a transparent flat-bottomed 96-well microplate. Absorbance was then 
read at 580 nm using a microplate reader (BioTek Power Wave XS). The assay was 
performed in triplicate. 
 
α-Amylase activity was determined as follows: 
 
Dextrinsing activity = (D0-D) / D0 x 100/10 
 
Where D is the absorbance of the enzyme sample and D0 is the absorbance of the 
amylase control without addition of the enzyme. 
 
9.2.3. α-Glucosidase assay 
 
The method employed by Sancheti et al. (2009) was adapted to determine the 
effects of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on the activity of the α-
glucosidase enzyme. 
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Mixtures consisting of 50 μl of the 0.1 M phosphate buffer, 25 μl of the 0.5 mm 4-
nitrophenyl-α-D-glucopyranoside solution, 10 μl of either the acarbose solution, 
cyclo(D-Phe-4I-Pro) or cyclo(L-Phe-4I-Pro) solution were incubated at 37ºC for 30 
minutes. After incubation, 100 μl of 0.2 M sodium carbonate solution was added to 
terminate the enzymatic reaction. The amount of p-nitrophenol released in the 
reaction was determined spectrophotometrically at 410 nm using a microplate reader 
(BioTek Power Wave XS). The amount of p-nitrophenol released was proportional to 
the enzymatic hydrolysis of the substrate. All experiments were performed in 
triplicate. 
 
α-Glucosidase inhibition was calculated as follows: 
Percentage inhibition = (Ac-As) x 100 
         ______ 
    Ac 
As is the change in absorbance that occurs between the time the substrate is added 
to the mixture and 30 minutes after incubation. Ac is the change in absorbance of the 
blank control. 
 
9.3. Statistical analysis 
 
All the results were obtained in triplicate values and represented as a mean ± 
standard deviation. The data was represented graphically with the aid of Microsoft 
Excel® and GraphPad Prism 5®. To determine if the cyclic dipeptides under study 
caused a statistically significant inhibition, student t-tests were conducted. Calculated 
P-values of less than 0.05 were defined as an indication of statistical significance. 
The samples that indicated greater than 10% of enzyme inhibition were considered 
relevant. 
 
9.4. Results and discussion 
 
The α-amylase inhibitory effects of acarbose, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-
4I-Pro) are shown in Figure 9.1. α-Amylase is the enzyme responsible for hydrolysis 
of carbohydrates, and inhibition of this enzyme results in decreased PPHG. Both 
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cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) showed some inhibitory effects, but the 
effects on the α-amylase enzyme are too little for them to be used therapeutically. 
 
 
Figure 9.1: α-Amylase inhibition caused by acarbose, cyclo(L-Phe-4I-Pro) and cyclo(D-Phe-4I-
Pro) 
 
The percentage α-amylase inhibition was determined at a very low concentration (1 
mM) for both cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro). The percentage inhibition 
caused by both cyclic dipeptides was significantly less when compared with 
acarbose. Acarbose caused a percentage inhibition of 55.51 ± 0.82% (P-value < 
0.0001). When compared with acarbose, cyclo(D-Phe-4I-Pro) at a screening 
concentration of 1 mM produced an inhibition of 5.99 ± 0.21% (P-value < 0.0001), 
similarly, cyclo(L-Phe-4I-Pro) at a screening concentration of 1 mM produced an 
inhibition of 5.49 ± 0.30 (P-value < 0.0001). The effects of cyclo(D-Phe-4I-Pro), 
cyclo(L-Phe-4I-Pro) and acarbose are illustrated in Table 9.2. 
 
Table 9.2: Percentage α-amylase inhibition caused by acarbose, cyclo(D-Phe-4I-Pro) and 
cyclo(L-Phe-4I-Pro) 
Agent Concentration Percentage 
Inhibition 
Acarbose 50 mM 55.51 ± 0.82 
Cyclo(D-Phe-4I-Pro) 1 mM 5.99 ± 0.21 
Cyclo(L-Phe-4I-Pro) 1 mM 5.49 ± 0.30 
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The α-glucosidase inhibitory effects of acarbose, cyclo(D-Phe-4I-Pro) and cyclo(L-
Phe-4I-Pro) are shown in Figure 9.2. α-Glucosidase is an enzyme responsible for 
digestion of carbohydrates and inhibition of this enzyme will result in reduced PPHG.  
 
 
Figure 9.2: α-Glucosidase inhibition caused by acarbose, cyclo(L-Phe-4I-Pro) and cyclo(D-Phe-
4I-Pro) 
 
The effects of both cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on the α-
glucosidase enzyme were determined at a very low concentration (1 mM). The 
percentage inhibition observed for both cyclic dipeptides was enormously less than 
that produced by acarbose. Acarbose caused a percentage inhibition of 51.11 ± 
1.02% (P-value > 0.0001). When compared with acarbose, cyclo(D-Phe-4I-Pro) at a 
screening concentration of 1 mM produced an inhibition of -7.75 ± 0.049% (P-value > 
0.0001), similarly, cyclo(L-Phe-4I-Pro) produced an inhibition of -3.03 ± 0.24% (P-
value > 0.0001). This means both cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
showed no inhibition of the α-glucosidase enzyme. The effects of acarbose, cyclo(D-
Phe-4I-Pro), cyclo(L-Phe-4I-Pro) and are illustrated in Table 9.3. 
 
Table 9.3: Percentage α-glucosidase inhibiton caused by acarbose, cyclo(D-Phe-4I-Pro) and 
cyclo(L-Phe-4I-Pro) 
Agent Concentration Percentage 
Inhibition 
Acarbose 50 mM 51.11 ± 1.02 
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Cyclo(D-Phe-4I-Pro) 1 mM -7.75 ± 0.49 
Cyclo(L-Phe-4I-Pro) 1 mM -3.03 ± 0.24 
 
 
9.5. Summary 
 
Peptides have become an interesting subject in the development of new drugs for 
treatment of diabetes. Several studies revealed that some peptides have benefits as 
antidiabetic agents by stimulating cAMP production and thus improving insulin 
secretion from the cells. Administration of those selected peptides therefore reduce 
blood glucose levels by increasing circulating insulin in obese diabetic patients (Irwin 
et al., 2007). 
 
Both cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) showed no antidiabetic potential 
against α-glucosidase and α-amylase as they both caused an enzyme inhibition of 
less than 10%. The assays were not conducted at higher concentrations due to the 
low solubility features of the compounds. 
 
It can be concluded that both cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) have no 
benefits against diabetes caused by stimulation of  α-glucosidase and α-amylase  
enzymes.  
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CHAPTER 10 
CONCLUSIONS AND RECOMMENDATIONS 
 
The cyclic dipeptides, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) were 
successfully synthesized using the method of Milne et al. (1992) and by boiling the 
linear unprotected counterparts under reflux in a neutral medium. Excellent yields of 
72% and 70% were obtained for cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
respectively. 
 
The structures of the cyclic dipeptides were confirmed using standard elucidation 
methods such as nuclear magnetic resonance, mass spectrometry, infrared 
spectroscopy and molecular modeling and computational chemistry.  
 
The physicochemical properties of the cyclic dipeptides were determined using 
scanning electron microscopy, differential scanning calorimetry, thermogravimetric 
analysis and X-ray powder diffraction.  
 
High-performance liquid chromatography and thin layer chromatography were used 
to determine the purity of the cyclic dipeptides and the results showed that the 
synthesized compounds had no impurities and could therefore be used for the 
biological studies. 
 
The objective of the study was also to investigate the biological potential of the 
compounds by conducting anticancer, antimicrobial, haematological and antidiabetic 
studies. Dimethyl sulphoxide was used to aid in dissolving the respective cyclic 
dipeptides and other compounds, but it was used at a minimum concentration to 
avoid interference with the biological studies. 
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Graz et al. (2000) revealed that cyclo(Phe-Pro) showed greater than 50% growth 
inhibition of four cancer cell lines. The results obtained in this study showed that 
cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) have potential as anticancer agents 
against the HeLa (cervical cancer), HT-29 (colon cancer) and MCF-7 (breast cancer) 
cell lines, when compared with mephalan (with PEG).  
 
The mode by which drugs are delivered to the required region has significant effects 
on the efficacy of drugs. Some drugs have an optimal concentration range, above or 
below this range, a drug produces toxic or no therapeutical effects. Drug delivery and 
drug targeting systems are currently under development and the objectives are (1) to 
minimize degradation or loss, (2) prevent harmful side effects and (3) increase the 
bioavailability and the fraction of the drug accumulating in the required region. 
Among the drug carriers identified are: (1) soluble polymers, (2) microparticles made 
of insoluble or degradable or natural and synthetic polymers, (3) microcapsules, (4) 
cells, (5) cell ghosts, (6) lipoproteins, (7) liposomes and (8) micelles. Liposomal 
formulations have been extensively studied to enhance the delivery of drugs via 
several routes (Kaparissides et al., 2006; Cunningham, 2006; Van der Merwe, 2005). 
The results of the anticancer studies confirmed that conjugation of anticancer agents 
with PEG, (a soluble polymer) enhanced their activity as higher percentage 
inhibitions were observed in such cases. Conjugation of PEG with the cyclic 
dipeptides also appeared to be beneficial as it has also shown to increase their 
activity. 
 
Cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) showed broad activity (more than 50% 
growth inhibition) against selected microorganisms. The broad activity exhibited by 
both the cyclic dipeptides may be as a result of their hydrophobic nature and their 
ability to cross the lipid membranes of the microorganisms. The ability to cross the 
lipid membranes may be enhanced by the halogen present in the cyclic dipeptide 
structure as the halogen bonding interactions are responsible for the different 
conformations of the molecules at the active site (Yunxiang et al., 2009). Further 
studies against more microorganisms should be performed in order to establish the 
potential of these compounds as possible antimicrobial agents of the future. It is also 
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recommended that the synergistic effect of these two compounds must be 
investigated. 
 
The haematological results revealed that both cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-
4I-Pro) showed no anticoagulant activity. They prolonged the clotting time in a 
concentration-dependent manner whereby the highest concentration (50 mM) 
showed the longest clotting time. Both cyclic dipeptides also showed a 
concentration-dependent decrease in fibrin formation when compared with heparin. 
When compared with thrombin, both cyclic dipeptides showed platelet aggregation at 
low concentrations and antiplatelet activity at high concentrations. 
 
Cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) exhibited no antidiabetic potential as 
they both caused an enzyme inhibition of less than 10%. The assays were not 
performed at higher concentrations due to the low solubility features of the 
compounds.  
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APPENDIX A 
LIST OF CHEMICALS 
 
Acarbose Sigma Chemical Co., USA 
Acetic acid SAARCHEM (Pty) Ltd, SA; Sigma 
Chemical Co., USA 
Acetonitrile BDH HypersolvTM for HPLC, BDH 
Laboratory supplies, England 
ACL-assay kit Instrumental Laboratory Corporation, 
Beckman 
Amoxicillin Chemistry Department, NMMU 
Anisole Sigma Chemical Co., USA 
Bovine serum albumin Highveld Biological, SA 
Sec-butanol BDH Laboratory supplies, England 
Calibration plasma Instrumental Laboratory Corporation, 
Beckman 
Chloramphenicol Chemistry Department, NMMU 
Chloroform SAARCHEM (Pty) Ltd, SA 
Diethylphosphoryl cyanide Sigma Chemical Co., USA 
1,2 Dimethoxyethane  Fluka Chemika-Biochemika, Switzerland 
DMSO Associated Chemical Enterprises (Pty) 
Ltd, SA 
DMSO-d6 SAARCHEM (Pty) Ltd, SA 
EDTA Merck, Germany 
Ethanol  Merck, Germany 
Fluorescein isothiocyanate BD Bioscience 
Foetal calf serum Adcock Ingram, SA 
Formic acid Merck, Germany 
Glucose SAARCHEM (Pty) Ltd, SA 
Heparin Bodene 
HEPES Sigma Chemical Co., USA 
N-hexane BDH Laboratory supplies, England 
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Hydrochloric acid Merck, England 
Iodine  SAARCHEM (Pty) Ltd, SA 
Magnesium chloride Associated Chemicals Enterprises (PTY), 
SA 
Melphalan Chemistry Department, NMMU 
Methanol BDH Laboratory supplies, England 
Mueller-Hinton broth Merck, Germany 
MTT Sigma Chemicals Co., USA 
3-Nitrobenzyl alcohol Merck, Germany 
4-Nitrophenyl-α-D-glucopyranoside Merck, Germany 
Nutrient agar Merck, Germany 
Boc-D-Phe-4I-OH Fluka Chemika-Biochemika, Switzerland 
Boc-L-Phe-4I-OH Fluka Chemika-Biochemika, Switzerland 
Polyethylene glycol Merck, Germany 
Potassium bromide Merck, SA 
Potassium chloride Merck, Germany 
Potassium iodine Merck, Germany 
Potato dextrose agar medium Merck, Germany 
L-Proline methyl ester hydrochloride Fluka Chemika-Biochemika, Switzerland 
Rat intestine acetone powder Sigma Chemicals Co., USA 
RPMI 1640 growth medium Sigma Chemicals Co., USA 
Sodium carbonate SAARCHEM (Pty) Ltd, SA; Labchem 
(Pty) Ltd 
Sodium chloride SAARCHEM (Pty) Ltd, SA; Labchem 
(Pty) Ltd 
Sodium citrate SAARCHEM (Pty) Ltd, SA 
Sodium hydrogen carbonate Merck, Germany 
Sodium hydrogen phosphate Associated Chemical Enterprises (Pty) 
Ltd, SA 
Sodium sulphate SAARCHEM (Pty) Ltd, SA 
Starch Sigma Chemical Co., USA 
Thrombin Beckman 
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Toluene BDH Laboratory supplies, England 
Triethylamine SAARCHEM (Pty) Ltd, SA; Labchem 
(Pty) Ltd 
Tris Roche Diagnostics GmbH, Mannheim 
Trypsin  Roche Diagnostic GmbH, Mannheim 
Water Ultra Clear TWF UF TM Reverse 
Osmotic water purification system SG® 
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APPENDIX B 
LIST OF SOLUTIONS 
 
Buffer A (Platelet aggregation) 
NaCl      145 mM 
KCl      5 mM 
HEPES     10 mM 
Na2HPO4     0.5 mM 
Glucose     6 mM 
Bovine serum albumin   0.2% 
Reverse osmosis water to   100%   (pH 7.4) 
 
Mueller-Hinton Broth Solution (Antimicrobial assay) 
Mueller-Hinton broth   23 g 
Reverse osmosis water to   1000 ml 
 
MTT solution 
3-[4,5-dimethylthiazol-2-yl]-2,5- 
diphenyltetrazolium bromide  0.5% (0.1 g)      
Reverse osmosis water   20 ml 
 
4-Nitrophenyl-α-D-glucopyranoside 
4-Nitrophenyl-α-D-glucopyranoside 1.5065 g 
Phosphate buffer 0.1 M   10 ml  
 
Nutrient agar solution (Antimicrobial assay) 
Nutrient agar     31 g 
Reverse osmosis water to    1000 ml 
 
Phosphate buffered saline (Antimicrobial assay) 
NaCl      8 g 
KH2PO4     0.24 g 
Na2HPO4.12H2O    1.44 g 
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KCl      0.2 g 
Reverse osmosis water to   1000 ml  (pH 7.4) 
 
Potato dextrose agar solution 
Potato dextrose agar   39 g 
Reverse osmosis water   1000 ml 
 
Sodium carbonate solution 
Sodium carbonate    1.06 g 
Reverse osmosis water   50 ml 
 
0.9% Sodium chloride (Coagulation assay) 
Sodium chloride    9.0 g 
Reverse osmosis water to   1000 ml 
 
Tyrode’s buffer 
Sodium chloride    140 mmol/L 
Glucose     10 mmol/L 
Tris/HCl     15 mmol/L    
Reverse osmosis water to   100%    pH (7.4) 
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APPENDIX C 
LIST OF EQUIPMENT 
 
Acetate filters (0.22 µM) MilliporeTM Cameo 25AS acetate filters, 
USA 
Acrodisc filters (0.22 µM) Sigma-Aldrich, USA 
Autoclave Model HA-3D, Hirayama Manufacturing 
Corporation, Japan 
Centrifuge Eppendof centrifuge 5804R, Germany 
Coagulation Beckman CL coagulation analyser S/N 217 
Computer modeling HyperChem® (Professional Version 7.0) 
Culture flask (25 cm3) Corningware, Cambridge, USA 
Electronic balance Mettler Toledo, AB104, Switzerland 
Humidifier Labotec® ThermoForma®, SA 
Incubator Labcon® orbital shaker, SA 
Infrared spectroscopy Shimadzu® Fourier-transform Infrared 
(FTIR-1800S) Spectrophotometer 
(Shimadzu® Corporation, Japan) 
 Perkin Elmer® Bench Press, Finland 
Laminar airflow units Labaire®, SA 
Mass spectrometry VG-7070E spectrometer (Biotech, UK) 
equipped with a VG2035 data system 
Microplate reader  Biotek Powerwave XS 
Microscale Sartorius GMBH, Germany 
Multichannel pipette Costar 
Neubauer chamber Bright-line Superior, Germany 
Nuclear magnetic resonance Bruker AMS 300 (Bruker, Germany) 
Plastic syringe (50 ml) Promex® , SA 
Platelet aggregation Beckman flow cytometer (Beckman 
Coultier, Cytomics FC 500) 
pH meter 744 pH meter, Metrohm, Switzerland 
Scanning Electron Microscopy  Philips® XL30 Scanning Electron 
Microscope, UK 
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 Novotech® SEMprep 2-sputter coater, 
Germany 
Screw-driven plastic syringe Hamilton® 
Spectrophotometer Pharmacia Biotech® Ultraspec 2000, UK 
Statistical software packages Microsoft Excel® (version 2007) 
 Graphpad Prism 5® 
Thermal analysis TA instruments Q600 SDT, USA 
Thin layer chromatography Silica-gel plates (Silica gel 60 F254, Merck, 
Germany) 
Venipuncture tubes BD Vacutainer systems, UK 
Vortex  Vortex Mixer BM300, Laboratory Supplies 
(PTY) Ltd, SA) 
Water purification system Ultra Clear TWF UF TM Reverse Osmotic 
water purification system SG® 
96-well flat-bottom microplates Costar, Corning 
X-ray powder diffraction Bruker Advanced Solutions XRD 
Commander (DiffracPlus Version 2.3) 
diffractometer, Germany 
Bruker Advanced X-ray Solutions Eva 
software (DiffracPlus Version 10.0 Rev.1) 
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Abstract 
Cyclic dipeptides have been widely used as pharmaceutical agents due to their 
favourable properties and the fact that they are more stable and membrane 
permeable than their linear analogues. These characteristics make cyclic dipeptides 
attractive to protein-based drug developers (Martins & Carvalho, 2007). Cyclic 
dipeptides and their derivatives continue to hold the attention of synthetic chemists 
and biologists alike. Given the continuing and growing interest in cyclic dipeptides 
and their chemistry, a review of the area seems timely (Lambert et al., 2001). The 
principal aim of the study was to synthesize, elucidate and determine the biological 
activity of cyclo(D-Phe-4I-Pro) and cyclo(Phe-4I-Pro) using a qualitative and 
quantitative approach. The objective of the study was to determine the biological 
activity of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) with regard to antimicrobial, 
anticancer, antidiabetic and haematological effects. Antimicrobial studies showed 
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that cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) inhibited the growth of selected 
Gram-positive, Gram-negative and fungal microorganisms. Both the cyclic dipeptides 
inhibited growth of the HeLa (cervical cancer), HT-29 (colon cancer) and MCF 
(breast cancer) cell lines. Both cyclic dipeptides showed some activity in 
haematological studies where they both prolonged the clotting time, reduced fibrin 
formation, enhanced platelet aggregation at low concentrations and inhibited platelet 
aggregation at high concentrations. Both cyclic dipeptides, however, failed to 
produce any antidiabetic effects. 
 
Introduction 
Cyclic dipeptides have found tremendous attention in diverse aspects of science 
ranging from rational drug design to nanomaterials. These diverse applications are 
due to: (1) their distinctive properties, such as ease of synthesis and 
characterization, (2) introduction of chemical diversity by simple amino acid 
substitution and (3) modulation of 3D structure by chemical modification. The 
application of peptides as drugs has become a priority especially because of their 
key role in many signal transduction pathways, which makes them an attractive 
avenue to target diseases (Marx, 2005; Teixido & Giralt, 2008). Cyclic dipeptides and 
their derivatives continue to hold the attention of synthetic chemists and biologists 
alike. Apart from the occurrence of a variety of naturally occurring bioactive 
metabolites, cyclic dipeptides are often more stable in vivo than their linear 
counterparts and therefore often represent promising drug candidates. Another 
feature that contributes to the appeal of cyclic dipeptides is their reduced 
conformational mobility which allows them to be used in the study and mimicry of 
protein folding and to present diverse functionality in a defined and predictable 
manner. Given the continuing and growing interest in cyclic dipeptides and their 
chemistry, a review of the area seems timely (Lambert et al., 2001). Cyclic 
dipeptides are important natural products. They have been widely used as 
pharmaceutical agents due to their favourable properties and the fact that they are 
more stable and membrane permeable than their linear analogues. These 
compounds have several advantages over ordinary peptides i.e., higher binding 
affinities and a greater degree of specificity in peptide-receptor interactions which 
may result after cyclization of the peptides. These characteristics make cyclic 
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dipeptides attractive to protein-based drug developers (Martins & Carvalho, 2007). 
An increasing number of multi-drug resistance diseases have become a serious 
problem for pharmaceutical manufacturers and this has led to intensive research 
efforts to develop new and more effective drugs. Antimicrobial peptides have already 
played a crucial role in pharmaceutical research as biomedically useful agents or as 
lead compounds for drug development (Shai, 2002). Milne et al. (1998) investigated 
the biological effects of cyclo(Phe-Pro), cyclo(Tyr-Pro), cyclo(Trp-Pro) and cyclo(Trp-
Trp) and revealed that they have antibacterial and anticancer activity. No extensive 
studies have been undertaken to determine the biological activities (anticancer, 
antidiabetic, antimicrobial and haematological effects) of cyclo(D-Phe-4I-Pro) and 
cyclo(L-Phe-4I-Pro), and since cyclo(Phe-Pro) have shown potential antibacterial 
and anticancer activity, the investigation of the biological activity of the halogenated 
cyclo(Phe-Pro) is therefore necessary. 
 
Materials and methods 
Molecular modeling 
TheHyperChem® (Professional Version 7.0) molecular modeling package was used 
to determine the energetically favourable conformation distributions of cyclo(D-Phe-
4I-Pro) and cyclo(L-Phe-4I-Pro) in the gas phase and water phase. Local minima 
conformations were obtained for each cyclic dipeptide by the use of molecular 
mechanics (AMBERforce field) optimization methods, due to the fact that it does not 
consider hydrogen explicitly (Wishart & Case, 2001).The cyclic dipeptides cyclo(D-
Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) were initially built by using the Hyperchem®,  
amino acid data base. A step-wise approach to energy minimization was then 
followed. Geometrical optimization was achieved by an initial Steepest-Descent run, 
which was run for at least 200 cycles or until the root mean square (RMS) of 0.1 
kcal.mol-1Å-1 was achieved. The calculation was performed in vacuum N2. The 
conjugate gradient method (Polak-Ribier method) was then used to further minimize 
the structures in repeated runs of 32650 cycles until the lowest energy conformations 
was 0.0001 kcal.mol-1 Ǻ-1. The calculation was performed in vacuum N2. 
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Ethical approval  
The Human Ethics Committee of the Nelson Mandela Metropolitan University 
approved the use of human blood samples for haematological studies (reference 
number: N 01/11/03/07 [HO6SB-003/Approval]). 
 
Anticancer activity of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
Methods employed by Huq et al. (2004) and Cunningham (2006) were adapted to 
develop a method to test the anticancer activity of cyclo(D-Phe-4I-Pro) and cyclo(L-
Phe-4I-Pro). Three cancerous cell lines, namely MCF-7 (breast cancer), HT-29 
(colon cancer) and HeLa (cervical cancer), were used in the experiments. All primary 
cell cultures were of human origin. Primary cell cultures were obtained from Highveld 
Biologicals, South Africa (SA), and stored in liquid nitrogen until needed. All 
experiments were done in accordance with standard sterile culture techniques and 
all procedures were carried out under aseptic conditions in laminar flow units to 
prevent the infection of cell cultures. The MCF-7, HT-29 and HeLa cell cultures were 
maintained in RPMI 1640 growth medium (Sigma-Aldrich) in culture flasks 
(Corningware, Cambridge, USA) containing 10% heat-inactivated foetal calf serum 
(FCS) (Adcock Ingram, SA) at 37ºC with 5% humidification 
(Labotec®ThermoForma®, SA). The RPMI 1640 (Sigma-Aldrich) growth medium was 
replaced every 48 hours by aspirating the old medium, washing twice with sterile 
phosphate buffered saline (PBS) and adding fresh medium. The cell lines were 
cultured until they achieved approximately 80% confluence and were then sub-
cultured by aspirating medium from the confluent flasks, and washed twice with 1 ml 
of 0.25% trypsin in ethylenediaminetetraacetic acid (EDTA), pre-warmed to 37°C. 
The cells were dissociated by adding 1 ml trypsin/EDTA for approximately 5 minutes 
at 37°C. The cells were incubated in a Labtec® humidified CO2 incubator (Labcon
®, 
SA) for 10 minutes and resuspended in 9 ml growth medium and incubated at 37°C. 
Portions from each sub-cultured generation were stored in liquid nitrogen for 
preservation of the cell lines. Prior to use, the cells were dissociated from the culture 
flask by adding 1 ml of 0.25% trypsin (Highveld Biologicals, SA). Trypsin was 
deactivated by adding 10 ml of RPMI 1640 (Sigma-Aldrich) growth medium. The 
cells were gently agitated to disperse and suspend them into single-cell 
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suspensions. The concentration of the cells was determined with a haemocytometer 
by utilizing tryphan-blue staining. The cell suspensions were then diluted with culture 
medium to contain a standard of 6000 cells/ml. A negative control representing 
100% viability of cell line growth was necessary for comparing the cell line growth in 
the presence of drug solutions. The negative control which was aseptically prepared 
consisted of 0.25% or 0.5% dimethyl suphoxide (DMSO) which aided in solubilization 
of the respective cyclic dipeptide solutions. This was then made up to volume with 
RPMI 1640 (Sigma-Aldrich) containing 10% FCS which was then pre-warmed to 
37°C. The solution was filter-sterilized through a sterile 0.22 µm acrodisc filter. A 100 
mM solution of the positive control, melphalan (Chemistry Department, NMMU) was 
prepared by dissolving 3.052 g in 100 ml of 1% ethanol. The stock solution was 
diluted to give a final concentration of 0.5 mM (152.6 µg/l) with RPMI medium 
containing 10% FCS, which was pre-warmed to 37°C. The stock solutions of 0.75 M 
cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) were prepared by adding 0.25% DMSO 
for the 1 mM concentration and 0.5% DMSO for the 2 mM concentration and the 
mixtures were then sonicated to aid in complete solubilization of the cyclic 
dipeptides. The solutions were then made up to volume with RPMI 1640 (Sigma-
Aldrich) medium supplemented with 10% foetal calf serum (FCS).MTT (Sigma 
Chemicals Co., USA) was made up with PBS (pH 7.4) to give a concentration of 5 
mg/ml. The solutions were filter-sterilized through sterile 0.22 µm acrodisc filters. 200 
µL of each cell suspension  containing 6000 cells/ml was transferred to the wells of 
96-well flat bottom microtitre plates and were incubated at 37ºC with 5% CO2 
humidification for 24 hours to allow the cells to attach to the bottom of the well. After 
incubation, the growth medium was aspirated off and there after 200 µl aliquots of 
the negative control, positive control and cyclic dipeptide solutions were added to the 
wells such that each concentration yielded results in triplicate. To each well, 50 µL of 
MTT solution was added. The microtitre plates were then incubated again at 37ºC 
with 5% CO2 humidification for 3 hours to allow for metabolic reduction of MTT which 
forms insoluble formazan precipitates. Incubation allowed the drug compound to 
interact with particular cell lines. MTT supernatant was aspirated off and 200 μL 
aliquots of DMSO were added to each well to dissolve the formazan precipitates. 
The microtitre plates were placed on a plate shaker for 5 minutes and the 
absorbance was read immediately at 540 nm on a microtitre plate spectrophotometer 
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(Multiscan MS®, (version 4.0) Labsystem® type 352, England) (Huq et al., 2004). The 
results were reported as percentage inhibition relative to the negative control.  
 
Antimicrobial activity of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
The methods employed by Stevens & Olsen (1993), Freimoser et al. (1999), Kilian 
(2002) and Janse van Rensburg (2006) were adapted to develop a method to test 
the antimicrobial activity of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) against 
selected microorganisms. The Gram-positive and Gram-negative bacteria were 
plated onto nutrient agar (Merck, Germany), and C. albicans was plated onto potato 
dextrose agar medium (Merck, Germany). This was done to maintain the integrity 
and viability of the cultures that were used. The organisms were then incubated 
overnight at 37ºC and 28ºC respectively with subsequent sub-culturing to ensure 
growth of pure colonies. Mueller-Hinton broth was used for overnight activation of 
microbial cultures. The test organisms were scraped off from the relevant agar plates 
using a flame sterilized platinum loop. The organisms were inoculated into 15 ml 
sterile Mueller-Hinton broth and incubated at 37°C (for bacteria) or 28°C (for C. 
albicans) in an orbital shaker at 100 rpm for 24 hours. The cultures were then sub-
cultured by transferring 100 μL of the test organism into 15 ml sterile Mueller-Hinton 
broth and the cultures were then incubated for 16 hours at 37ºC for bacteria and 
28ºC for C. albicans, in an orbital shaker at 100 rpm. The turbidity of the test cultures 
was measured at 540 nm (for Gram-positive and Gram-negative bacteria) and 600 
nm (for C. albicans) using sterile Mueller-Hinton broth as the blank.50 μl of each test 
organism was aseptically transferred into sterile 96-well microplates, thereafter 50 μl 
of cyclic dipeptides at concentrations of 1 mM and 2 mM were added which resulted 
in final concentrations of 0.5 mM and 1 mM in each well. 50 μL of each of the 
positive controls were pipetted into the respective cells according to the test 
organism cultures giving final concentrations of 0.25 mg/ml and 0.5 mg/ml 
(chloramphenicol) and 0.5 mg/ml and 1 mg/ml (amoxicillin) in the respective wells. 
50 μL of the negative control was pipette to the separate wells to indicate 100% 
viability of test organism growth. The 96-well microplates were incubated at 37°C for 
bacteria and 28ºC for C. albicans in an orbital shaker at 100 rpm for 24 hours. After 
incubation, 40μlof MTT dye (0.5 mg/ml) was added to each well. Absorbance was 
immediately measured on a microplate reader to obtain zero reading time at 540 nm 
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for bacteria and 600 nm for C. albicans. The plates were again incubated at 37°C in 
an orbital shaker at 100 rpm for 4 hours to allow for the metabolic reduction of MTT. 
The plates were subsequently removed from the incubator and centrifuged at 3000 
rpm (Eppendorf 5804R, Germany)for 7 minutes to pellet the insoluble formazan 
product (Freimoser et al., 1999). The supernatant of each well was aspirated off and 
discarded. The formazan product present was dissolved in 90 μl DMSO and placed 
on a plate shaker for four minutes. Absorbance was then read at 540 nm for bacteria 
and 600 nm for C. albicans. Experiments were conducted in triplicate.  
 
Haematological activity of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
A coagulation assay for prothrombin (PT) and activated partial thromboplastin time 
(APTT), a fibrinolysis assay (D-Dimer and Fib-C) and a platelet aggregation assay 
were utilized to investigate the effects of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-
Pro) on haemostasis. Water required for experimentation was obtained from an Ultra 
ClearTWF UF TM Reverse Osmotic water purification system SG®. To ensure 
reproducibility, all assays were performed in triplicate. Calibration plasma was used 
to conduct the coagulation studies (PT, APTT) and fibrinolysis studies (D-Dimer and 
Fib-C). Healthy donors were used to prepare calibrated plasma. A CL coagulation 
analyser S/N 217 (Instrumental Laboratory Corporation, Beckman) and ACL-assay 
reagent kit (Instrumental Laboratory Corporation, Beckman) were used to perform 
the assays. The Clinical and Laboratory Standards Institute (CLSI) guidelines and 
manufacturer‟s package insert guidelines were used to perform the in vitro tests. The 
PT test was performed according to the manufacturer‟s instructions. A 
RecombiPlastin kit (Beckman) was used in the assay. The thromboplastin reagent 
(phospholipid/tissue factor preparation) included in the RecombiPlastin kit, is a 
liposomal preparation which constitutes of recombinant human tissue factor in a 
phospholipid mixture with calcium chloride, buffer and a preservative. The calibration 
plasma (cal plasma) was first diluted (1: 40) and 25 µL of cal plasma was then 
diluted with 1000 µL of factor diluent. 200 µL RecombiPlastin was incubated at 37˚C 
for 180 sec on the CL Analyser (IVD, Beckman Coultier). 100 μL of diluted plasma 
and 50 µL of either the diluent factor, heparin (0.1 U/ml) (Bodene) or cyclic dipeptide 
solutions were premixed and incubated in separate cuvettes for 180 sec at 37˚C. 150 
μL of the premixed solutions were added to the RecombiPlastin (200 μL) and the 
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clotting time was measured. To evaluate the effect of the cyclic dipeptides on APTT, 
100 μL of the APTT reagent was added to cuvettes containing 100 μL of plasma and 
either the diluent factor, cyclic dipeptide solutions, or heparin (0.1 U/mL). The 
premixed solutions were incubated at 37˚C for 180 sec on the CL Analyser, after 
which 100 μL of 0.025 M CaCl2 solution was added to initiate the activation of the 
intrinsic pathway. The clotting time was determined, and the anticoagulatory activity 
of the test samples evaluated relative to the untreated control. 
 
The fibrinogen-C assay was performed according to the manufacturer‟s instructions. 
200 µL of diluted plasma (1: 9 dilution, 200 µL of plasma was diluted with 1800 µL of 
diluent factor) was incubated with 50 μL of either the diluent factor, cyclic dipeptide 
solutions, or heparin (0.1 U/mL) at 37˚C on the CL Analyser for 180 sec. After the 
incubation period, a thrombin (Beckman) solution of 100 μL was added and the 
effect on the conversion of fibrinogen to fibrin was determined by comparing the 
fibrin levels of the treated plasma with that of the untreated plasma control. 
 
The D-Dimer assay (Beckman) was performed according to the manufacturer‟s 
instructions. The buffer (150 μL) was added to 42 μL of plasma containing 8 μL of 
either the diluent factor, cyclic dipeptide solutions, or heparin (0.1 U/mL). The 
mixtures were then incubated at 37˚C in the CL Analyser for 15 minutes and 
thereafter the Latex D-Dimer was added. The rate of fibrinolysis was determined by 
comparing the protein levels of the treated plasma with that of the untreated plasma 
control.  
 
Blood was drawn by venipuncture from the forearm of healthy human subjects. 
Sodium citrate (0.105 M, 10 µL) was used as an anticoagulant to prevent the blood 
from clotting. The healthy subjects used were individuals who have not been sick in 
the past three months and who had not taken any medication. Platelet rich plasma 
(PRP) was obtained by centrifugation (Eppendorf centrifuge 5804R) at 300 x g for 10 
minutes while Platelet poor plasma (PPP) was obtained by centrifugation (Eppendorf 
centrifuge 5804R) at 900 x g for 15 minutes. The PRP and PPP were then gently 
suspended in a buffer composed of 145 mM NaCl, 5 mM KCl, 10 mM HEPES, 0.5 
mM Na2HPO4, 6 mM glucose and 0.2% bovine serum albumin (BSA), (pH 7.4) 
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(buffer A). The platelet suspension was kept at room temperature and utilized within 
an hour. Prior to use, the platelet suspension was warmed at 37ºC (Bellavite et al., 
1994). Volumes of 200 µL of platelet suspension were pipetted into 96-well microtiter 
plates for measurement of turbidity (Bio TekPower Wave XS) at 600 nm. Each 
sample was also used to obtain triplicate platelet counts using a haemocytometer 
chamber. A standard curve correlating absorbance to the number of platelets was 
obtained. The method of determining the number of platelets in a suspension was 
developed by Walkowiak et al. (1997).  
 
The method for the platelet aggregation was adapted from Michelson et al. (2000). A 
platelet rich plasma suspension containing a platelet count of 30 x 106 platelets/ml 
was used. A volume of 40 µL of PRP was pipette into tubes containing a saturated 
concentration of fluorescein isothiocyanate (FITC)-PAC1 (BD Bioscience) (10 µL). 2 
µL of 2,5mmol/L of peptide glycyl-L-propyl-L-arginyl-L-proline (GPRP) (Sigma) was 
added to inhibit polymerization of fibrin. A thrombin stock solution of 50 U/ml was 
added to the tubes to give a final concentration of 10 U/ml. The same volume of 
buffer was added to the untreated control and cyclic dipeptide solutions. Unstained 
cells were used to determine background staining. The tubes were incubated at 
room temperature for 15 minutes and thereafter mixed with a 2:1 ratio of 1% 
formaldehyde and buffer A (145 mM NaCl, 5 mM, KCl, 10 mM HEPES, 0.5 mM 
Na2HPO4, 6 mM glucose, 0.2% bovine serum albumin) (BSA), (pH 7.4) and then 
incubated for 30 minutes at room temperature. A threefold volume of Tyrode‟s buffer 
(140 mmol/L NaCl, 10 mmol/L glucose and 15 mmol/L Tris/HCl, pH 7.4) was added 
and the cells were analyzed with a Beckman flow cytometer (Beckman Coultier, 
Cytomics FC 500). Twenty thousand events were counted to measure fluorescent 
light scattering with each analyzed sample. The parameters were collected in list 
mode files and analyzed. 
 
 
The antidiabetic activity of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
The antidiabetic potential of the compounds was determined by conducting an α-
amylase assay and an α-glucosidase assay. The methodology developed by Fuwa, 
(1954) and modified by Xiao et al. (2006) was adapted to determine the effects of 
202 
 
cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro). 40 μl of starch (Sigma) solution and 40 
μl of the α-amylase enzyme (in 0.1 M phosphate buffer, pH 7.0) was pipette into 
microplate wells and incubated at 50ºC for 30 minutes. After incubation, 20 μl of 1 M 
HCl was added to terminate the enzymatic reaction. 100 μl of iodine reagent (5 mM 
iodine and 5 mM potassium iodine) was then added. After colour development, 150 
μl of the iodine-treated sample was transferred to a transparent flat-bottomed 96-well 
microplate. Absorbance was then read at 580 nm using a microplate reader (BioTek 
Power Wave XS). The assay was performed in triplicate.  
 
The method employed by Sancheti et al. (2009) was adapted to determine the 
effects of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on the activity of α-
glucosidase enzyme. Mixtures consisting of 50 μl of the 0.1 M phosphate buffer, 25 
μl of the 0.5 mm 4-nitrophenyl-α-D-glucopyranoside solution, 10 μl of either the 
acarbose solution, cyclo(D-Phe-4I-Pro) or cyclo(L-Phe-4I-Pro) solution were 
incubated at 37ºC for 30 minutes. After incubation, 100 μl of 0.2 M sodium carbonate 
solution was added to terminate the enzymatic reaction. The amount of p-nitrophenol 
released in the reaction was determined spectrophotometrically at 410 nm using a 
microplate reader (BioTek Power Wave XS). The amount of p-nitrophenol released 
was proportional to the enzymatic hydrolysis of the substrate. All experiments were 
performed in triplicate. 
 
Statistical analysis 
All results were obtained in triplicate values and represented as a mean ± standard 
deviation (SD). Data was represented graphically with the aid of Microsoft Excel® and 
Graphpad Prism 5®. To determine whether the cyclic dipeptides under study caused 
statistically significant results, student t-tests were conducted. Calculated P-values of 
less than 0.05 were defined as an indication of statistical significance. 
 
Results and discussion 
Molecular modeling 
The results obtained from the conformational investigations of cyclo(D-Phe-4I-Pro) 
and cyclo(L-Phe-4I-Pro) are illustrated in Figures 1 to 28. For both compounds, 
conformer 1 matches the structure with the lowest energy, therefore conformer 1 is 
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the most stable structure which is most likely to be found under standard conditions. 
No results were obtained for the compounds in DMSO. The experiment was run 
several times and every time the following message was received “failure to convert 
error”. The structural geometry of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) is 
mainly influenced by the substituents on their respective side chains at the α-
carbons. They both contain carbonyl groups in the DKP structure. The chemistry of 
an organic molecule is not only established by the size and complexity but also by 
the functional groups it contains (McMurray, 2000). When studying the structures of 
both cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro), it can be established that the 
biological activity of these cyclic dipeptides is mainly due to the C=O functional 
groups located in the DKP structure, that binds to a receptor by means of the Emil 
Fisher‟s “lock and key” principle (Kessler, 1982). The extended conformation of the 
aromatic side chain was observed for all the different conformers. This can be 
attributed to the steric hinderance caused by the halogens. 
 
 
Anticancer activity of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
Percentage growth inhibitions of the HeLa, MCF-7 and HT-29 cancer cell lines by 
cyclo(D-Phe-4I-Pro), cyclo(L-Phe-4I-Pro) and melphalan, with and without PEG, are 
illustrated in Figures 29 to 32. Percentage growth inhibitions produced by all 
screening concentrations of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) were 
notably less than that produced by melphalan. Melphalan with PEG showed growth 
inhibitions of 86.88 ± 1.12 % (P-value = 0.0001), 82.39 ± 0.32 % (P-value < 0.0001), 
and 71.30 ± 0.94 % (P-value < 0.0001) against the HeLa, MCF-7 and HT-29 cell 
lines respectively. Mephalan without PEG showed growth inhibitions of 54.47 ± 
1.12% (P-value = 0.0002), 56.06 ± 0.32% (P-value < 0.0001) and 58.87 ± 0.94% (P-
value < 0.0001) against the HeLa, MCF-7 and HT-29 cell lines respectively. Cyclo(D-
Phe-4I-Pro) with PEG at screening concentrations of 1 mM and 2 mM showed 
growth inhibitions of 41.48 ± 5.50% (P-value = 0.0028) and 62.32 ± 2.73% (P-value 
= 0.0004) against the HeLa cell line respectively. Growth inhibitions of 72.87 ± 1.19% 
(P-value = 0.0001) and 65.51 ± 1.05% (P-value = 0.0004) against the MCF-7 and 
HT-29 cell lines were observed at a screening concentration of 2 mM. Cyclo(D-Phe-
4I-Pro) with PEG at a screening concentration of 1 mM caused growth inhibitions of 
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60.97 ± 4.47% (P-value = 0.321) and 53.85 ± 0.91% (P-value < 0.0001) against the 
MCF-7 and HT-29 cell lines respectively. Cyclo(D-Phe-4I-Pro) without PEG at a 
screening concentration of 2 mM showed growth inhibitions of 31.12 ± 0.08% (P-
value < 0.0001), 41.92 ± 2.52 (P-value = 0.0004) and 36.12 ± 3.43% (P-value = 
0.0021) against the HeLa, MCF-7 and HT-29 cell lines respectively. At the screening 
concentration of 1 mM, cyclo(D-Phe-4I-Pro) without PEG caused growth inhibitions 
of 46.52 ± 0.03% (HeLa cell line) (P-value < 0.0001), 9.92 ± 0.12% (MCF-7 cell line) 
(P-value < 0.0001) and 20.52 ± 1.18 (HT-29 cell line) (P-value = 0.0001). Cyclo(L-
Phe-4I-Pro) with PEG at concentrations of 1 mM and 2 mM showed growth 
inhibitions of 29.82 ± 2.83% (P-value = 0.001) and 58.88 ± 2.73% (P-value = 0.001) 
against the HeLa cell line respectively. Growth inhibitions of 61.26 ± % 0.45 (P-value 
= 0.0001) and 61.39 ± 2.18% (P-value = 0.0204) were observed against the MCF-7 
and HT-29 cell lines at a screening concentration of 2 mM. Cyclo(L-Phe-4I-Pro) with 
PEG at screening concentration of 1 mM caused growth inhibitions of 43.85 ± 1.21% 
(P-value = 0.008) and 40.05 ± 0.41% (P-value < 0.0001) against the MCF-7 and HT-
29 cell lines respectively. Cyclo(L-Phe-4I-Pro) without PEG at a screening 
concentration of 2 mM showed growth inhibitions of 19.19 ± 0.27% (P-value = 
0.0002), 51.43 ± 2.52 (P-value = 0.0012) and 49.84 ± 3.43% (P-value = 0.0821) 
against the HeLa, MCF-7 and HT-29 cell lines respectively. At the screening 
concentration of 1 mM, cyclo(L-Phe-4I-Pro) without PEG caused growth inhibitions of 
40.63 ± 0.09% (P-value < 0.0001) against the HeLa cell line, 14.6 ± 0.17% (P-value 
< 0.0001) against the MCF-7 cell line and 7.01 ± 1.92 (P-value = 0.0002) against the 
HT-29 cell line. 
 
Antimicrobial activity of cyclo(D-Phe-4I-Pro) 
Percentage growth inhibitory effects caused by different screening concentrations of 
cyclo(D-Phe-4I-Pro), cyclo(L-Phe-4I-Pro), chloramphenicol and amoxicillin against 
selected microorganisms after 24 hours exposure are illustrated in Figures 33 to 37. 
Cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) showed greater percentage growth 
inhibitions than the effects exhibited by chloramphenicol and amoxicillin. Amoxicillin 
at screening concentrations of 0.5 mg/ml and 1 mg/ml showed growth inhibitions of 
28.25 ± 0.02% (P-value < 0.0001) and31.78 ± 0.02% (P-value < 0.0001)against S. 
aureus, 77.6 ± 0.48% (P-value < 0.0001) and 88.97 ± 0.31% (P-value < 0.0001) 
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against B. subtilis,  2.37 ± 0.01% (P-value < 0.0001) and 12.37 ± 0.02% (P-value < 
0.0001) against E. coli, 52.66 ± 0.28% (P-value < 0.0001) and 55.68 ± 0.21% (P-
value < 0.0001) against P. aeruginosa and 23.41 ± 0.04% (P-value < 0.0001) and 
30.97 ± 0.03% (P-value < 0.0001) against C. albicans respectively. Chloramphenicol 
at screening concentrations of 0.25 mg/ml and 0.5 mg/ml showed growth inhibitions 
of 63.64 ± 0.39% (P-value < 0.0001) and 71.14 ± 1.07% (P-value = 0.002) against S. 
aureus, 12.14 ± 0.02 (P-value < 0.0001) and 25.86 ± 0.04 (P-value < 0.0001)  
against B. subtilis, 56.39 ± 0.16% (P-value = 0.0008) and 60.44 ± 0.78% (P-value < 
0.003) against E. coli, 45.42 ± 0.37% (P-value < 0.0001) and 47.80 ± 0.21% (P-value 
< 0.0001) against P. aeruginosa and 79.39 ± 0.83% (P-value < 0.0001) and 83.25 ± 
0.93% (P-value = 0.0005) against C. albicans respectively. Cyclo(D-Phe-4I-Pro) at 
screening concentrations of 0.5 mM and 1 mM showed growth inhibitions of 96.66 ± 
0.03% (P-value < 0.0001) and 96.72 ± 0.03% (P-value < 0.0001) against S. aureus, 
94.07 ± 0.02% (P-value < 0.0001) and 94.37 ± 0.02% (P-value < 0.0001) against B. 
subtilis, 94.09 ± 0.01% (P-value < 0.0001) and 94.78 ± 0.02% (P-value < 0.0001) 
against E. coli, 88.97 ± 0.02% and 89.87 ± 0.01% (P-value < 0.0001) against P. 
aeruginosa and 92.12 ± 0.03% (P-value < 0.0001) and 94.06 ± 0.03% against C. 
albicans respectively. Cyclo(L-Phe-4I-Pro) at screening concentrations of 0.5 mM 
and 1 mM showed growth inhibition of 92.90 ± 0.02% (P-value < 0.0001) and 93.38 ± 
0.02% (P-value < 0.0001) against S. aureus, 93.55 ± 0.03% (P-value < 0.0001) and 
95.71± 0.02% (P-value < 0.0001) against B. subtilis, 90.26 ± 0.02% (P-value < 
0.0001) and 91.03 ± 0.02% (P-value < 0.0001) against E. coli, 92.64 ± 0.02% and 
93.13 ± 0.02% (P-value < 0.0001) against P. aeruginosa and 90.47 ± 0.03% (P-value 
< 0.0001) and 99.13 ± 0.03% (P-value < 0.0001) against C. albicans respectively. 
Both cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) showed excellent antibacterial 
and antifungal activity against the Gram-positive bacteria (B. subtilis and S. aureus) 
and the Gram-negative bacteria (E. coli and P. aeruginosa) and fungus (C. albicans). 
This increased activity is usually seen in cyclic dipeptides of hydrophobic nature 
because of their ability to cross the lipid membrane of the microorganism. The ability 
to cross the lipid membrane may be enhanced by the halogen present in the cyclic 
dipeptide structure as the halogen bonding interactions are responsible for the 
different conformations of the molecules at the active site (Yunxiang et al., 2009). It 
can be concluded that cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) showed good 
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antibacterial activity. It is recommended that these two compounds must be tested 
against other organisms as well to establish their potential as future antibacterial 
agents. 
 
 
Haematological activity of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
Figures 38 to 47 illustrate the effects caused by cyclo(D-Phe-4I-Pro) and cyclo(L-
Phe-4I-Pro) on clotting time, fibrin formation and platelet aggregation. Heparin (0.1 
U/ml) prolonged the PT and  APTT clotting time to 21.6 ± 0.25 and 70.5 ± 0.31 
seconds respectively, decreased fibrin formation and D-Dimer formation to 88 ± 1 
mg/dl and 22.0 ± 1.0 ng/ml respectively. Cyclo(D-Phe-4I-Pro) at concentrations of 
12.5 mM, 25 mM and  50 mM prolonged the PT clotting time to 23.8 ± 0.15  seconds 
(P = 0.0003),  26.4 ± 0.15 seconds (P = 0.0005) and 29.4 ± 0.25 seconds (P < 
0.0001), prolonged the APTT clotting time to 29.7 ± 0.15 (P < 0.0001), 38.8 ± 0.10 (P 
< 0.0001) and 47.5 ± 0.20 seconds (P < 0.0001), decreased fibrin formation to 487.3 
± 3.1 mg/dl (P < 0.0001), 461.7 ± 6.5 mg/dl (P < 0.0001) and 242.3 ± 4.6 mg/dl (P = 
0.0002), ) and decreased D-Dimer formation to 43.3 ± 1.5 ng/ml (P = 0.002), 28.0 ± 
1.0 ng/ml (P = 0.02) and 21.3 ± 1.5 ng/ml (P = 0.001) respectively. Cyclo(L-Phe-4I-
Pro) at concentrations of 12.5 mM, 25 mM and 50 mM prolonged the clotting time to 
23.6 ± 0.26 seconds (P = 0.0001), 25.5 ± 0.21 seconds (P = 0.0001), 28.5 ± 0.25 
seconds (P = 0.0001), ) prolonged the APTT clotting time to 31.9 ± 0.53 (P < 
0.0001), 44.4 ± 0.21 (P < 0.0001) and 55.5 ± 0.31 (P < 0.0001) seconds, decreased 
fibrin formation to 492.3 ± 5.5 mg/dl (P < 0.0001), 466.3 ± 1.5 mg/dl (P < 0.0001) and 
394.7 ± 6.5 mg/dl (P < 0.0001) and decreased D-Dimer formation to 48.0 ± 1.0 ng/ml 
(P = 0.0002), 38.0 ± 1.0 ng/ml (P = 0.002) and 33.7 ± 1.5 ng/ml (P = 0.005) 
respectively. The untreated control showed cell density and platelet aggregation of 
6.4%. The positive control showed cell density and platelet aggregation of 10.3%. 
Cyclo(D-Phe-4I-Pro) at screening concentrations of 12.5 mM, 25 mM and 50 mM 
showed cell density and platelet aggregation of  20.3%, 18.7% and 12.9% 
respectively. Cyclo(L-Phe-4I-Pro) at screening concentrations of 12.5 mM, 25 mM 
and 50 mM showed cell density and platelet aggregation of 31.8%, 30.6% and 
17.7% respectively. Both cyclic dipeptides showed less platelet aggregation at higher 
concentrations which shows that they exhibit antiplatelet activity at high 
concentrations. 
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Antidiabetic activity of cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
The α-amylase and α-glucosidase inhibitory effects of acarbose, cyclo(D-Phe-4I-Pro) 
and cyclo(L-Phe-4I-Pro) are shown in Figure 48 to 49. Percentage growth inhibitions 
caused by both cyclic dipeptides was significantly less when compared with 
acarbose. Acarbose caused percentage inhibitions of 55.51 ± 0.82% (P-value < 
0.0001) and 51.11 ± 1.02% (P-value > 0.0001) against α-amylase and α-glucosidase 
respectively. Cyclo(D-Phe-4I-Pro) at a screening concentration of 1 mM exhibited 
growth inhibitions of 5.99 ± 0.21% (P-value < 0.0001) and -7.75 ± 0.49% (P-value > 
0.0001) against α-amylase and α-glucosidase respectively. Cyclo(L-Phe-4I-Pro) at a 
screening concentration of 1 mM caused growth inhibitions of 5.49 ± 0.30% (P-value 
< 0.0001) and -3.03 ± 0.24% (P-value > 0.0001) against α-amylase and α-
glucosidase respectively. Both cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) showed 
no antidiabetic potential as they both caused an enzyme inhibition of less than 10%. 
The assays were not conducted at higher concentrations due to the low solubility 
features of the compounds. It can be concluded that both cyclo(D-Phe-4I-Pro) and 
cyclo(L-Phe-4I-Pro) have no clinical benefits as antidiabetic agents. 
 
Conclusion 
The cyclic dipeptides, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) were 
successfully synthesized using the method of Milne et al. (1992) and by boiling the 
linear unprotected counterparts under reflux in a neutral medium. Excellent yields of 
72% and 70% were obtained for cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) 
respectively. 
 
The structures of the cyclic dipeptides were confirmed using standard elucidation 
methods such as nuclear magnetic resonance, mass spectrometry, infrared 
spectroscopy and molecular modeling and computational chemistry.  
 
The physicochemical properties of the cyclic dipeptides were determined using 
scanning electron microscopy, differential scanning calorimetry, thermogravimetric 
analysis and X-ray powder diffraction.  
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High-performance liquid chromatography and thin layer chromatography were used 
to determine the purity of the cyclic dipeptides and the results showed that the 
synthesized compounds had no impurities and could therefore be used for the 
biological studies. 
 
The objective of the study was also to investigate the biological potential of the 
compounds by conducting anticancer, antimicrobial, haematological and antidiabetic 
studies. Dimethyl sulphoxide was used to aid in dissolving the respective cyclic 
dipeptides and other compounds, but it was used at a minimum concentration to 
avoid interference with the biological studies. 
 
Graz et al. (2000) revealed that cyclo(Phe-Pro) showed greater than 50% growth 
inhibition of four cancer cell lines. The results obtained in this study showed that 
cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) have potential as anticancer agents 
against the HeLa (cervical cancer), HT-29 (colon cancer) and MCF-7 (breast cancer) 
cell lines, when compared with mephalan (with PEG). 
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The mode by which drugs are delivered to the required region has significant effects 
on the efficacy of drugs. Some drugs have an optimal concentration range, above or 
below this range, a drug produces toxic or no therapeutical effects. Drug delivery and 
drug targeting systems are currently under development and the objectives are (1) to 
minimize degradation or loss, (2) prevent harmful side effects and (3) increase the 
bioavailability and the fraction of the drug accumulating in the required region. 
Among the drug carriers identified are: (1) soluble polymers, (2) microparticles made 
of insoluble or degradable or natural and synthetic polymers, (3) microcapsules, (4) 
cells, (5) cell ghosts, (6) lipoproteins, (7) liposomes and (8) micelles. Liposomal 
formulations have been extensively studied to enhance the delivery of drugs via 
several routes (Kaparissides et al., 2006; Cunningham, 2006; Van der Merwe, 
2005).The results of the anticancer studies confirmed that conjugation of anticancer 
agents with PEG, (a soluble polymer) enhanced their activity as higher percentage 
inhibitions were observed in such cases. Conjugation of PEG with the cyclic 
dipeptides also appeared to be beneficial as it has also shown to increase their 
activity. 
 
Cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) showed broad activity (more than 50% 
growth inhibition) against selected microorganisms. The broad activity exhibited by 
both the cyclic dipeptides may be as a result of their hydrophobic nature and their 
ability to cross the lipid membranes of the microorganisms. The ability to cross the 
lipid membranes may be enhanced by the halogen present in the cyclic dipeptide 
structure as the halogen bonding interactions are responsible for the different 
conformations of the molecules at the active site (Yunxiang et al., 2009). Further 
studies against more microorganisms should be performed in order to establish the 
potential of these compounds as possible antimicrobial agents of the future. It is also 
recommended that the synergistic effects of these two compounds must be 
investigated. 
 
The haematological results revealed that both cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-
4I-Pro) showed no anticoagulant activity. They prolonged the clotting time in a 
concentration-dependent manner whereby the highest concentration (50 mM) 
showed the longest clotting time. Both cyclic dipeptides also showed a 
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concentration-dependent decrease in fibrin formation when compared with heparin. 
When compared with thrombin, both cyclic dipeptides showed platelet aggregation at 
low concentrations and antiplatelet activity at high concentrations. 
 
Cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) exhibited no antidiabetic potential as 
they both caused an enzyme inhibition of less than 10%. The assays were not 
performed at higher concentrations due to the low solubility features of the 
compounds. 
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LIST OF ABREVIATIONS 
APTT    Activated partial thromboplastin time 
C-M    Chloroform-methanol 
C-M-A    Chloroform-methanol-acetic acid 
CLSI    Clinical and Laboratory Standards Institution 
DMSO   Dimethyl sulphoxide 
MTT  3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide 
EDTA    Ethylenediaminetetraacetic acid  
Fib-C    Fibrinogen C 
FITC    Fluorescein isothiocyanate 
GPRP    Glycyl-L-propyl-L-arginyl-L-proline 
HPLC    High-performance liquid chromatography 
I    Iodine 
μL    Microliter 
mg    Milligram 
mg/dl    Milligram per deciliter 
mg/ml    Milligram per milliliter 
ml    Milliliter 
mm    Millimeter 
mM    Millimolar 
mmol/L   Millimole per liter 
M    Molar concentration 
ng/ml    Nanogram per milliliter 
nm    Nanometer 
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%    Percentage 
Phe    Phenylalanine 
PBS    Phosphate buffered saline 
PAI-1    Plasminogen activator inhibitor-1 
PPP    Platelet poor plasma 
PRP    Platelet rich plasma 
PEG    Polyethylene glycol 
Pro    Proline 
PT    Prothrombin Time 
rpm    Revolution per minute 
RPMI    Rosewell Park Memorial Institute 
Sec    Seconds 
SA    South Africa 
t-Boc    tert-butyloxycarbonyl 
TLC    Thin layer chromatography 
Tyr    Tyrosine 
UV    Ultraviolet 
USA    United States of America 
U/ml    Units per milliliter 
 
 
  
Figure 1: Conformation of conformer 1 of cyclo(D-Phe-4I-Pro) in the gas phase 
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Figure 2: Conformation of conformer 2 of cyclo(D-Phe-4I-Pro) in the gas phase 
 
 
  
Figure 3: Conformation of conformer 3 of cyclo(D-Phe-4I-Pro) in the gas phase 
 
 
  
Figure 4: Overlays of conformer 1 and 2 of cyclo(D-Phe-4I-Pro) in the gas phase 
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Figure 5: Overlays of conformer 1 and 3 of cyclo(D-Phe-4I-Pro) in the gas phase 
 
   
Figure 6: Overlays of conformer 2 and 3 of cyclo(D-Phe-4I-Pro) in the gas phase 
 
 
  
Figure 7: Overlays of conformer 1, 2 and 3 of cyclo(D-Phe-4I-Pro) in the gas phase 
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Figure 8: Conformation of conformer 1 of cyclo(D-Phe-4I-Pro) in the aqueous phase 
 
 
 
 
Figure 9: Conformation of conformer 2 of cyclo(D-Phe-4I-Pro) in the aqueous phase 
 
 
  
Figure 10: Conformation of conformer 3 of cyclo(D-Phe-4I-Pro) in the aqueous phase 
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Figure 11: Overlays of conformer 1 and 2 of cyclo(D-Phe-4I-Pro) in the aqueous phase 
  
 
Figure 12: Overlays of conformer 1 and 3 of cyclo(D-Phe-4I-Pro) in the aqueous phase 
 
   
Figure 13: Overlays of conformer 2 and 3 of cyclo(D-Phe-4I-Pro) in the aqueous phase 
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Figure 14: Overlays of conformer 1, 2 and 3 of cyclo(D-Phe-4I-Pro) in the aqueous phase 
 
 
 
 
 
Figure 15: Conformation of conformer 1 of cyclo(L-Phe-4I-Pro) in the gas phase 
 
 
  
Figure 16: Conformation of conformer 2 of cyclo(L-Phe-4I-Pro) in the gas phase 
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Figure 17: Conformation of conformer 3 of cyclo(L-Phe-4I-Pro) in the gas phase 
 
 
  
Figure 18: Overlays of conformer 1 and 2 of cyclo(L-Phe-4I-Pro) in the gas phase 
 
 
 
 
Figure 19: Overlays of conformer 1 and 3 of cyclo(L-Phe-4I-Pro) in the gas phase 
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Figure 20: Overlays of conformer 2 and 3 of cyclo(L-Phe-4I-Pro) in the gas phase 
 
 
  
Figure 21: Overlays of conformer 1, 2 and 3 of cyclo(L-Phe-4I-Pro) in the gas phase 
 
 
 
 
Figure 22: Conformation of conformer 1 of cyclo(L-Phe-4I-Pro) in the aqueous phase 
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Figure 23: Conformation of conformer 2 of cyclo(L-Phe-4I-Pro) in the aqueous phase 
 
  
 
Figure 24: Conformation of conformer 3 of cyclo(L-Phe-4I-Pro) in the aqueous phase 
 
 
  
Figure 25: Overlays of conformer 1 and 2 of cyclo(L-Phe-4I-Pro) in the aqueous phase 
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Figure 26: Overlays of conformer 1 and 3 of cyclo(L-Phe-4I-Pro) in the aqueous phase 
 
 
  
Figure 27: Overlays of conformer 2 and 3 of cyclo(L-Phe-4I-Pro) in the aqueous phase 
 
 
  
Figure 28: Overlays of conformer 1, 2 and 3 of cyclo(L-Phe-4I-Pro) in the aqueous phase 
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Figure 29: The percentage inhibition of growth of the HeLa, MCF-7 and HT-29 cell lines caused 
by melphalan (0.5 mM) and cyclo(D-Phe-4I-Pro) at screening concentrations of 1 mM and 2 
mM, all conjugated with PEG 
 
 
Figure 30: The percentage inhibition of growth of the HeLa, MCF-7 and HT-29 cell lines caused 
by melphalan (0.5 mM) and cyclo(D-Phe-4I-Pro) at screening concentrations of 1 mM and 2 
mM, all without PEG 
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Figure 31: The percentage inhibition of growth of the HeLa, MCF-7 and HT-29 cell lines caused 
by melphalan (0.5 mM) and cyclo(L-Phe-4I-Pro) at screening concentrations of 1 mM and 2 mM, 
all conjugated with PEG 
 
 
 
Figure 32: The percentage inhibition of growth of the HeLa, MCF-7 and HT-29 cell lines caused 
by melphalan (0.5 mM) and cyclo(L-Phe-4I-Pro) at screening concentrations of 1 mM and 2 mM, 
all without PEG 
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Figure 33: Percentage growth inhibitions of S. aureus after 24 hours exposure to cyclo(D-Phe-
4I-Pro), cyclo(L-Phe-4I-Pro),chloramphenicol and amoxicillin 
 
 
 
Figure 34: Percentage growth inhibitions of B. subtilis after 24 hours exposure to cyclo(D-Phe-
4I-Pro), cyclo(L-Phe-4I-Pro),chloramphenicol and amoxicillin 
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Figure 35: Percentage growth inhibitions of E. coli after 24 hours exposure to cyclo(D-Phe-4I-
Pro), cyclo(L-Phe-4I-Pro),chloramphenicol and amoxicillin 
 
 
 
Figure 36: Percentage growth inhibitions of P. aeruginosa after 24 hours exposure to cyclo(D-
Phe-4I-Pro), cyclo(L-Phe-4I-Pro),chloramphenicol and amoxicillin 
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Figure 37: Percentage growth inhibitions of C.albicans after 24 hours exposure to cyclo(D-Phe-
4I-Pro), cyclo(L-Phe-4I-Pro),chloramphenicol and amoxicillin 
 
 
 
Figure 38: The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on the PT 
clotting time 
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Figure 39: The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on the APTT 
clotting time 
 
 
Figure 40: The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) onfibrin 
formation 
 
230 
 
 
Figure 41: The effects of heparin, cyclo(D-Phe-4I-Pro) and cyclo(L-Phe-4I-Pro) on D-Dimer 
formation 
  
Figure 42: Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by 12.5 mM cyclo(D-Phe-4I-Pro) 
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Figure 43: Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by 25 mM cyclo(D-Phe-4I-Pro) 
 
  
Figure 44: Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by 50 mM cyclo(D-Phe-4I-Pro) 
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Figure 45: Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by 12.5 mM cyclo(L-Phe-4I-Pro) 
 
  
Figure 46: Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by 25 mM cyclo(L-Phe-4I-Pro) 
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Figure 47: Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by 50 mM cyclo(L-Phe-4I-Pro) 
 
 
 
Figure 48: α-Amylase inhibition caused by acarbose,cyclo(L-Phe-4I-Pro) and cyclo(D-phe-4I-
Pro) 
 
 
234 
 
 
Figure 49: α-Glucosidase inhibition caused by acarbose, cyclo(L-Phe-4I-Pro) and cyclo(D-Phe-
4I-Pro) 
 
 
 
 
 
 
 
 
 
 
 
 
 
